

Oncology Global Medical Affairs

Piqray® (alpelisib)

Study No. CBYL719C2005

Non-Interventional Study Final Report

**Survey among healthcare professionals treating patients
with metastatic breast cancer in selected European
countries to evaluate their knowledge on management of
hyperglycemia when using alpelisib**

Author  PhD, MSPH

Document Status Final

Date of final version of the study report 25-Apr-2025

EU PAS register number EUPAS42022

Property of Novartis
Confidential

May not be used, divulged, published or otherwise disclosed
without the consent of Novartis
NIS Report Template Version 4.0, Effective from 06-Aug-2021

PASS information

Title	Survey among healthcare professionals treating patients with metastatic breast cancer in selected European countries to evaluate their knowledge on management of hyperglycemia when using alpelisib
Version identifier of the final study report	1.0
Date of last version of the final study report	25-Apr-2025
EU PAS register number	EUPAS42022
NIS Type	NIS with Primary Data Collection
Active substance	Alpelisib (ATC code L01EM03)
Medicinal product	Piqray® (alpelisib)
Product reference	EU/1/20/1455/001-009
Procedure number	EMA/H/C/004804
Marketing authorization holder	Novartis Europharm Limited
Joint PASS	No

Research question and objectives

The objective of this survey is to confirm that HCPs received the Piqray educational material, and to assess HCPs' knowledge and management of hyperglycemia in patients treated with Piqray.

The primary objective is to assess HCPs' knowledge and understanding of the key information included in the Piqray Prescriber's/HCP Guide for hyperglycemia:

- Risk of hyperglycemia and its potential risk factors
- Signs and symptoms of hyperglycemia
- Recommendations for monitoring for hyperglycemia prior to, and during, treatment with Piqray
- Recommendations for managing hyperglycemia during treatment with Piqray

Secondary objectives are:

- Assess HCPs' reported levels of receipt, and reading, of the Piqray Prescriber's/HCP Guide for hyperglycemia

Assess HCPs' knowledge levels for each survey question regarding knowledge of, and management of hyperglycemia

- Assess the primary source from which HCPs learned about the messages included in the Piqray Prescriber's/HCP Guide for hyperglycemia

Country(-ies) of study

Austria, Croatia, Finland, Italy, Luxembourg, the Netherlands, Norway, Poland, Slovenia, Spain, and Sweden

Main author

[REDACTED] PhD, MSPH

[REDACTED]

[REDACTED]

Marketing authorization holder

Marketing authorization
holder(s)

Novartis Europharm Limited

MAH contact person

[REDACTED], Pharm. MA (IBA)

[REDACTED], Novartis Oncology

Lichtstrasse 35

CH-4056 Basel, Switzerland

Table of contents

	Table of contents	5
	List of tables	8
	List of figures	11
1	Abstract.....	12
2	List of abbreviations	14
3	Investigators	15
4	Other responsible parties	15
5	Milestones.....	15
6	Rationale and background	15
7	Research question and Objectives	16
	7.1 Primary Objective.....	16
	7.2 Secondary Objectives	16
8	Amendments and updates to the protocol	17
9	Research methods.....	18
	9.1 Study design	18
	9.2 Setting.....	20
	9.3 Subjects.....	20
	9.3.1 Inclusion criteria.....	20
	9.3.2 Exclusion criteria	20
	9.4 Variables.....	20
	9.4.1 Primary endpoint variables	20
	9.4.2 Secondary endpoint variables	22
	9.4.3 Covariates.....	23
	9.4.4 Survey administration and eligibility	23
	9.5 Data sources and measurement.....	24
	9.6 Bias	24
	9.7 Study size.....	25
	9.8 Data transformation	25
	9.9 Statistical methods	25
	9.9.1 Main summary measures.....	25
	9.9.2 Main statistical methods.....	26
	9.9.3 Missing values.....	26
	9.9.4 Sensitivity analyses	26
	9.9.5 Amendments to the statistical analysis plan.....	26
9.10	Quality control.....	26

10	Results	26
10.1	Participants	26
10.2	Descriptive data	32
10.3	Outcome data	32
10.4	Main results	32
10.4.1	HCPs' knowledge of the key information included in the Piqray prescriber's / HCP guide for hyperglycemia.....	32
10.4.2	Primary endpoints – composite score: overall and by country	33
10.4.3	Primary endpoints – composite score – overall and by healthcare professional characteristics	37
10.4.4	Primary endpoint – knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia (Q5c) – correct responders – overall and by healthcare professional characteristics.....	38
10.4.5	Primary endpoint – knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqray (Q6) – correct responders – overall and by healthcare professional characteristics.....	41
10.4.6	Primary endpoint – knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray (Q8b) – correct responders – overall and by healthcare professional characteristics	44
10.4.7	Primary endpoint – knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10) – correct responders – overall and by healthcare professional characteristics.....	47
10.4.8	Primary endpoint – knowledge that for fasting glucose values that are ≤250 mg/dL (≤13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12) – correct responders – overall and by healthcare professional characteristics.....	50
10.4.9	Primary endpoint – knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13) – correct responders – overall and by healthcare professional characteristics	53
10.4.10	Primary endpoint – knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14) – correct responders – overall and by healthcare professional characteristics	56

10.4.11	Primary endpoint – knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15) – correct responders – overall and by healthcare professional characteristics.....	59
10.5	Other analyses.....	62
10.5.1	Other endpoints –knowledge levels: overall	62
10.5.2	Other endpoints — knowledge levels: receipt and reading of the Piqray prescriber’s/HCP guide for hyperglycemia, overall	63
10.5.3	Other endpoints –knowledge: primary source from which HCPs learned about the messages included in the Piqray prescriber’s/HCP guide for hyperglycemia, overall.....	64
10.6	Adverse events/adverse reactions	64
11	Discussion.....	65
11.1	Key results	65
11.2	Limitations	65
11.3	Interpretation.....	65
11.4	Generalizability	66
12	Other information	66
13	Conclusion	66
14	References	68
15	Appendices	69
15.1	Appendix 1 – List of stand-alone documents	69
15.2	Appendix 2 – Additional relevant statistical information.....	70
15.2.1	Additional Tables	70
15.3	Appendix 3 – Survey Administration and Analysis Sets, and Survey eligibility.....	155
15.3.1	Austria.....	155
15.3.2	Croatia.....	155
15.3.3	Italy	155
15.3.4	Luxembourg	155
15.3.5	Netherlands	155
15.3.6	Norway	155
15.3.7	Poland.....	156
15.3.8	Slovenia.....	156
15.3.9	Spain.....	156
15.3.10	Sweden	156

List of tables

Table 4-1 Other responsible parties.....	15
Table 5-1 Study milestones	15
Table 8-1 Amendments and updates to the protocol	17
Table 9-1 Primary endpoints collected in the survey	21
Table 9-2 Covariates collected in the survey.....	23
Table 9-3 Precision and 95% confidence intervals for various combinations of sample size and knowledge levels.....	25
Table 10-1 Survey eligibility, overall and by country.....	29
Table 10-2 Respondent characteristics overall and by country	30
Table 10-3 Primary endpoints – knowledge levels: Individual questions – overall.....	32
Table 10-4 Primary endpoints – composite score: overall and by country	35
Table 10-5 Primary Endpoints – Individual Scores: Overall	36
Table 10-6 Primary endpoints – composite score – by healthcare professional characteristics.....	37
Table 10-7 Primary endpoint – knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia (Q5c) – correct responders – by healthcare professional characteristics.....	39
Table 10-8 Primary endpoint – knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqrax (Q6) – correct responders – by healthcare professional characteristics.....	42
Table 10-9 Primary endpoint – knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqrax (Q8b) – correct responders – by healthcare professional characteristics.....	45
Table 10-10 Primary endpoint – knowledge of when a FPG test should be performed after starting treatment with Piqrax (Q10) – correct responders – by healthcare professional characteristics.....	48
Table 10-11 Primary endpoint – knowledge that for fasting glucose values that are ≤250 mg/dL (≤13.9 mmol/L), no Piqrax dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12) – correct responders – by healthcare professional characteristics.....	51
Table 10-12 Primary endpoint – knowledge of which fasting glucose values require Piqrax dosing to be interrupted (Q13) – correct responders – by healthcare professional characteristics.....	54
Table 10-13 Primary endpoint – knowledge that “if Piqrax dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5	

days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14) – correct responders – by healthcare professional characteristics	57
Table 10-14 Primary endpoint – knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15) – correct responders – by healthcare professional characteristics	60
Table 10-15 Other endpoints – knowledge levels: overall	62
Table 10-16 Other endpoints – knowledge levels: receipt and reading of the Piqray prescriber’s/HCP guide for hyperglycemia, overall.....	63
Table 10-17 Other endpoints –knowledge: primary source from which HCPs learned about the messages included in the Piqray prescriber’s/HCP guide for hyperglycemia, overall	64
Table 15-1 Survey administration and analysis sets, overall and by country.....	70
Table 15-2 Other endpoints collected in the survey	71
Table 15-3 Primary endpoints – knowledge levels: individual questions – overall and by country.....	75
Table 15-4 Primary endpoints – individual scores: overall and by country	80
Table 15-5 Primary endpoints – composite score – overall, by country and by healthcare professional characteristics	81
Table 15-6 Primary endpoint – knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia (Q5c) – correct responders – overall, by country and by healthcare professional characteristics	87
Table 15-7 Primary endpoint – knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqray (Q6) – correct responders – overall, by country and by healthcare professional characteristics.....	94
Table 15-8 Primary endpoint – knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray (Q8b) – correct responders – overall, by country and by healthcare professional characteristics	101
Table 15-9 Primary endpoint – knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10) – Correct responders – overall, by country and by healthcare professional characteristics.....	108
Table 15-10 Primary endpoint – knowledge that for fasting glucose values that are ≤250 mg/dL (≤13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12) – correct responders – overall, by country and by healthcare professional characteristics	115

Table 15-11 Primary endpoint – knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13) – correct responders – overall, by country and by healthcare professional characteristics.....	122
Table 15-12 Primary endpoint – knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14) – correct responders – overall, by country and by healthcare professional characteristics	129
Table 15-13 Primary endpoint – knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15) – correct responders – overall, by country and by healthcare professional characteristics.....	135
Table 15-14 Other endpoints – knowledge levels: overall and by country	141
Table 15-15 Other endpoints – knowledge levels: receipt and reading of the Piqray Prescriber’s/HCP Guide for Hyperglycemia, overall and by country.	150
Table 15-16 Other endpoints – knowledge: primary source from which HCPs learned about the messages included in the Piqray Prescriber’s/HCP Guide for Hyperglycemia, overall and by country	152

List of figures

Figure 9-1 Study flow chart.....	19
Figure 10-1 HCP eligibility	28

1 Abstract

Title

Survey among healthcare professionals treating patients with metastatic breast cancer in selected European countries to evaluate their knowledge on management of hyperglycemia when using alpelisib

Version and date

Version 1.0 25-Apr-2025

NIS Type

NIS with Primary Data Collection

Name and affiliation of main author

██████████ PhD, MSPH

██████████

██████████

Keywords

Alpelisib, Breast Cancer, Hyperglycemia, PI3K (phosphatidylinositol 3-kinase) Inhibitor, Risk Minimization Measure

Rationale and background

Piqray (alpelisib) is an oral PI3K inhibitor approved by EMA for use with fulvestrant in treating HR-positive, HER2-negative, locally advanced or metastatic breast cancer (MBC) with a PIK3CA mutation after ET failure. Hyperglycemia is a side effect of PI3K inhibition. To mitigate this risk, Piqray was approved with an additional risk minimization measure, a prescriber's guide for hyperglycemia, as outlined in the EU RMP v1.3.

Under the EU RMP, Novartis conducted a Post-Authorization Safety Study (PASS), Study C2005, to assess the effectiveness of educational material among healthcare professionals treating MBC patients with Piqray in the EU/EEA.

Research question and objectives

Study C2005 assessed physicians' knowledge, understanding, and behavior relating to hyperglycemia management as per educational material and the (SmPC).

Study design

Study C2005 was a multinational, non-interventional, cross-sectional survey conducted to assess the effectiveness of Piqray educational materials among prescribers. The primary objective was to evaluate Healthcare Professional's (HCP) knowledge of hyperglycemia management in Piqray-treated patients.

Setting

The survey targeted HCPs from the Piqray educational materials dissemination list in 11 EU/EEA countries. Eligibility was determined through screening questions and consent to participate.

HCPs received a survey link, and eligible prescribers then completed the survey.

Subjects and study size, including dropouts

Inclusion Criteria

- Has prescribed Piqray to at least 1 locally advanced or MBC patient within 6 months prior to survey completion
- Provides permission to share their anonymized responses in aggregate with EMA or NCAs, if requested

Exclusion Criteria

- HCPs who are direct employees of Novartis, the EMA, [REDACTED].

The primary endpoint of Study C2005 was prescribers' knowledge of Piqray-associated hyperglycemia risks and recommended management practices, measured as the weighted composite percentage of correct responses to key questions.

A sample size of 100 HCPs was chosen to estimate the minimum knowledge level with a precision of 10.2% or better. With a targeted knowledge level of $\geq 70\%$, this sample size ensured a precision range of 9.4%-17.4% for the estimate.

Variables and data sources

Section 9.4

Statistical methods

All Study C2005 variables were analyzed using descriptive statistics to summarize HCP characteristics and other clinical variables of interest. Counts and percentages were provided when performing descriptive analysis of categorical data (n, %).

Results

In Study C2005, success criteria on the primary endpoint is defined as a weighted composite knowledge level of at least 70% across key questions. This endpoint was designed to assess overall knowledge retention and comprehension among HCPs. Overall, a composite score of 81.3% (95% CI: 79.1-83.4) was achieved by HCPs, thereby meeting the primary objective.

Discussion

The results suggest the Novartis provision of the SmPC and the Piqray Prescriber's/HCP Guide for Hyperglycemia were effective across all regions, with strong overall HCP understanding of hyperglycemia risks and management. Over 70% of HCPs achieved more than 70% accuracy, demonstrating effective knowledge retention and application.

Conclusion

The study met its primary endpoint, achieving a weighted composite knowledge score of 81.3% (95% CI: 79.1-83.4). Findings indicate strong awareness among HCPs regarding hyperglycemia risks, symptom identification, and pre-treatment considerations, supporting patient safety and treatment optimization.

The Piqray SmPC was the most cited educational source. Which highlights its importance in clinical decision-making.

Marketing Authorization Holder(s)

Novartis Europharm Limited

Name(s) and Affiliation(s) of Principal Investigator(s)

Not Applicable

2 List of abbreviations

ATC	Anatomical Therapeutic Code
CI	Confidence Interval
EC	Ethics Committee
EEA	European Economic Area
EMA	European Medicines Agency
ET	Endocrine Therapy
EU	European Union
FG	Fasting Glucose
FPG	Fasting Plasma Glucose
FMV	Fair Market Value
GVP	Good Pharmacovigilance Practices
HA	Health Authority
HbA1C	Hemoglobin A1C
HCP	Health Care Professional
HER2	Human Epidermal Growth Factor Receptor 2
HR	Human Receptor
MAH	Marketing Authorization Holder
MBC	Metastatic Breast Cancer
NCA	National Competent Authority
NIS	Non-Interventional Study
PI3K	Phosphatidylinositol 3-kinase
PASS	Post-Authorization Safety Study
RMP	Risk Management Plan
SmPC	Summary of Product Characteristics

3 Investigators

Not Applicable

4 Other responsible parties

Table 4-1 Other responsible parties

Role	Person
Main Author	[REDACTED], PhD, MSPH
Scientific Lead	[REDACTED], PhD, MSc, MLT

5 Milestones

Table 5-1 Study milestones

Milestone	Planned date	Actual date	Comments
Start of data collection	28-Feb-2021	28-Feb-2022	
End of data collection	30-Jun-2023	05-Jun-2024	
Registration in the EU PAS register	Prior to start of data collection	20-Jul-2021	
Final Study Report	31-May-2025	25-Apr-2025	

6 Rationale and background

Piqray (alpelisib) is an orally administered alpha specific PI3K (phosphatidylinositol 3-kinase) inhibitor indicated in the European Union/European Economic Area (EU/EEA) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative, locally advanced or metastatic breast cancer (MBC) with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy ([Piqray SmPC 2020](#)).

Hyperglycemia is an expected on-target effect of PI3K inhibition, since targeting p110 α can block glucose uptake into skeletal muscle and adipose tissue, resulting in hyperglycemia ([Goncalves et al 2018](#)). To minimize the risk of hyperglycemia (including life-threatening and fatal events), Piqray was approved with a requirement for an additional risk minimization measure using educational material. Piqray Prescriber's/HCP guide for hyperglycemia was agreed to be the educational material in the Piqray European Risk Management Plan (EU RMP) v1.3 (dated 19 May 2020), for which EC Decision was granted on 28 May 2020. The

educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray, for the identification and management of hyperglycemia.

As part of the EU RMP for Piqray, Novartis was required to conduct a Post-authorization Safety Study (PASS) to assess the effectiveness of the Piqray educational material among HCPs who treat patients with locally advanced or MBC in the EU/EEA. This CBYL719C2005 study (named hereafter as Study C2005) was designed and conducted in accordance with Good Pharmacovigilance Practices (GVP) Modules VIII and XVI for a Category 3 PASS.

7 Research question and Objectives

The objective of the Study C2005 non-interventional, cross-sectional survey, conducted in selected countries in the EU/EEA, was to assess prescribing physicians' knowledge, understanding, and behavior relating to the management of hyperglycemia as detailed in the educational material and Summary of Product Characteristics (SmPC) provided to them. Additional objectives were to evaluate the dissemination of the educational material and receipt of the materials.

The educational material provides additional guidance to the SmPC, to be used prior to and during treatment with Piqray, on the management of hyperglycemia, particularly focusing on testing fasting plasma glucose (FPG) and HbA1c, and optimizing blood glucose levels prior to treatment initiation, monitoring FG and HbA1c during treatment, and management of hyperglycemia if it occurs.

7.1 Primary Objective

The objective of Study C2005 was to assess HCPs' knowledge of the key information included in the Piqray Prescriber's/HCP Guide for hyperglycemia.

To meet this objective, the HCP survey assessed the HCP's knowledge of the:

- Risk of and risk factors for hyperglycemia
- Signs and symptoms of hyperglycemia
- Recommendations for monitoring for hyperglycemia prior to and during treatment with Piqray
- Recommendations for managing hyperglycemia during treatment with Piqray

The primary endpoint is a composite endpoint based on the percentages of HCPs with correct responses to all the above questions.

7.2 Secondary Objectives

The secondary objectives of Study C2005 were:

- To assess HCPs' reported levels of receipt and reading of the Piqray Prescriber's/HCP Guide for hyperglycemia

- To assess HCPs' knowledge levels for each survey question regarding knowledge of and management of hyperglycemia
- To assess the primary source from which HCPs learned about the messages included in the Piqray Prescriber's/HCP Guide for hyperglycemia

8 Amendments and updates to the protocol

Table 8-1 Amendments and updates to the protocol

Number	Date	Section of study protocol	Amendment or update	Reason
1	22-Oct-2021	2 and 4	Updated main author, survey countries, sample size, study milestones	Requested changes from HA
2	22-Oct-2021	7, 7.4, 7.5	Amend survey countries, sample size, survey period, inclusion of procedures to distribute surveys through local Novartis country affiliates, estimated percentage of survey completers	Requested changes from HA, survey distribution procedure added to potentially increase survey completion percentage
3	22-Oct-2021	7.6	Clarification that respondents will not be able to return to previously answered questions	Requested changes from HA
4	22-Oct-2021	7.7.2	Include plan to highlight gaps in HCP knowledge as demonstrated by survey results	Requested changes from HA
5	22-Oct-2021	7.10.1	Inclusion of procedure for survey translations and review by local Novartis affiliate	Added to clarify procedure for translating surveys into local language


9 Research methods

9.1 Study design

This was a multinational, non-interventional, cross-sectional survey to evaluate the effectiveness of the educational materials for Piqray. The survey was conducted among HCPs based in the EU/EEA who prescribe Piqray. The primary objective of the survey was to assess the knowledge of HCPs who prescribe Piqray, specifically regarding their understanding and management of hyperglycemia in patients who are being treated with Piqray. As per RMP requirement, the survey endeavored to collect a minimum of 100 completed surveys. The PASS was conducted in 11 countries in the EU/EEA where Piqray is reimbursed and commercially available: Austria, Croatia, Finland, Italy, Luxembourg, the Netherlands, Norway, Poland, Slovenia, Spain, and Sweden. This broad geographical reach helped ensure that the survey captured a diverse sample of HCPs practicing in different healthcare systems, which could provide valuable insights into the consistency of the knowledge regarding management of Piqray-induced hyperglycemia. To ensure that HCPs were familiar with the drug's use in real-world clinical settings, the HCPs were mandated, as per inclusion criteria of Study C2005, to have prescribed Piqray to at least one patient with locally advanced or MBC within the past 6 months.

HCPs were recruited from a targeted population of those who prescribe Piqray and were included in the distribution lists for the Piqray Prescriber's/HCP Guide for hyperglycemia. Invitations to participate in the survey were sent via e-mail, containing details about the survey, a unique access code, and instructions for participation. The data collection was conducted through a web-based survey across the 11 countries. HCPs who met the screening criteria were granted access to complete the full survey. Information collected included receipt and reading of the Piqray educational material, and knowledge of the key messages included in the Piqray educational materials. The survey questions are detailed within the protocol contained within [Appendix 1-Section 15.1.1](#). Recruitment took place after at least 6 months following the reimbursement and launch of Piqray in each participating country. Follow-up reminders were sent to non-respondents to support achieving the target sample size and reducing the impact of selection bias. [Figure 9-1](#) depicts recruitment and survey participation (also see the protocol contained within [Appendix 1-Section 15.1.1](#)).

Figure 9-1 Study flow chart



Source: [Appendix 1-Section 15.1.1](#)

9.2 Setting

The target population for completing this survey were HCPs who were part of the Piqrax educational materials dissemination list in any of the 11 participating countries.

Screening questions for eligibility and completion of an agreement to participate preceded the survey entry. The survey comprised a total of 20 questions collecting data on HCPs' characteristics, and their knowledge, understanding and management of hyperglycemia in patients treated with Piqrax. Questions were primarily in multiple choice or true/false format. "I do not know/I am not sure" was included as a response option in the understanding section and its selection was considered an incorrect response. The survey questions are detailed within the protocol contained within [Appendix 1-Section 15.1.1](#). Completion of the survey was expected to take approximately 20 minutes. A link to the survey and a unique code to enable access to the HCP were provided in the invitation. Upon entering the survey, HCPs were asked to choose their country and language. Following this selection, they were advanced to the HCP consulting agreement which they accepted or declined after reviewing its terms. If accepted, the HCPs then completed three eligibility screening questions. Only the eligible prescribers were able to continue to the main questions of the survey. During the data collection period of the survey, reports were extracted from the electronic data entry system on a weekly basis to track survey completion and response rates.

9.3 Subjects

9.3.1 Inclusion criteria

HCPs who met the following inclusion criteria were eligible to participate in the survey:

- Has prescribed Piqrax to at least 1 locally advanced or MBC patient within 6 months prior to completing the survey.
- Provides permission to share their anonymized responses in aggregate with EMA or NCAs, if requested.

9.3.2 Exclusion criteria

HCPs were considered as non-eligible for participation if they fulfilled any of the following criteria:

- HCPs who are direct employees of Novartis, the EMA, [REDACTED]

9.4 Variables

The survey questionnaire included a survey introduction and screening questions to ensure the HCP was eligible to participate in the survey. The main survey questions are described in [Section 9.4.1](#), [Section 9.4.2](#), [Section 9.4.3](#) and [Table 9-1](#), [Table 9-2](#), and [Table 15-2](#). The survey questions are also detailed within the protocol contained within [Appendix 1-Section 15.1.1](#).

9.4.1 Primary endpoint variables

In Study C2005, the primary endpoint variables were:

- Levels of knowledge of the risk for hyperglycemia, and risk factors for hyperglycemia, (survey question 4A, 6),
- Levels of knowledge of signs and symptoms of hyperglycemia (survey questions 5A-C),
- Levels of knowledge of recommendations for monitoring for hyperglycemia prior to, and during, treatment with Piqray (survey questions 8A-C, 10, 15), and
- Levels of knowledge of recommendations for managing hyperglycemia during treatment with Piqray (survey questions 12-14).

The primary endpoint is a composite endpoint that combines correct responses given by HCPs to questions included in the composite. Specifically, the primary endpoint is a weighted composite knowledge score aggregated across the following survey questions: 4A, 5A-C, 6, 8A-C, 10, and 12-15. It is calculated as the number of all correctly answered questions divided by the number of all answered questions (i.e. questions that were answered as either correct and not correct – unanswered questions are excluded).

Success criteria on the primary endpoint is defined as a weighted composite knowledge level of at least 70% across these key questions.

Table 9-1 Primary endpoints collected in the survey

Study C2005 objective assessed	Corresponding variable	Operational definition
Knowledge of the risk for hyperglycemia and risk factors for hyperglycemia	Knowledge that hyperglycemia is a risk associated with treatment with Piqray.	Calculated as the percentage of respondents who "Checked" question 4A
	Knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqray	Calculated as the percentage of respondents who responded only "body mass index <30 kg/m ² " for question 6
Knowledge of the signs and symptoms of hyperglycemia	Knowledge that excessive thirst is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who "Checked" question 5A
	Knowledge that increased frequency or amount of urination is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who "Checked" question 5B
	Knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who "Checked" question 5C

Study C2005 objective assessed	Corresponding variable	Operational definition
Knowledge of recommendations for monitoring for hyperglycemia prior to, and during, treatment with Piqray	Knowledge that a fasting glucose and HbA1c should be obtained before a patient starts treatment with Piqray	Calculated as the percentage of respondents who "Checked" question 8A
	Knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray	Calculated as the percentage of respondents who "Checked" question 8B
	Knowledge that the patient should be counselled about the risk of hyperglycemia before a patient starts treatment with Piqray	Calculated as the percentage of respondents who "Checked" question 8C
	Knowledge of when a FPG test should be performed after starting treatment with Piqray	Calculated as the percentage of respondents who responded "at weeks 1, 2, 4, 6, and 8, after treatment start, then monthly thereafter" to question 10
	Knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications	Calculated as the percentage of respondents who responded "weekly for at least 8 weeks, followed by once every 2 weeks, and consider consultation with a healthcare professional with expertise in the treatment of hyperglycemia" to question 15
Knowledge of recommendations for managing hyperglycemia during treatment with Piqray	Knowledge that for fasting glucose values that are ≤ 250 mg/dL (≤ 13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment	Calculated as the percentage of respondents who responded "true" to question 12
	Knowledge of which fasting glucose values require Piqray dosing to be interrupted	Calculated as the percentage of respondents who responded "any fasting glucose value > 250 mg/dL (> 13.9 mmol/L)" to question 13
	Knowledge that "if Piqray dosing is interrupted due to elevations in fasting glucose > 250 mg/dL (> 13.9 mmol/L), and fasting glucose decreases to ≤ 160 mg/dL (≤ 8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300mg/day" is not accurate	Calculated as the percentage of respondents who responded "false" to question 14

Source: [Appendix 1-Section 15.1.1](#)

9.4.2 Secondary endpoint variables

Other endpoints to be assessed include the following that are detailed in the table below. Corresponding analyses of these endpoints are detailed in [Table 15-2](#).

- Levels of reported receipt and reading of the Piqray Prescriber's/HCP Guide for hyperglycemia, assessed as the percentages of HCPs who report receipt and reading of the same (survey questions 1, 2)

- HCPs' knowledge levels for each survey question regarding knowledge of, and management of, hyperglycemia, assessed as the percentages of HCPs with correct responses to each question (survey questions 4-15)
- The distribution of responses regarding the primary source from which HCPs learned about the messages included in the Piqrax Prescriber's/HCP Guide for Hyperglycemia, assessed as the percentages of HCPs who report using each of the possible sources as the primary source they used (survey question 3).

9.4.3 Covariates

Covariates include HCP characteristics as shown in [Table 9-2](#) (also see the protocol contained within [Appendix 1-Section 15.1.1](#)).

Table 9-2 Covariates collected in the survey

Original data collected	Variable type	Operational definition/derivation
Primary medical specialty	Categorical	Surgeon/surgical oncologist, radiation oncologist/radiologist, medical oncologist, other
Years working with oncology patients	Categorical	<5 years, 5 to <10 years, 10 to <15 years, >15 years, prefer not to answer
Number of patients for which the HCP has prescribed Piqrax in past 12 months	Categorical	1-5 patients, 6-10 patients, >10 patients, I don't know/am not sure
Last time prescribed Piqrax	Categorical	<3 months ago, 3-6 months ago, I don't know/am not sure
Investigator for a Piqrax clinical trial	Categorical	Yes, no, I don't know/am not sure

Source: [Appendix 1-Section 15.1.1](#)

9.4.4 Survey administration and eligibility

The following variables were described overall and by country:

- Survey status:
 - Number and percentage of surveys with completed screening questions (question S1-S3, as applicable, the survey stopped as soon as the HCP was deemed ineligible, in which case subsequent screening questions were not applicable)
 - Number and percentage of surveys with all primary effectiveness endpoint questions completed (Questions 4A, 5A-C, 6, 8A-C, 10, 12-15)
 - Number and percentage of surveys with all primary and secondary endpoint questions completed (Questions 1-15)
- Eligibility (Yes/No):
 - If No, reasons for exclusion:

- HCP did not agree to share their anonymized survey responses, aggregated with all other survey responses, with the European Medicines Agency or National Competent Authorities
- HCP has not prescribed Piqray to at least 1 patient with locally advanced or metastatic breast cancer within the past 6 months
- HCP is direct employee of [REDACTED], Novartis, or the EMA
- Analysis sets (number and percentage of HCPs in the primary analysis set, and in the secondary analysis set)

9.5 Data sources and measurement

Invitations to participate were sent to 422 HCPs via e-mail. The invitation letter included information about the survey, a unique code, and instructions for accessing the survey. The unique code was used to track who had already completed a survey so that reminders were only sent to HCPs who had not yet completed the survey. All data for the survey were collected by web-based data capture. The survey was available for completion in English or the native language spoken in participating countries, depending on HCPs' preference.

As an acknowledgement of their time and input, HCPs who completed the survey received fair market value (FMV) compensation if allowed by local regulations. The FMV compensation was based on a survey that should take 20 minutes to complete.

9.6 Bias

A potential limitation of self-reporting is social desirability bias, where prescribers may have inaccurately reported information due to reluctance to acknowledge gaps in knowledge or attitudes and behaviors that do not align with societal expectations. This bias could have led to overreporting of guideline-adherent practices or underreporting of challenges faced in clinical decision-making, ultimately resulting in inaccurate or misleading study findings. Additionally, recall bias may have affected responses, as HCPs might have unintentionally misremembered or selectively reported their experiences.

To mitigate these biases, we administered the survey online rather than in person and ensured the anonymity of participating HCPs, which likely reduced pressure to provide socially desirable responses. However, conducting the survey online may have introduced selection bias, potentially excluding HCPs who are less comfortable with digital surveys or have limited internet access, though this number is expected to be low. Moreover, response bias could have influenced the results, as HCPs who chose to participate may differ systematically from HCPs who did not, potentially leading to an overrepresentation of HCPs with greater familiarity or engagement with Piqray prescribing practices.

Finally, relying solely on paper surveys, while reducing the risk of digital exclusion, would have increased respondent burden and potentially lowered participation rates, further influencing the generalizability of the findings.

9.7 Study size

The primary evaluation criteria (i.e., endpoints) are prescribers' knowledge of the risks of hyperglycemia with Piqray and practices recommended to minimize this risk, expressed as the weighted composite percentage of HCPs with correct responses to the key question set. The sample size is based on the primary endpoint; a sample size of 100 HCPs allows estimation of a minimum HCP knowledge level with a precision of 10.2% or better.

Table 9-3 provides the precision and corresponding 2-sided 95% exact confidence intervals (CI) around expected levels of knowledge by various numbers of completed surveys for Study C2005. With a targeted weighted composite knowledge level of $\geq 70\%$ for the primary endpoint, a sample size of 100 HCPs allows estimation of a minimum HCP knowledge level of at least 70% with a precision ranging between 9.4%-17.4% (Table 9-3).

Table 9-3 Precision and 95% confidence intervals for various combinations of sample size and knowledge levels

Sample Size	Range for Knowledge Level									
	50%		60%		70%		80%		90%	
	Pn (%)	95%CI	Pn (%)	95%CI	Pn (%)	95%CI	Pn (%)	95%CI	Pn (%)	95%CI
30	18.7	31.3-68.7	18.4	40.6-77.3	17.4	50.6-85.3	15.5	61.4-92.3	12.2	73.5-97.9
50	14.5	35.5-64.5	14.2	45.2-73.6	13.4	55.4-82.1	11.8	66.3-90.0	9.2	78.2-96.7
100	10.2	39.8-60.2	10	49.7-69.7	9.4	60.0-78.8	8.3	70.8-87.3	6.4	82.4-95.1
150	8.3	41.7-58.3	8.1	51.7-67.9	7.6	62.0-77.2	6.7	72.7-86.1	5.1	84.0-94.3
200	7.1	42.9-57.1	7.0	52.9-66.8	6.6	63.1-76.3	5.8	73.8-85.3	4.4	85.0-93.8
300	5.8	44.2-55.8	5.7	54.2-65.6	5.3	64.5-75.1	4.7	75.0-84.4	3.6	86.0-93.2

9.8 Data transformation

Not Applicable

9.9 Statistical methods

9.9.1 Main summary measures

Descriptive statistics were used to analyze responses of all HCPs. All variables in Study C2005 were categorical and summarized using frequencies and percentages. Additionally, 95% confidence intervals (CI) were presented for the proportions of HCPs with correct answers pertaining to the knowledge, understanding and management of hyperglycemia in patients treated with Piqray. No hypothesis testing was performed, as the analysis was purely descriptive. The data analysis was conducted using SAS version 9.4.

9.9.2 Main statistical methods

All Study C2005 variables were analyzed using descriptive statistics to summarize HCP characteristics and other clinical variables of interest. Counts and percentages were provided when performing descriptive analysis of categorical data (n, %).

Point-estimates with two-sided 95% confidence intervals (CIs) for percentages for binary data (i.e., Clopper- Pearson method, as appropriate) were calculated to describe the proportion of HCPs aware of the Piqray Prescriber's/HCP Guide for Hyperglycemia and assess HCPs' knowledge of the key information included in the Piqray Prescriber's/HCP Guide for hyperglycemia.

All endpoint questions are presented overall and by country.

9.9.3 Missing values

Missing data were reported, but no replacement or imputation was performed. To limit missing responses, the survey was set up in a manner that the HCPs were not allowed to skip any questions and had to respond to certain questions before proceeding to the next.

9.9.4 Sensitivity analyses

Not Applicable

9.9.5 Amendments to the statistical analysis plan

Not Applicable

9.10 Quality control

To ensure that the HCPs completed the survey, the electronic data entry system required that the HCPs answered certain questions before proceeding. The data was stored on a secure and validated cloud-based data storage system, with access for only authorized personnel from the Study C2005 team and their delegates.

10 Results

10.1 Participants

[Figure 10-1](#) depicts specific HCP eligibility. [Table 10-1](#) presents survey eligibility, overall, and by country.

Out of the 125 HCPs included in Study C2005, 22 HCPs (24.4%) were excluded from the analysis. The most common reason for exclusion was that the HCP had not prescribed Piqray to at least one patient with locally advanced or metastatic breast cancer (95.5%). The majority of these cases were in Italy, followed by Poland and the Netherlands.

[Table 10-2](#) presents the overall characteristics of the eligible HCPs, stratified by country.

Among the 103 eligible HCPs, 81.6% recorded oncologist as their primary medical specialty. The highest proportion of non-oncologists was observed in Austria (37.5%) and Croatia (50.0%). Regarding experience in oncology, most HCPs (46.6%) had 15 or more years of

experience, followed by 25.2% with 10 to less than 15 years, and 21.4% with 5 to less than 10 years. A very small proportion of HCPs (1.9%) had less than 5 years of experience. The largest proportion of HCPs who had 15 or more years of experience had practices in Norway (100%), Sweden (66.7%) and Croatia (65.0%).

In the past 12 months, 79.6% of HCPs had prescribed Piqray to 1-5 patients. Only 3.9% of HCPs prescribed Piqray to more than 10 patients. Regarding the last prescription, 54.4% of HCPs had prescribed Piqray within the past three months. A total of 26.2% of HCPs had served as investigators in Piqray clinical trials, with the highest proportion in Italy (69.2%) and Spain (42.9%). The majority (68.0%) of HCPs had not been involved in clinical trials related to Piqray.

Figure 10-1 HCP eligibility




Table 10-1 Survey eligibility, overall and by country

[illegible]

Table 10-2 Respondent characteristics overall and by country

	Overall N=103 n (%)	Austria N=8 n (%)	Croatia N=20 n (%)	Italy N=13 n (%)	Luxembourg N=2 n (%)	Netherlands N=18 n (%)	Norway N=1 n (%)	Poland N=12 n (%)	Slovenia N=9 n (%)	Spain N=14 n (%)	Sweden N=6 n (%)
Primary medical specialty (Q16)											
Oncologist*	84 (81.6)	5 (62.5)	10 (50.0)	12 (92.3)	2 (100)	13 (72.2)	1 (100)	12 (100)	9 (100)	14 (100)	6 (100)
Other	16 (15.5)	3 (37.5)	10 (50.0)	0 (-)	0 (-)	3 (16.7)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Missing Data	3 (2.9)	0 (-)	0 (-)	1 (7.7)	0 (-)	2 (11.1)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Years working with oncology patients (Q17)											
<5 years	2 (1.9)	0 (-)	0 (-)	0 (-)	0 (-)	1 (5.6)	0 (-)	0 (-)	0 (-)	1 (7.1)	0 (-)
5-<10 years	22 (21.4)	2 (25.0)	5 (25.0)	2 (15.4)	1 (50.0)	5 (27.8)	0 (-)	0 (-)	4 (44.4)	3 (21.4)	0 (-)
10-<15 years	26 (25.2)	1 (12.5)	2 (10.0)	4 (30.8)	1 (50.0)	4 (22.2)	0 (-)	5 (41.7)	3 (33.3)	4 (28.6)	2 (33.3)
≥15 years	48 (46.6)	4 (50.0)	13 (65.0)	6 (46.2)	0 (-)	6 (33.3)	1 (100)	6 (50.0)	2 (22.2)	6 (42.9)	4 (66.7)
Prefer not to answer	2 (1.9)	1 (12.5)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	1 (8.3)	0 (-)	0 (-)	0 (-)
Missing Data	3 (2.9)	0 (-)	0 (-)	1 (7.7)	0 (-)	2 (11.1)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Within the past 12 months, how many patients have you prescribed Piqray (Q18)											
1-5	82 (79.6)	4 (50.0)	15 (75.0)	8 (61.5)	2 (100)	15 (83.3)	0 (-)	12 (100)	8 (88.9)	13 (92.9)	5 (83.3)
6-10	11 (10.7)	3 (37.5)	4 (20.0)	0 (-)	0 (-)	0 (-)	1 (100)	0 (-)	1 (11.1)	1 (7.1)	1 (16.7)
>10	4 (3.9)	1 (12.5)	1 (5.0)	1 (7.7)	0 (-)	1 (5.6)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
I don't know/am not sure	3 (2.9)	0 (-)	0 (-)	3 (23.1)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Missing Data	3 (2.9)	0 (-)	0 (-)	1 (7.7)	0 (-)	2 (11.1)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Last time you prescribed Piqray (Q19)											
<3 months ago	56 (54.4)	5 (62.5)	12 (60.0)	3 (23.1)	2 (100)	12 (66.7)	1 (100)	6 (50.0)	4 (44.4)	6 (42.9)	5 (83.3)
3-<6 months ago	33 (32.0)	2 (25.0)	6 (30.0)	6 (46.2)	0 (-)	4 (22.2)	0 (-)	5 (41.7)	2 (22.2)	7 (50.0)	1 (16.7)

	Overall N=103 n (%)	Austria N=8 n (%)	Croatia N=20 n (%)	Italy N=13 n (%)	Luxembourg N=2 n (%)	Netherlands N=18 n (%)	Norway N=1 n (%)	Poland N=12 n (%)	Slovenia N=9 n (%)	Spain N=14 n (%)	Sweden N=6 n (%)
I don't know/am not sure	10 (9.7)	1 (12.5)	2 (10.0)	2 (15.4)	0 (-)	0 (-)	0 (-)	1 (8.3)	3 (33.3)	1 (7.1)	0 (-)
Missing Data	4 (3.9)	0 (-)	0 (-)	2 (15.4)	0 (-)	2 (11.1)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Past investigator for one of the Piqray clinical trials (Q20)											
Yes	27 (26.2)	1 (12.5)	3 (15.0)	9 (69.2)	0 (-)	4 (22.2)	0 (-)	1 (8.3)	2 (22.2)	6 (42.9)	1 (16.7)
No	70 (68.0)	6 (75.0)	17 (85.0)	2 (15.4)	2 (100)	11 (61.1)	1 (100)	11 (91.7)	7 (77.8)	8 (57.1)	5 (83.3)
I don't know/am not sure	2 (1.9)	1 (12.5)	0 (-)	0 (-)	0 (-)	1 (5.6)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
Missing Data	4 (3.9)	0 (-)	0 (-)	2 (15.4)	0 (-)	2 (11.1)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)

N=Number of eligible healthcare professionals

*Oncologist= "Surgeon/surgical oncologist" + "Radiation oncologist/radiologist" + "Medical oncologist"

10.2 Descriptive data

Not Applicable

10.3 Outcome data

Study C2005 was purely descriptive in nature, focusing on the analysis of survey data rather than evaluating outcomes or predictors. The aim is to summarize and describe the characteristics, experiences, and behaviors of HCPs in relation to Piqray and the management of hyperglycemia in patients. The data collected through the survey are analyzed to provide insights into HCPs' specialties, experience, prescribing patterns, and involvement in clinical trials, without testing causal relationships or examining predictors of specific outcomes.

10.4 Main results

10.4.1 HCPs' knowledge of the key information included in the Piqray prescriber's / HCP guide for hyperglycemia

Table 10-3 illustrates HCPs' knowledge of the risk for hyperglycemia and risk factors for hyperglycemia associated with Piqray treatment. Nearly all HCPs (98.0%) correctly identified hyperglycemia as a risk associated with Piqray treatment. Additionally, knowledge of key symptoms, such as excessive thirst (97.1%) and increased urination (96.1%), was also very high. Knowledge that increased appetite with weight loss is a sign of hyperglycemia was 76.5%.

Understanding of risk factors for developing hyperglycemia while taking Piqray was also relatively strong, with 77.5% recognizing that diabetes, elevated fasting glucose levels, and age over 75 are additional risk factors.

Regarding best practices before initiating Piqray treatment, there was strong awareness of the need to obtain fasting glucose and HbA1c levels (93.1%) and to counsel patients about the risk of hyperglycemia (90.2%). However, fewer HCPs (72.5%) recognized the importance of optimizing blood glucose levels prior to starting treatment and 74.8% recognized the importance of performing a FPG test after starting treatment with Piqray.

While 88.3% of HCPs correctly identified that fasting glucose values ≤ 250 mg/dL (≤ 13.9 mmol/L) do not require a Piqray dose adjustment, 80.2% knew which values necessitate an interruption of Piqray dosing. Furthermore, knowledge of the accuracy of Piqray resumption guidelines following glucose elevation was lower (63.0%), highlighting a potential gap in understanding appropriate dose adjustments based on glucose fluctuations.

Knowledge of how frequently fasting glucose should be monitored when hyperglycemia occurs in patients receiving antihyperglycemic medications was identified correctly by 50.0% of HCPs.

Table 10-3 Primary endpoints – knowledge levels: Individual questions – overall

	Overall N=103 n/M (%) 95% CI
Knowledge that hyperglycemia is a risk associated with treatment with Piqray (Q4a)	100/102 (98.0) [93.1; 99.8]

	Overall N=103 n/M (%) 95% CI
Knowledge that excessive thirst is a sign/symptom of hyperglycemia (Q5a)	99/102 (97.1) [91.6; 99.4]
Knowledge that increased frequency or amount of urination is a sign/symptom of hyperglycemia (Q5b)	98/102 (96.1) [90.3; 98.9]
Knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia (Q5c)	78/102 (76.5) [67.0; 84.3]
Knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqray (Q6)	79/102 (77.5) [68.1; 85.1]
Knowledge that a fasting glucose and HbA1c should be obtained before a patient starts treatment with Piqray (Q8a)	95/102 (93.1) [86.4; 97.2]
Knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray (Q8b)	74/102 (72.5) [62.8; 80.9]
Knowledge that the patient should be counselled about the risk of hyperglycemia before a patient starts treatment with Piqray (Q8c)	92/102 (90.2) [82.7; 95.2]
Knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10)	77/103 (74.8) [65.2; 82.8]
Knowledge that for fasting glucose values that are ≤250 mg/dL (≤13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12)	91/103 (88.3) [80.5; 93.8]
Knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13)	81/101 (80.2) [71.1; 87.5]
Knowledge that "if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day" is not accurate (Q14)	63/100 (63.0) [52.8; 72.4]
Knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15)	50/100 (50.0) [39.8; 60.2]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals who answered the question; CI=Confidence Interval.

Source: [Table 15-3](#)

10.4.2 Primary endpoints – composite score: overall and by country

[Table 10-5](#) displays the composite scores by deciles. [Table 10-4](#) illustrates the composite score for all HCPs, overall and by country.

The success criteria on the primary endpoint was defined as an observed estimate of the weighted composite knowledge of at least 70% across these key questions.

The primary endpoints were aggregated, and a composite knowledge score was calculated as the number of all correctly answered questions divided by the number of all answered questions.

Overall, a composite score of 81.3% [95% CI: 79.1-83.4] was achieved by HCPs thereby meeting the primary objective ([Table 10-4](#)). Among the individual countries, Luxembourg and Slovenia exhibited the highest scores (92.3%, 95% CI: 74.9%-99.1% and 92.3%, 95% CI: 85.9%-96.4%, respectively). In contrast, Norway, with only 1 HCP, recorded the lowest composite score (69.2%, 95% CI: 38.6-90.9) and the only score below the 70% threshold.

Among HCPs, 36.9% (n=38) correctly answered more than 90% of the primary endpoint questions, followed by 21.4% (n=22) who answered more than 80 to -90% correctly. Additionally, 15.5% (n=16) answered more than 70 to 80% correctly, while 17.5% (n=18) answered more than 60 to 70% correctly ([Table 10-5](#)).

Table 10-4 Primary endpoints – composite score: overall and by country

	Overall N=103	Austria N=8	Croatia N=20	Italy N=13	Luxembourg N=2	Netherlands N=18	Norway N=1	Poland N=12	Slovenia N=9	Spain N=14	Sweden N=6
	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)	q/Q (%)
	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI
Composite primary endpoint*											
	1057/1300	82/104	214/260	115/156	24/26	174/208	9/13	122/156	108/117	151/182	58/78
	(81.3)	(78.8)	(82.3)	(73.7)	(92.3)	(83.7)	(69.2)	(78.2)	(92.3)	(83.0)	(74.4)
	[79.1; 83.4]	[69.7; 86.2]	[77.1; 86.7]	[66.1; 80.4]	[74.9; 99.1]	[77.9; 88.4]	[38.6; 90.9]	[70.9; 84.4]	[85.9; 96.4]	[76.7; 88.1]	[63.2; 83.6]

N=Number of eligible healthcare professionals; CI=Confidence Interval.

*Weighted composite knowledge score (i.e., primary endpoint) is an aggregate of the following survey questions: 4A, 5A-C, 6, 8A-C, 10, and 12-15. It is calculated as q, the number of all correctly answered questions divided by Q, the number of all answered questions (i.e., questions that were answered either correct or not correct – unanswered questions are excluded). Success criteria on the primary endpoint is defined as the observed estimate of the weighted composite knowledge level of at least 70% across these key questions.

Table 10-5 Primary Endpoints – Individual Scores: Overall

			Overall N=103 n (%)
Composite percentage correct (%)	primary endpoint*	individual	
0-10			0 (-)
>10-20			1 (1.0)
>20-30			0 (-)
>30-40			1 (1.0)
>40-50			2 (1.9)
>50-60			2 (1.9)
>60-70			18 (17.5)
>70-80			16 (15.5)
>80-90			22 (21.4)
>90-100			38 (36.9)
Missing			3 (2.9)

N=Number of eligible healthcare professionals

*Composite primary endpoint percentage per individual is calculated by dividing the number of all correctly answered questions per the number of all answered questions (i.e., questions that were answered either correct or not correct - unanswered questions are excluded). Success criteria on the primary endpoint is defined as the observed estimate of the weighted composite knowledge level of at least 70% across these key questions.

Source: [Table 15-4](#)

10.4.3 Primary endpoints – composite score – overall and by healthcare professional characteristics

Table 10-6 presents composite scores by country and HCP characteristics.

Oncologists had an overall composite score of 80.7% whereas other specialties had an overall composite score of 84.6%. HCPs with 5–<10 years of oncology experience showed the highest composite scores (87.4%; 250/286), while HCPs with less than five years had the lowest (65.4%; 17/26).

When comparing the composite scores in relation to the number of patients the HCP treated with Piqray within the past 12 months, HCPs who prescribed Piqray to more than 10 patients had the highest composite scores at 92.3%. HCPs who prescribed Piqray within the last three months had a similar composite score at 83.4% as HCPs who last prescribed it 3–6 months ago at 79.7%.

HCPs who reported receiving the Piqray Prescriber's/HCP Guide for Hyperglycemia scored 82.3%, while HCPs who reported not receiving it scored 74.7%. HCPs who read the guide entirely had a similar score (83.2%) as HCPs who read only part of it (81.4%). Of note, the reading question only applied to those who acknowledged receiving the guide. Similarly, scores were similar between HCPs who were past investigators in clinical trials and non-investigators with scores at 80.9% and 81.9%, respectively.

Table 10-6 Primary endpoints – composite score – by healthcare professional characteristics

	Overall N=100 q/Q (%) 95% CI
Primary medical specialty (Q16)	
Oncologist**	881/1092 (80.7) [78.2; 83.0]
Other	176/208 (84.6) [79.0; 89.2]
Years working with oncology patients (Q17)	
<5 years	17/26 (65.4) [44.3; 82.8]
5–<10 years	250/286 (87.4) [83.0; 91.0]
10–<15 years	273/338 (80.8) [76.2; 84.8]
≥15 years	510/624 (81.7) [78.5; 84.7]
Prefer not to answer	7/26 (26.9) [11.6; 47.8]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1–5	870/1066 (81.6) [79.2; 83.9]
6–10	108/143 (75.5) [67.6; 82.3]
>10	48/52 (92.3) [81.5; 97.9]
I don't know/am not sure	31/39 (79.5) [63.5; 90.7]
Last time you prescribed Piqray (Q19)	
<3 months ago	607/728 (83.4) [80.5; 86.0]
3–<6 months ago	342/429 (79.7) [75.6; 83.4]

	Overall N=100 q/Q (%) 95% CI
I don't know/am not sure	95/130 (73.1) [64.6; 80.5]
Missing Data	13/13 (100) [75.3; 100.0]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	284/351 (80.9) [76.4; 84.9]
No	745/910 (81.9) [79.2; 84.3]
I don't know/am not sure	15/26 (57.7) [36.9; 76.6]
Missing Data	13/13 (100) [75.3; 100.0]
Received the Guide for HCPs (Q1)	
Yes	909/1105 (82.3) [79.9; 84.5]
No	68/91 (74.7) [64.5; 83.3]
I don't know/am not sure	80/104 (76.9) [67.6; 84.6]
Read the Guide for HCPs (Q2)	
Yes***	890/1079 (82.5) [80.1; 84.7]
Yes, all of it	541/650 (83.2) [80.1; 86.0]
Yes, some of it	349/429 (81.4) [77.3; 84.9]
No	8/13 (61.5) [31.6; 86.1]
I don't know/am not sure	11/13 (84.6) [54.6; 98.1]
Missing Data	148/195 (75.9) [69.3; 81.7]

N=Number of eligible healthcare professionals with an individual composite primary endpoint score;
CI=Confidence Interval.

*Weighted composite knowledge score (i.e., primary endpoint) is an aggregate of the following survey questions: 4A, 5A-C, 6, 8A-C, 10, and 12-15. It is calculated as q, the number of all correctly answered questions divided by Q, the number of all answered questions (i.e., questions that were answered either correct or not correct – unanswered questions are excluded). Success criteria on the primary endpoint is defined as the observed estimate of the weighted composite knowledge level of at least 70% across these key questions.

**Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

***Yes= "Yes, some of it" + "Yes, all of it".

Source: [Table 15-5](#)

10.4.4 Primary endpoint – knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia (Q5c) – correct responders – overall and by healthcare professional characteristics

[Table 10-7](#) describes the proportion of correct responses to knowledge of increased appetite with weight loss as a sign/ symptom of hyperglycemia by HCP characteristics. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question ([Table 10-3](#), [Table 10-7](#)): 78 out of 102 HCPs answered correctly
- 76.2% of oncologists answered correctly and 87.5% of other specialists answered correctly
- Both HCPs who had less than 5 years of experience answered this question correctly

- All HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 78.6% of HCPs who prescribed Piqray within the last three months answered correctly, and 78.8% of those who prescribed Piqray in the last 3-6 months answered correctly
- 59.3% of HCPs who were previously an investigator for one of the Piqray clinical trials answered correctly
- 75.9% of HCPs who received the HCP guide answered correctly
- 75.3% of HCPs who reported reading the HCP guide answered correctly

Table 10-7 Primary endpoint – knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia (Q5c) – correct responders – by healthcare professional characteristics

	Overall N=102 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	64/84 (76.2) [65.7; 84.8]
Other	14/16 (87.5) [61.7; 98.4]
Missing Data	0/2 (0.0) [0.0; 84.2]
Years working with oncology patients (Q17)	
<5 years	2/2 (100.0) [15.8; 100.0]
5-<10 years	16/22 (72.7) [49.8; 89.3]
10-<15 years	21/26 (80.8) [60.6; 93.4]
≥15 years	38/48 (79.2) [65.0; 89.5]
Prefer not to answer	1/2 (50.0) [1.3; 98.7]
Missing Data	0/2 (0.0) [0.0; 84.2]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	65/82 (79.3) [68.9; 87.4]
6-10	7/11 (63.6) [30.8; 89.1]
>10	4/4 (100.0) [39.8; 100.0]
I don't know/am not sure	2/3 (66.7) [9.4; 99.2]
Missing Data	0/2 (0.0) [0.0; 84.2]
Last time you prescribed Piqray (Q19)	
<3 months ago	44/56 (78.6) [65.6; 88.4]
3-<6 months ago	26/33 (78.8) [61.1; 91.0]
I don't know/am not sure	7/10 (70.0) [34.8; 93.3]
Missing Data	1/3 (33.3) [0.8; 90.6]

	Overall N=102 n/M (%) 95% CI
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	16/27 (59.3) [38.8; 77.6]
No	60/70 (85.7) [75.3; 92.9]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	1/3 (33.3) [0.8; 90.6]
Received the Guide for HCPs (Q1)	
Yes	66/87 (75.9) [65.5; 84.4]
No	7/7 (100.0) [59.0; 100.0]
I don't know/am not sure	5/8 (62.5) [24.5; 91.5]
Read the Guide for HCPs (Q2)	
Yes**	64/85 (75.3) [64.7; 84.0]
Yes, all of it	38/51 (74.5) [60.4; 85.7]
Yes, some of it	26/34 (76.5) [58.8; 89.3]
No	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	1/1 (100.0) [2.5; 100.0]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Source: [Table 15-6](#)

10.4.5 Primary endpoint – knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqray (Q6) – correct responders – overall and by healthcare professional characteristics

[Table 10-8](#) describes the characteristics of HCPs who correctly identified the risk factors for developing hyperglycemia while taking Piqray. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question ([Table 10-3](#), [Table 10-8](#)): 79 out of 102 HCPs answered correctly
- 73.8% of oncologists answered correctly and 93.8% of other specialists answered correctly
- One of the two HCPs who had less than 5 years of experience answered this question correctly
- All HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 78.6% of HCPs who prescribed Piqray within the last three months answered correctly, and 75.8% of those who prescribed Piqray in the last 3-6 months answered correctly
- 81.5% of HCPs who were previously an investigator for one of the Piqray clinical trials answered correctly
- 78.2% of HCPs who received the HCP guide answered correctly
- 80.0% of HCPs who reported reading the HCP guide answered correctly

Table 10-8 Primary endpoint – knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqray (Q6) – correct responders – by healthcare professional characteristics

	Overall N=102 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	62/84 (73.8) [63.1; 82.8]
Other	15/16 (93.8) [69.8; 99.8]
Missing Data	2/2 (100.0) [15.8; 100.0]
Years working with oncology patients (Q17)	
<5 years	1/2 (50.0) [1.3; 98.7]
5-<10 years	20/22 (90.9) [70.8; 98.9]
10-<15 years	18/26 (69.2) [48.2; 85.7]
≥15 years	38/48 (79.2) [65.0; 89.5]
Prefer not to answer	0/2 (0.0) [0.0; 84.2]
Missing Data	2/2 (100.0) [15.8; 100.0]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	63/82 (76.8) [66.2; 85.4]
6-10	8/11 (72.7) [39.0; 94.0]
>10	4/4 (100.0) [39.8; 100.0]
I don't know/am not sure	2/3 (66.7) [9.4; 99.2]
Missing Data	2/2 (100.0) [15.8; 100.0]
Last time you prescribed Piqray (Q19)	
<3 months ago	44/56 (78.6) [65.6; 88.4]
3-<6 months ago	25/33 (75.8) [57.7; 88.9]
I don't know/am not sure	7/10 (70.0) [34.8; 93.3]
Missing Data	3/3 (100.0) [29.2; 100.0]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	22/27 (81.5) [61.9; 93.7]
No	53/70 (75.7) [64.0; 85.2]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	3/3 (100.0) [29.2; 100.0]
Received the Guide for HCPs (Q1)	
Yes	68/87 (78.2) [68.0; 86.3]
No	4/7 (57.1) [18.4; 90.1]
I don't know/am not sure	7/8 (87.5) [47.3; 99.7]
Read the Guide for HCPs (Q2)	
Yes**	68/85 (80.0) [69.9; 87.9]

	Overall N=102 n/M (%) 95% CI
Yes, all of it	42/51 (82.4) [69.1; 91.6]
Yes, some of it	26/34 (76.5) [58.8; 89.3]
No	0/1 (0.0) [0.0; 97.5]
I don't know/am not sure	0/1 (0.0) [0.0; 97.5]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Source: [Table 15-7](#)

10.4.6 Primary endpoint – knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray (Q8b) – correct responders – overall and by healthcare professional characteristics

Table 10-9 describes the characteristics of HCPs who correctly identified that blood glucose levels should be optimized before start of Piqray treatment. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question (Table 10-3, Table 10-9): 74 out of 102 HCPs answered correctly
- 71.4% of oncologists answered correctly and 75.0% of other specialists answered correctly
- 50% of HCPs who had less than 5 years of experience answered this question correctly
- All HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 67.9% who prescribed Piqray within the last three months answered correctly, and 72.7% of those who prescribed Piqray in the last 3-6 months answered correctly
- 63.0% who were previously an investigator for one of the Piqray clinical trials answered correctly
- 70.1% of HCPs who received the HCP guide answered correctly
- 69.4% of HCPs who reported reading the HCP guide answered correctly

Table 10-9 Primary endpoint – knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray (Q8b) – correct responders – by healthcare professional characteristics

	Overall N=102 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	60/84 (71.4) [60.5; 80.8]
Other	12/16 (75.0) [47.6; 92.7]
Missing Data	2/2 (100.0) [15.8; 100.0]
Years working with oncology patients (Q17)	
<5 years	1/2 (50.0) [1.3; 98.7]
5-<10 years	17/22 (77.3) [54.6; 92.2]
10-<15 years	17/26 (65.4) [44.3; 82.8]
≥15 years	37/48 (77.1) [62.7; 88.0]
Prefer not to answer	0/2 (0.0) [0.0; 84.2]
Missing Data	2/2 (100.0) [15.8; 100.0]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	56/82 (68.3) [57.1; 78.1]
6-10	9/11 (81.8) [48.2; 97.7]
>10	4/4 (100.0) [39.8; 100.0]
I don't know/am not sure	3/3 (100.0) [29.2; 100.0]
Missing Data	2/2 (100.0) [15.8; 100.0]
Last time you prescribed Piqray (Q19)	
<3 months ago	38/56 (67.9) [54.0; 79.7]
3-<6 months ago	24/33 (72.7) [54.5; 86.7]
I don't know/am not sure	9/10 (90.0) [55.5; 99.7]
Missing Data	3/3 (100.0) [29.2; 100.0]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	17/27 (63.0) [42.4; 80.6]
No	53/70 (75.7) [64.0; 85.2]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	3/3 (100.0) [29.2; 100.0]
Received the Guide for HCPs (Q1)	
Yes	61/87 (70.1) [59.4; 79.5]
No	6/7 (85.7) [42.1; 99.6]
I don't know/am not sure	7/8 (87.5) [47.3; 99.7]
Read the Guide for HCPs (Q2)	
Yes**	59/85 (69.4) [58.5; 79.0]

	Overall N=102 n/M (%) 95% CI
Yes, all of it	40/51 (78.4) [64.7; 88.7]
Yes, some of it	19/34 (55.9) [37.9; 72.8]
No	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	1/1 (100.0) [2.5; 100.0]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it"

Source: [Table 15-8](#)

10.4.7 Primary endpoint – knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10) – correct responders – overall and by healthcare professional characteristics

Table 10-10 describes the characteristics of HCPs who are knowledgeable about the timing of testing FPG after starting Piqray. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question (Table 10-3, Table 10-10): 77 out of 103 HCPs answered correctly
- 76.2% of oncologists answered correctly and 68.8% of other specialists answered correctly
- 50% of HCPs who had less than 5 years of experience answered this question correctly
- 75.0% of HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 78.6% of HCPs who prescribed Piqray within the last three months answered correctly, and 78.8% of those who prescribed Piqray in the last 3-6 months answered correctly
- 81.5% who were previously an investigator for one of the Piqray clinical trials answered correctly
- 78.4% of HCPs who received the HCP guide answered correctly
- 79.1% of HCPs who reported reading the HCP guide answered correctly

Table 10-10 Primary endpoint – knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10) – correct responders – by healthcare professional characteristics

	Overall N=103 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	64/84 (76.2) [65.7; 84.8]
Other	11/16 (68.8) [41.3; 89.0]
Missing Data	2/3 (66.7) [9.4; 99.2]
Years working with oncology patients (Q17)	
<5 years	1/2 (50.0) [1.3; 98.7]
5-<10 years	20/22 (90.9) [70.8; 98.9]
10-<15 years	20/26 (76.9) [56.4; 91.0]
≥15 years	34/48 (70.8) [55.9; 83.0]
Prefer not to answer	0/2 (0.0) [0.0; 84.2]
Missing Data	2/3 (66.7) [9.4; 99.2]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	63/82 (76.8) [66.2; 85.4]
6-10	7/11 (63.6) [30.8; 89.1]
>10	3/4 (75.0) [19.4; 99.4]
I don't know/am not sure	2/3 (66.7) [9.4; 99.2]
Missing Data	2/3 (66.7) [9.4; 99.2]
Last time you prescribed Piqray (Q19)	
<3 months ago	44/56 (78.6) [65.6; 88.4]
3-<6 months ago	26/33 (78.8) [61.1; 91.0]
I don't know/am not sure	4/10 (40.0) [12.2; 73.8]
Missing Data	3/4 (75.0) [19.4; 99.4]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	22/27 (81.5) [61.9; 93.7]
No	51/70 (72.9) [60.9; 82.8]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	3/4 (75.0) [19.4; 99.4]
Received the Guide for HCPs (Q1)	
Yes	69/88 (78.4) [68.4; 86.5]
No	4/7 (57.1) [18.4; 90.1]
I don't know/am not sure	4/8 (50.0) [15.7; 84.3]
Read the Guide for HCPs (Q2)	
Yes**	68/86 (79.1) [69.0; 87.1]

	Overall N=103 n/M (%) 95% CI
Yes, all of it	41/52 (78.8) [65.3; 88.9]
Yes, some of it	27/34 (79.4) [62.1; 91.3]
No	0/1 (0.0) [0.0; 97.5]
I don't know/am not sure	1/1 (100.0) [2.5; 100.0]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it"

Source: [Table 15-9](#)

10.4.8 Primary endpoint – knowledge that for fasting glucose values that are ≤ 250 mg/dL (≤ 13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12) – correct responders – overall and by healthcare professional characteristics

Table 10-11 describes the characteristics of HCPs who were aware that for fasting glucose values that are ≤ 250 mg/dL (≤ 13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question (Table 10-3, Table 10-11): 91 out of 103 HCPs answered correctly
- 85.7% of oncologists answered correctly and 100.0% of other specialists answered correctly
- All HCPs who had less than 5 years of experience answered this question correctly
- All HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 92.9% of HCPs who prescribed Piqray within the last three months answered correctly, and 84.8% of those who prescribed Piqray in the last 3-6 months answered correctly
- 85.2% of HCPs who were previously an investigator for one of the Piqray clinical trials answered correctly
- 88.6% of HCPs who received the HCP guide answered correctly
- 88.4% of HCPs who reported reading the HCP guide answered correctly

Table 10-11 Primary endpoint – knowledge that for fasting glucose values that are ≤ 250 mg/dL (≤ 13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12) – correct responders – by healthcare professional characteristics

	Overall N=103 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	72/84 (85.7) [76.4; 92.4]
Other	16/16 (100.0) [79.4; 100.0]
Missing Data	3/3 (100.0) [29.2; 100.0]
Years working with oncology patients (Q17)	
<5 years	2/2 (100.0) [15.8; 100.0]
5-<10 years	20/22 (90.9) [70.8; 98.9]
10-<15 years	23/26 (88.5) [69.8; 97.6]
≥ 15 years	42/48 (87.5) [74.8; 95.3]
Prefer not to answer	1/2 (50.0) [1.3; 98.7]
Missing Data	3/3 (100.0) [29.2; 100.0]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	72/82 (87.8) [78.7; 94.0]
6-10	10/11 (90.9) [58.7; 99.8]
>10	4/4 (100.0) [39.8; 100.0]
I don't know/am not sure	2/3 (66.7) [9.4; 99.2]
Missing Data	3/3 (100.0) [29.2; 100.0]
Last time you prescribed Piqray (Q19)	
<3 months ago	52/56 (92.9) [82.7; 98.0]
3-<6 months ago	28/33 (84.8) [68.1; 94.9]
I don't know/am not sure	7/10 (70.0) [34.8; 93.3]
Missing Data	4/4 (100.0) [39.8; 100.0]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	23/27 (85.2) [66.3; 95.8]
No	63/70 (90.0) [80.5; 95.9]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	4/4 (100.0) [39.8; 100.0]
Received the Guide for HCPs (Q1)	
Yes	78/88 (88.6) [80.1; 94.4]
No	5/7 (71.4) [29.0; 96.3]
I don't know/am not sure	8/8 (100.0) [63.1; 100.0]
Read the Guide for HCPs (Q2)	
Yes**	76/86 (88.4) [79.7; 94.3]

	Overall N=103 n/M (%) 95% CI
Yes, all of it	48/52 (92.3) [81.5; 97.9]
Yes, some of it	28/34 (82.4) [65.5; 93.2]
No	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	1/1 (100.0) [2.5; 100.0]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Source: [Table 15-10](#)

10.4.9 Primary endpoint – knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13) – correct responders – overall and by healthcare professional characteristics

Table 10-12 describes the knowledge of Piqray dose interruption regimens based on FPG values by HCP characteristics. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question (Table 10-3, Table 10-12): 81 out of 101 HCPs answered correctly
- 84.5% of oncologists answered correctly and 56.3% of other specialists answered correctly
- All HCPs who had less than 5 years of experience answered this question correctly
- 75.0% of HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 78.6% who prescribed Piqray within the last three months answered correctly, and of those who prescribed Piqray in the last 3-6 months answered correctly
- 85.2% of HCPs who were previously an investigator for one of the Piqray clinical trials answered correctly
- 84.9% of HCPs who received the HCP guide answered correctly
- 84.5% of HCPs who reported reading the HCP guide answered correctly

Table 10-12 Primary endpoint – knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13) – correct responders – by healthcare professional characteristics

	Overall N=101 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	71/84 (84.5) [75.0; 91.5]
Other	9/16 (56.3) [29.9; 80.2]
Missing Data	1/1 (100.0) [2.5; 100.0]
Years working with oncology patients (Q17)	
<5 years	2/2 (100.0) [15.8; 100.0]
5-<10 years	19/22 (86.4) [65.1; 97.1]
10-<15 years	21/26 (80.8) [60.6; 93.4]
≥15 years	37/48 (77.1) [62.7; 88.0]
Prefer not to answer	1/2 (50.0) [1.3; 98.7]
Missing Data	1/1 (100.0) [2.5; 100.0]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	69/82 (84.1) [74.4; 91.3]
6-10	6/11 (54.5) [23.4; 83.3]
>10	3/4 (75.0) [19.4; 99.4]
I don't know/am not sure	2/3 (66.7) [9.4; 99.2]
Missing Data	1/1 (100.0) [2.5; 100.0]
Last time you prescribed Piqray (Q19)	
<3 months ago	44/56 (78.6) [65.6; 88.4]
3-<6 months ago	29/33 (87.9) [71.8; 96.6]
I don't know/am not sure	6/10 (60.0) [26.2; 87.8]
Missing Data	2/2 (100.0) [15.8; 100.0]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	23/27 (85.2) [66.3; 95.8]
No	55/70 (78.6) [67.1; 87.5]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	2/2 (100.0) [15.8; 100.0]
Received the Guide for HCPs (Q1)	
Yes	73/86 (84.9) [75.5; 91.7]
No	4/7 (57.1) [18.4; 90.1]
I don't know/am not sure	4/8 (50.0) [15.7; 84.3]
Read the Guide for HCPs (Q2)	
Yes**	71/84 (84.5) [75.0; 91.5]
Yes, all of it	41/50 (82.0) [68.6; 91.4]

	Overall N=101 n/M (%) 95% CI
Yes, some of it	30/34 (88.2) [72.5; 96.7]
No	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	1/1 (100.0) [2.5; 100.0]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Source: [Table 15-11](#)

10.4.10 Primary endpoint – knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14) – correct responders – overall and by healthcare professional characteristics

Table 10-13 describes knowledge of the recommendation with regards to restarting of Piqray after elevated fasting glucose by HCP’s characteristics. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question (Table 10-3, Table 10-13): 63 out of 100 HCPs answered correctly
- 61.9% of oncologists answered correctly and 68.8% of other specialists answered correctly
- None of the HCPs who had less than 5 years of experience answered this question correctly
- All HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 66.1% of HCPs who prescribed Piqray within the last three months answered correctly , and 57.6% of those who prescribed Piqray in the last 3-6 months answered correctly
- 55.6% of HCPs who were previously an investigator for one of the Piqray clinical trials answered correctly
- 67.1% of HCPs who received the HCP guide answered correctly
- 67.5% of HCPs who reported reading the HCP guide answered correctly

Table 10-13 Primary endpoint – knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14) – correct responders – by healthcare professional characteristics

	Overall N=100 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	52/84 (61.9) [50.7; 72.3]
Other	11/16 (68.8) [41.3; 89.0]
Years working with oncology patients (Q17)	
<5 years	0/2 (0.0) [0.0; 84.2]
5-<10 years	19/22 (86.4) [65.1; 97.1]
10-<15 years	17/26 (65.4) [44.3; 82.8]
≥15 years	27/48 (56.3) [41.2; 70.5]
Prefer not to answer	0/2 (0.0) [0.0; 84.2]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	54/82 (65.9) [54.6; 76.0]
6-10	3/11 (27.3) [6.0; 61.0]
>10	4/4 (100.0) [39.8; 100.0]
I don't know/am not sure	2/3 (66.7) [9.4; 99.2]
Last time you prescribed Piqray (Q19)	
<3 months ago	37/56 (66.1) [52.2; 78.2]
3-<6 months ago	19/33 (57.6) [39.2; 74.5]
I don't know/am not sure	6/10 (60.0) [26.2; 87.8]
Missing Data	1/1 (100.0) [2.5; 100.0]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	15/27(55.6) [35.3; 74.5]
No	46/70 (65.7) [53.4; 76.7]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	1/1(100.0) [2.5; 100.0]
Received the Guide for HCPs (Q1)	
Yes	57/85 (67.1) [56.0; 76.9]
No	2/7 (28.6) [3.7; 71.0]
I don't know/am not sure	4/8 (50.0) [15.7; 84.3]
Read the Guide for HCPs (Q2)	
Yes**	56/83 (67.5) [56.3; 77.4]
Yes, all of it	37/50 (74.0) [59.7; 85.4]

	Overall N=100 n/M (%) 95% CI
Yes, some of it	19/33 (57.6) [39.2; 74.5]
No	0/1 (0.0) [0.0; 97.5]
I don't know/am not sure	1/1 (100.0) [2.5; 100.0]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Source: [Table 15-12](#)

10.4.11 Primary endpoint – knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15) – correct responders – overall and by healthcare professional characteristics

Table 10-14 describes knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs, and patients are treated with antihyperglycemic medications by HCP characteristics. The data below are based on HCPs who answered the question correctly.

- Among HCPs who answered this question (Table 10-3, Table 10-14): 50 out of 100 HCPs answered correctly
- 48.8% of oncologists answered correctly and 56.3% of other specialists answered correctly
- None of the HCPs who had less than 5 years of experience answered this question correctly
- 50.0% of HCPs who prescribed Piqray to more than 10 patients within the past 12 months answered this question correctly
- 57.1% of HCPs who prescribed Piqray within the last three months answered correctly , and 42.4% of those who prescribed Piqray in the last 3-6 months answered correctly
- 59.3% of HCPs who were previously an investigator for one of the Piqray clinical trials answered correctly
- 54.1% of HCPs who received the HCP guide answered correctly
- 55.4% of HCPs who reported reading the HCP guide answered correctly

Table 10-14 Primary endpoint – knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15) – correct responders – by healthcare professional characteristics

	Overall N=100 n/M (%) 95% CI
Primary medical specialty (Q16)	
Oncologist*	41/84 (48.8) [37.7; 60.0]
Other	9/16 (56.3) [29.9; 80.2]
Years working with oncology patients (Q17)	
<5 years	0/2 (0.0) [0.0; 84.2]
5-<10 years	12/22 (54.5) [32.2; 75.6]
10-<15 years	12/26 (46.2) [26.6; 66.6]
≥15 years	26/48 (54.2) [39.2; 68.6]
Prefer not to answer	0/2 (0.0) [0.0; 84.2]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	
1-5	41/82 (50.0) [38.7; 61.3]
6-10	6/11 (54.5) [23.4; 83.3]
>10	2/4 (50.0) [6.8; 93.2]
I don't know/am not sure	1/3 (33.3) [0.8; 90.6]
Last time you prescribed Piqray (Q19)	
<3 months ago	32/56 (57.1) [43.2; 70.3]
3-<6 months ago	14/33 (42.4) [25.5; 60.8]
I don't know/am not sure	3/10 (30.0) [6.7; 65.2]
Missing Data	1/1 (100.0) [2.5; 100.0]
Past investigator for one of the Piqray clinical trials (Q20)	
Yes	16/27 (59.3) [38.8; 77.6]
No	32/70 (45.7) [33.7; 58.1]
I don't know/am not sure	1/2 (50.0) [1.3; 98.7]
Missing Data	1/1 (100.0) [2.5; 100.0]
Received the Guide for HCPs (Q1)	
Yes	46/85 (54.1) [43.0; 65.0]
No	2/7 (28.6) [3.7; 71.0]
I don't know/am not sure	2/8 (25.0) [3.2; 65.1]
Read the Guide for HCPs (Q2)	
Yes**	46/83 (55.4) [44.1; 66.3]
Yes, all of it	24/50 (48.0) [33.7; 62.6]
Yes, some of it	22/33 (66.7) [48.2; 82.0]
No	0/1 (0.0) [0.0; 97.5]

	Overall N=100 n/M (%) 95% CI
I don't know/am not sure	0/1 (0.0) [0.0; 97.5]

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Source: [Table 15-13](#)

10.5 Other analyses

10.5.1 Other endpoints –knowledge levels: overall

Table 10-15 presents HCPs' knowledge levels around other risk factors of Piqray.

While 79.4% of HCPs correctly identified that severe cutaneous reactions are a known risk of Piqray, only 40.2% were aware that pneumonitis is a known risk associated with Piqray. However, there was less awareness of nausea/vomiting (47.1%) and headaches (37.3%) as symptoms of hyperglycemia. Knowledge of difficulty breathing as a sign/symptom of hyperglycemia was low at 2.0%. Additionally, only 53.4% correctly identified the monitoring schedules of fasting glucose vary based on risk factors.

Table 10-15 Other endpoints – knowledge levels: overall

	Overall N=103 n/M (%) 95% CI
Knowledge that pneumonitis is a risk associated with treatment with Piqray (Q4b)	41/102 (40.2) [30.6; 50.4]
Knowledge that severe cutaneous reactions are a risk associated with treatment with Piqray (Q4c)	81/102 (79.4) [70.3; 86.8]
Knowledge that suicidal ideation is not a risk associated with treatment with Piqray (Q4d)	100/102 (98.0) [93.1; 99.8]
Knowledge that onychomycosis is not a risk associated with treatment with Piqray (Q4e)	98/102 (96.1) [90.3; 98.9]
Knowledge that inability to swallow is not a sign/symptom of hyperglycemia (Q5d)	98/102 (96.1) [90.3; 98.9]
Knowledge that yellowing of the skin is not a sign/symptom of hyperglycemia (Q5e)	79/102 (77.5) [68.1; 85.1]
Knowledge that difficulty breathing is a sign/symptom of hyperglycemia (Q5f)	2/102 (2.0) [0.2; 6.9]
Knowledge that nausea and/or vomiting is a sign/symptom of hyperglycemia (Q5g)	48/102 (47.1) [37.1; 57.2]
Knowledge that headache is a sign/symptom of hyperglycemia (Q5h)	38/102 (37.3) [27.9; 47.4]
Knowledge that for patients at higher risk for developing hyperglycemia, an HCP/endocrinologist experienced in the treatment of hyperglycemia should be consulted(Q7)	82/102 (80.4) [71.4; 87.6]
Knowledge that the dose of their current antihyperglycemia medication, if applicable, does not need to be increased before a patient starts treatment with Piqray (Q8d)	74/102 (72.5) [62.8; 80.9]
Knowledge that the Piqray Prescriber's/HCP Guide for Hyperglycemia and SmPC does not require a diabetologist to be consulted for patients who are not diabetic before a patient starts treatment with Piqray (Q8e)	89/102 (87.3) [79.2; 93.0]
Knowledge that "the monitoring schedule of fasting glucose levels for patients receiving Piqray is the same for all patients with, and without, risk factors for hyperglycemia" is not correct (Q9)	55/103 (53.4) [43.3; 63.3]
Knowledge of the frequency for HbA1c testing to be performed for all patients treated with Piqray (Q11)	75/102 (73.5) [63.9; 81.8]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=non-missing; CI=Confidence Interval.

Source: Table 15-14

10.5.2 Other endpoints — knowledge levels: receipt and reading of the Piqray prescriber's/HCP guide for hyperglycemia, overall

Table 10-16 showed a majority (85.4%) of HCPs confirmed receiving the guide, with only a small proportion (6.8%) indicating they did not receive it, and 7.8% being unsure if they had received it. Among HCPs who received the guide, nearly all (97.7%) reported having read it to some extent, which indicated a strong interest and perceived relevance of the content. Notably, 59.1% of recipients reported reading the entire guide, while 38.6% read parts of it.

Table 10-16 Other endpoints – knowledge levels: receipt and reading of the Piqray prescriber's/HCP guide for hyperglycemia, overall

	Overall N=103 n/M (%) 95% CI
Received the Guide for HCPs (Q1)	
Yes	88/103 (85.4) [77.1; 91.6]
No	7/103 (6.8) [2.8; 13.5]
I don't know/am not sure	8/103 (7.8) [3.4; 14.7]
Read the Guide for HCPs (Q2)	
Yes*	86/88 (97.7) [92.0; 99.7]
Yes, all of it	52/88 (59.1) [48.1; 69.5]
Yes, some of it	34/88 (38.6) [28.4; 49.6]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals who answered the question; CI=Confidence Interval.

*Yes= "Yes, some of it" + "Yes, all of it".

Source: Table 15-15

10.5.3 Other endpoints –knowledge: primary source from which HCPs learned about the messages included in the Piqray prescriber's/HCP guide for hyperglycemia, overall

Table 10-17 shows that Piqray SmPC was the most referenced primary source, cited by 33.0% of HCPs, followed closely by the Piqray Prescriber's/HCP Guide for Hyperglycemia (30.1%). Clinical Practice Guidelines (8.7%) and Professional Society or Congress materials (7.8%) were also notable sources. Regulatory and pharmaceutical websites, including the European Medicines Agency (EMA) website (4.9%), the Piqray product website (3.9%), and the National Competent Authority website (1.9%), are utilized to a lesser extent; these websites also reference the SmPC. Consultation with a representative from Novartis was infrequent (3.9%).

All of the surveyed individuals had at least one preferred source of information on Piqray's use and risks, as none selected 'I don't know/am not sure' (0.0%) for their source of information. This suggests a high level of awareness and diligence among HCPs in ensuring they access reliable sources for clinical decision-making.

Table 10-17 Other endpoints –knowledge: primary source from which HCPs learned about the messages included in the Piqray prescriber's/HCP guide for hyperglycemia, overall

	Overall N=103 n/M (%) 95% CI
Primary source of the indication, precautions for use, and potential risks for Piqray (Q3)	
Piqray Summary of Product Characteristics	34/103 (33.0) [24.1; 43.0]
Piqray Prescriber's/HCP Guide for Hyperglycemia	31/103 (30.1) [21.5; 39.9]
National Competent Authority website	2/103 (1.9) [0.2; 6.8]
Professional Society or Congress	8/103 (7.8) [3.4; 14.7]
The Piqray product website	4/103 (3.9) [1.1; 9.6]
The European Medicines Agency website	5/103 (4.9) [1.6; 11.0]
Clinical practice guidelines	9/103 (8.7) [4.1; 15.9]
A representative from Novartis	4/103 (3.9) [1.1; 9.6]
Other	6/103 (5.8) [2.2; 12.2]
I don't know/am not sure	0/103 (0.0) [0.0; 3.5]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=non-missing; CI=Confidence Interval.

Source: Table 15-16

10.6 Adverse events/adverse reactions

Not Applicable

11 Discussion

11.1 Key results

The findings indicate that overall knowledge regarding hyperglycemia risks and management in the context of Piqray treatment is high, particularly in recognizing hyperglycemia as a risk (98.0%) and identifying common symptoms of hyperglycemia such as excessive thirst (97.1%) and increased urination (96.1%). Most HCPs demonstrated strong awareness of pre-treatment considerations, including the necessity of fasting glucose and HbA1c testing (93.1%), as well as counseling patients on hyperglycemia risks (90.2%).

In Study C2005, success criteria on the primary endpoint is defined as a weighted composite knowledge level of at least 70% across the key questions. This endpoint was designed to assess overall knowledge retention and comprehension among HCPs. Overall, a composite score of 81.3% (95% CI: 79.1-83.4) was achieved by HCPs thereby meeting the primary objective.

Results varied across countries, with the highest knowledge level observed in Luxembourg and Slovenia (92.3% for both) and the lowest in Norway (69.2%, n=1). The data indicate that 36.9% of HCPs achieved a composite primary endpoint of over 90%.

When comparing the composite score by the number of patients the HCP treated with Piqray within the past 12 months, HCPs who prescribed Piqray to more than 10 patients had the highest composite scores at 92.3%. Experience appears to play a role in knowledge levels, with HCPs working for 5–<10 years having the highest composite scores (87.4%), while HCPs with less than five years of experience show the lowest composite scores (65.4%). It was also found that participation in Piqray clinical trials did not significantly impact composite scores. Healthcare professionals who read the entire Piqray Prescriber's/HCP Guide for Hyperglycemia, performed comparably (83.2%) compared to those who read only parts of it (81.4%). Healthcare professionals who read the Piqray Prescriber's/HCP Guide for Hyperglycemia, performed better compared to those who received it but did not read it (61.5%) and those who either did not receive it (74.7%) or did not know/where not sure if they had received it (76.9%).

11.2 Limitations

Not all HCPs may be comfortable with or have access to digital tools. This could have led to the exclusion of certain groups, particularly those with less experience using online surveys or those working in settings with limited internet access. In an online survey, respondents may misinterpret questions or instructions or translations without the opportunity to ask for clarification from the survey administrator, leading to misunderstanding or inaccurate responses. To mitigate this issue, each translated questionnaire was validated for accuracy, contextualization and interpretability by a native-speaking Novartis affiliate in each country. Unlike in-person surveys, researchers have no control over the environment in which respondents complete online surveys.

11.3 Interpretation

The data suggest the Novartis provision of the SmPC and the Piqray Prescriber's/HCP Guide for Hyperglycemia were effective across all regions where applicable. Furthermore, these

findings highlight a strong overall understanding among HCPs regarding the risks and basic management of hyperglycemia in the context of Piqray treatment.

The distribution suggests that most HCPs performed well, with over 70% achieving more than the predefined composite score threshold of 70%. This is a promising outcome, indicating that the vast majority of HCPs were able to recall and apply key information when answering the survey.

Artime et al. conducted a systematic review in 2019 to evaluate the effectiveness of Risk minimization measures in Europe. Their analysis was based on 24 cross-sectional surveys and showed that many surveys did not meet their pre-specified sample sizes. The same review reported response rates ranging from 0.5% to 10.3% with the exception of one study which was restricted to Denmark only, with a small but targeted number of HCPs invited achieving a response rate of 26.0% (32/123; [Artime et al 2019](#)). In Study C2005, the target sample size was achieved and Study C2005 was able to achieve a higher response rate (24.4%; 103/422) compared to all but one of the studies evaluated in the review, supporting the robustness of the Study C2005 HCP survey results.

It is important to note the absence of missing information in Study C2005 due to partially completed surveys. The set up of survey platform used for Study C2005 incorporated features that ensure completeness by alerting respondents if they leave required fields blank. Minimizing or eliminating missing data due to partially completed surveys is a significant advantage in our survey design and data collection process; it enhanced data reliability, reduces bias, improved the quality of analysis, and ensured that the findings are as accurate and actionable as possible.

11.4 Generalizability

The data from ten countries was analyzed in Study C2005; however, only 2 countries had individual sample sizes >15 HCPs. The small size of these subgroups precluded meaningful analysis and comparison of the knowledge levels across various countries. Furthermore, small sample sizes in subgroups can significantly affect the generalizability of the findings. When a subgroup is too small, it may not be representative of the larger population, leading to potential bias or skewed results. As a result, the conclusions drawn from this data may not apply accurately to the broader population. However, the consistency of the results across countries suggests that the results may be interpreted similarly across the overall population, despite small HCP numbers in some countries.

12 Other information

Not Applicable

13 Conclusion

Study C2005 was a multinational, non-interventional, cross-sectional survey aimed at evaluating the effectiveness of educational materials for Piqray including the Piqray Prescriber's/HCP Guide for hyperglycemia. The survey was conducted among HCPs based in the EU/EEA who prescribe Piqray. The primary focus of the survey was to assess the knowledge of these HCPs regarding the management of hyperglycemia in patients treated with Piqray.

In Study C2005 success criteria for the primary objective was met, which was defined as a weighted composite knowledge level of at least 70% across key questions. This endpoint was

designed to assess the overall knowledge retention and comprehension among HCPs. Overall, a composite score of 81.3% (95% CI: 79.1-83.4) was achieved by HCPs thereby meeting the primary objective.

The findings highlight a commendable level of knowledge among healthcare professionals regarding the risks and management of hyperglycemia in the context of Piqray treatment. The high recognition of hyperglycemia as a potentially occurring event, along with the ability to identify common symptoms and the awareness of pre-treatment considerations, underscores the preparedness of HCPs. This strong foundation is essential for ensuring patient safety and optimizing treatment outcomes. Also, this knowledge was independent (and acceptable regardless) of receiving the guide vs. not receiving it, and reading the guide in its entirety vs. reading only part of it.

The “Piqray Summary of Product Characteristics” (SmPC) was the most commonly cited source of education, with 34 out of 103 HCPs identifying it as the primary source of information. On the “National Competent Authority” and “European Medicines Agency” websites, visitors would primarily find the SmPC as a source of useful prescribing information. Those 1.9% and 4.9% of HCPs who indicated “National Competent Authority” and “European Medicines Agency” websites, respectively, as source of information are also quite likely to be referencing the SmPC. This is also likely applicable for the “Piqray product website”, which was given by 3.9% of HCPs as primary source of information (Table 10-17). On this website, the visitor would also retrieve the SmPC. Taken together, those 4 individual responses suggest that up to approximately 43.7% of all prescribers would use the SmPC as a primary source of information. A total of 30.1% of all HCPs (31/103) indicated using the Piqray Prescriber’s/HCP Guide for hyperglycemia as a primary source of information. Note that the same information regarding recognition and management of hyperglycemia is also contained in the Piqray SmPC. This highlights the central role that the SmPC plays in educating HCPs. Moreover, the SmPC may be viewed as one of the most reliable and widely used sources of information regarding Piqray’s indication, precautions, and risks, underscoring its importance in clinical decision-making and patient safety. Piqray has been approved in the EU for almost five years and has an established safety profile. Its renewal for marketing authorization was granted with unlimited validity, reflecting the long-term confidence in its safety and efficacy. This extended approval period further strengthens the credibility of the SmPC as a key source for accurate, trusted information for HCPs.

14 References

Artime E, Qizilbash N, Garrido-Esteba M, et al (2019). Are risk minimization measures for approved drugs in Europe effective? A systematic review, *Expert Opinion on Drug Safety*, 18:5, 443-54.

Goncalves MD, Hopkins BD, Cantley LC (2018) Phosphatidylinositol 3-kinase, growth disorders, and cancer. *N Engl J Med*; 379(21):2052-62.

Piqray SmPC (2020). Piqray Summary of Product Characteristics, 27 July 2020. Available at: ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Accessed 24-May-2021.

15 Appendices

15.1 Appendix 1 – List of stand-alone documents

Appendix	Appendix Title	Documents included
15.1.1	Protocol and protocol amendments	
15.1.2	Signature page of final study report	
15.1.3	Documentation of statistical methods (SAP)	

15.2 Appendix 2 – Additional relevant statistical information

15.2.1 Additional Tables

Table 15-1 Survey administration and analysis sets, overall and by country

	Overall N=422* n (%)	Austria N=71 n (%)	Croatia N=50 n (%)	Italy N=87 n (%)	Luxembourg N=12 n (%)	Netherlands N=63 n (%)	Norway N=2 n (%)	Poland N=40 n (%)	Slovenia N=20 n (%)	Spain N=63 n (%)	Sweden N=11 n (%)
Survey Status											
N (invited)	422	71	50	87	12	63	2	40	20	63	11
Completed the eligibility questions	125 (29.6)	8 (11.3)	21 (42.0)	29 (33.3)	2 (16.7)	20 (31.7)	1 (50.0)	15 (37.5)	9 (45.0)	14 (22.2)	6 (54.5)
Completed all primary endpoint questions ^a	100 (23.7)	8 (11.3)	20 (40.0)	12 (13.8)	2 (16.7)	16 (25.4)	1 (50.0)	12 (30.0)	9 (45.0)	14 (22.2)	6 (54.5)
Completed all primary and secondary endpoint questions ^b	100 (23.7)	8 (11.3)	20 (40.0)	12 (13.8)	2 (16.7)	16 (25.4)	1 (50.0)	12 (30.0)	9 (45.0)	14 (22.2)	6 (54.5)
Not agree to take part in this survey	1 (0.2)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	1 (1.6)	0 (-)
Eligibility											
N (completed eligibility questions)	125	8	21	29	2	20	1	15	9	14	6
Yes	103 (82.4)	8 (100)	20 (95.2)	13 (44.8)	2 (100)	18 (90.0)	1 (100)	12 (80.0)	9 (100)	14 (100)	6 (100)
No	22 (17.6)	0 (-)	1 (4.8)	16 (55.2)	0 (-)	2 (10.0)	0 (-)	3 (20.0)	0 (-)	0 (-)	0 (-)
N (Analysis set)	103	8	20	13	2	18	1	12	9	14	6

*N=422 includes 3 invitations sent to healthcare professionals (HCP) from Finland who did not respond at all.

^aPrimary endpoint questions: 4A, 5A-C, 6, 8A-C, 10, and 12-15.

^bPiqray Prescriber's/HCP Guide for hyperglycemia: Questions 1-15.

Table 15-2 Other endpoints collected in the survey

Study objective assessed	Corresponding variable	Operational definition
Assess whether HCPs received and read the Piqray Prescriber's/HCP Guide for Hyperglycemia	Received the Guide for HCPs	Calculated as the percentage of respondents who responded "Yes" to question 1
	Read the Guide for HCPs	Calculated as the percentage of respondents who responded "Yes, all of it" + "Yes, some of it" to question 2. Of note, the question was asked only to HCPs who responded "Yes" to question 1.
HCPs' knowledge levels for each survey question regarding knowledge of, and management of, hyperglycemia, assessed as the percentages of HCPs with correct responses to each question	Knowledge that hyperglycemia is a risk associated with treatment with Piqray.	Calculated as the percentage of respondents who "Checked" question 4A
	Knowledge that pneumonitis is a risk associated with treatment with Piqray	Calculated as the percentage of respondents who "Checked" question 4B
	Knowledge that severe cutaneous reactions are a risk associated with treatment with Piqray	Calculated as the percentage of respondents who "Checked" question 4C
	Knowledge that suicidal ideation is not a risk associated with treatment with Piqray	Calculated as the percentage of respondents who "Did not check" question 4D
	Knowledge that onychomycosis is not a risk associated with treatment with Piqray	Calculated as the percentage of respondents who "Did not check" question 4E
	Knowledge that excessive thirst is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who "Checked" question 5A
	Knowledge that increased frequency or amount of urination is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who "Checked" question 5B
	Knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who "Checked" question 5C
	Knowledge that inability to swallow is not a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who "Did not check" question 5D

Study objective assessed	Corresponding variable	Operational definition
	Knowledge that yellowing of the skin is not a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who “Did not check” question 5E
	Knowledge that difficulty breathing is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who “Checked” question 5F
	Knowledge that nausea and/or vomiting is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who “Checked” question 5G
	Knowledge that headache is a sign/symptom of hyperglycemia	Calculated as the percentage of respondents who “Checked” question 5H
	Knowledge that being diabetic/pre-diabetic, having a fasting blood glucose	Calculated as the percentage of respondents who responded only “body mass index <30 kg/m ² ” for question 6
	Knowledge that for patients at higher risk for developing hyperglycemia, an HCP/endocrinologist experienced in the treatment of hyperglycemia should be consulted	Calculated as the percentage of respondents who responded “false” to question 7
	Knowledge that a fasting glucose and HbA1c should be obtained before a patient starts treatment with Piqray	Calculated as the percentage of respondents who “Checked” question 8A
	Knowledge that the patient’s level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray	Calculated as the percentage of respondents who “Checked” question 8B
	Knowledge that the patient should be counselled about the risk of hyperglycemia before a patient starts treatment with Piqray	Calculated as the percentage of respondents who “Checked” question 8C
	Knowledge that the dose of their current antihyperglycemia medication, if applicable, does not need to be increased before a patient starts treatment with Piqray	Calculated as the percentage of respondents who “Did not check” question 8D

Study objective assessed	Corresponding variable	Operational definition
	Knowledge that the Piqray Prescriber's/HCP Guide for Hyperglycemia and SmPC does not require a diabetologist to be consulted for patients who are not diabetic before a patient starts treatment with Piqray	Calculated as the percentage of respondents who "Did not check" question 8E
	Knowledge that "the monitoring schedule of fasting glucose levels for patients receiving Piqray is the same for all patients with, and without, risk factors for hyperglycemia" is not correct	Calculated as the percentage of respondents who responded "false" to question 9
	Knowledge of when a FPG test should be performed after starting treatment with Piqray	Calculated as the percentage of respondents who responded "at weeks 1, 2, 4, 6, and 8, after treatment start, then monthly thereafter" to question 10
	Knowledge of the frequency for HbA1c testing to be performed for all patients treated with Piqray	Calculated as the percentage of respondents who responded "4 weeks after treatment start, then every 3 months thereafter" to question 11
	Knowledge that for fasting glucose values that are ≤ 250 mg/dL (≤ 13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment	Calculated as the percentage of respondents who responded "true" to question 12
	Knowledge of which fasting glucose values require Piqray dosing to be interrupted	Calculated as the percentage of respondents who responded "any fasting glucose value > 250 mg/dL (> 13.9 mmol/L)" to question 13

Study objective assessed	Corresponding variable	Operational definition
	Knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300mg/day” is not accurate	Calculated as the percentage of respondents who responded “false” to question 14
	Knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications	Calculated as the percentage of respondents who responded “weekly for at least 8 weeks, followed by once every 2 weeks, and consider consultation with a healthcare professional with expertise in the treatment of hyperglycemia” to question 15
Primary source of the indication, precautions for use, and potential risks for Piqray	Response choices: Piqray SmPC, Piqray Guide for HCPs, NCA website, Professional society or congress, Piqray product website, EMA website, Clinical practice guidelines, Novartis representative, Other	Calculated as the percentage of respondents who responded any of the response choices to question 3

Table 15-3 Primary endpoints – knowledge levels: individual questions – overall and by country

[illegible]

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Knowledge that being diabetic/pre-diabetic, having a fasting blood glucose >13.9 mmol/L (250 mg/dL), and being 75 years of age or older are additional risk factors for developing hyperglycemia while taking Piqray (Q6)	78/102 (76.5) [67.0; 84.3]	4/8 (50.0) [15.7; 84.3]	19/20 (95.0) [75.1; 99.9]	6/13 (46.2) [19.2; 74.9]	2/2 (100.0) [15.8; 100.0]	11/17 (64.7) [38.3; 85.8]	1/1 (100.0) [2.5; 100.0]	10/12 (83.3) [51.6; 97.9]	9/9 (100.0) [66.4; 100.0]	11/14 (78.6) [49.2; 95.3]	5/6 (83.3) [35.9; 99.6]
Knowledge that a fasting glucose and HbA1c should be obtained before a patient starts treatment with Piqray (Q8a)	79/102 (77.5) [68.1; 85.1]	6/8 (75.0) [34.9; 96.8]	17/20 (85.0) [62.1; 96.8]	9/13 (69.2) [38.6; 90.9]	2/2 (100.0) [15.8; 100.0]	14/17 (82.4) [56.6; 96.2]	0/1 (0.0) [0.0; 97.5]	7/12 (58.3) [27.7; 84.8]	8/9 (88.9) [51.8; 99.7]	12/14 (85.7) [57.2; 98.2]	4/6 (66.7) [22.3; 95.7]
Knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray (Q8b)	95/102 (93.1) [86.4; 97.2]	7/8 (87.5) [47.3; 99.7]	19/20 (95.0) [75.1; 99.9]	12/13 (92.3) [64.0; 99.8]	2/2 (100.0) [15.8; 100.0]	16/17 (94.1) [71.3; 99.9]	1/1 (100.0) [2.5; 100.0]	12/12 (100.0) [73.5; 100.0]	8/9 (88.9) [51.8; 99.7]	13/14 (92.9) [66.1; 99.8]	5/6 (83.3) [35.9; 99.6]
	74/102	6/8	18/20	7/13	2/2	12/17	1/1	7/12	8/9	10/14	3/6

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Knowledge that the patient should be counselled about the risk of hyperglycemia before a patient starts treatment with Piqray (Q8c)	(72.5) [62.8; 80.9]	(75.0) [34.9; 96.8]	(90.0) [68.3; 98.8]	(53.8) [25.1; 80.8]	(100.0) [15.8; 100.0]	(70.6) [44.0; 89.7]	(100.0) [2.5; 100.0]	(58.3) [27.7; 84.8]	(88.9) [51.8; 99.7]	(71.4) [41.9; 91.6]	(50.0) [11.8; 88.2]
	92/102 (90.2) [82.7; 95.2]	7/8 (87.5) [47.3; 99.7]	19/20 (95.0) [75.1; 99.9]	11/13 (84.6) [54.6; 98.1]	2/2 (100.0) [15.8; 100.0]	15/17 (88.2) [63.6; 98.5]	1/1 (100.0) [2.5; 100.0]	9/12 (75.0) [42.8; 94.5]	9/9 (100.0) [66.4; 100.0]	14/14 (100.0) [76.8; 100.0]	5/6 (83.3) [35.9; 99.6]
Knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10)	77/103 (74.8) [65.2; 82.8]	7/8 (87.5) [47.3; 99.7]	14/20 (70.0) [45.7; 88.1]	10/13 (76.9) [46.2; 95.0]	2/2 (100.0) [15.8; 100.0]	13/18 (72.2) [46.5; 90.3]	1/1 (100.0) [2.5; 100.0]	8/12 (66.7) [34.9; 90.1]	7/9 (77.8) [40.0; 97.2]	10/14 (71.4) [41.9; 91.6]	5/6 (83.3) [35.9; 99.6]
Knowledge that for fasting glucose values that are ≤ 250 mg/dL (≤ 13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12)	91/103 (88.3)	7/8 (87.5)	19/20 (95.0)	9/13 (69.2)	2/2 (100.0)	16/18 (88.9)	1/1 (100.0)	12/12 (100.0)	8/9 (88.9)	12/14 (85.7)	5/6 (83.3)

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13)	[80.5; 93.8]	[47.3; 99.7]	[75.1; 99.9]	[38.6; 90.9]	[15.8; 100.0]	[65.3; 98.6]	[2.5; 100.0]	[73.5; 100.0]	[51.8; 99.7]	[57.2; 98.2]	[35.9; 99.6]
	81/101 (80.2)	7/8 (87.5)	9/20 (45.0)	11/12 (91.7)	2/2 (100.0)	15/17 (88.2)	0/1 (0.0)	11/12 (91.7)	9/9 (100.0)	14/14 (100.0)	3/6 (50.0)
	[71.1; 87.5]	[47.3; 99.7]	[23.1; 68.5]	[61.5; 99.8]	[15.8; 100.0]	[63.6; 98.5]	[0.0; 97.5]	[61.5; 99.8]	[66.4; 100.0]	[76.8; 100.0]	[11.8; 88.2]
Knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14)	63/100 (63.0)	5/8 (62.5)	11/20 (55.0)	6/12 (50.0)	2/2 (100.0)	13/16 (81.3)	0/1 (0.0)	8/12 (66.7)	9/9 (100.0)	6/14 (42.9)	3/6 (50.0)
	[52.8; 72.4]	[24.5; 91.5]	[31.5; 76.9]	[21.1; 78.9]	[15.8; 100.0]	[54.4; 96.0]	[0.0; 97.5]	[34.9; 90.1]	[66.4; 100.0]	[17.7; 71.1]	[11.8; 88.2]
Knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15)	50/100	4/8	9/20	4/12	0/2	10/16	0/1	5/12	7/9	8/14	3/6

Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
(50.0) [39.8; 60.2]	(50.0) [15.7; 84.3]	(45.0) [23.1; 68.5]	(33.3) [9.9; 65.1]	(0.0) [0.0; 84.2]	(62.5) [35.4; 84.8]	(0.0) [0.0; 97.5]	(41.7) [15.2; 72.3]	(77.8) [40.0; 97.2]	(57.1) [28.9; 82.3]	(50.0) [11.8; 88.2]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals who answered the question; CI=Confidence Interval.

Table 15-4 Primary endpoints – individual scores: overall and by country

	Overall N=103 n (%)	Austria N=8 n (%)	Croatia N=20 n (%)	Italy N=13 n (%)	Luxembourg N=2 n (%)	Netherlands N=18 n (%)	Norway N=1 n (%)	Poland N=12 n (%)	Slovenia N=9 n (%)	Spain N=14 n (%)	Sweden N=6 n (%)
Composite primary endpoint* individual percentage correct (%)											
0-10	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
>10-20	1 (1.0)	1 (12.5)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
>20-30	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
>30-40	1 (1.0)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	1 (8.3)	0 (-)	0 (-)	0 (-)
>40-50	2 (1.9)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	2 (33.3)
>50-60	2 (1.9)	0 (-)	1 (5.0)	1 (7.7)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)
>60-70	18 (17.5)	0 (-)	3 (15.0)	5 (38.5)	0 (-)	3 (16.7)	1 (100)	3 (25.0)	0 (-)	3 (21.4)	0 (-)
>70-80	16 (15.5)	1 (12.5)	3 (15.0)	4 (30.8)	0 (-)	3 (16.7)	0 (-)	1 (8.3)	0 (-)	4 (28.6)	0 (-)
>80-90	22 (21.4)	2 (25.0)	6 (30.0)	0 (-)	0 (-)	4 (22.2)	0 (-)	4 (33.3)	3 (33.3)	1 (7.1)	2 (33.3)
>90-100	38 (36.9)	4 (50.0)	7 (35.0)	2 (15.4)	2 (100)	6 (33.3)	0 (-)	3 (25.0)	6 (66.7)	6 (42.9)	2 (33.3)
Missing	3 (2.9)	0 (-)	0 (-)	1 (7.7)	0 (-)	2 (11.1)	0 (-)	0 (-)	0 (-)	0 (-)	0 (-)

N=Number of eligible healthcare professionals

*Composite primary endpoint percentage per individual is calculated by dividing the number of all correctly answered questions per the number of all answered questions (i.e., questions that were answered either correct or not correct - unanswered questions are excluded). Success criteria on the primary endpoint is defined as the observed estimate of the weighted composite knowledge level of at least 70% across these key questions.

Table 15-5 Primary endpoints – composite score – overall, by country and by healthcare professional characteristics

	Overall N=100 q/Q (%) 95% CI	Austria N=8 q/Q (%) 95% CI	Croatia N=20 q/Q (%) 95% CI	Italy N=12 q/Q (%) 95% CI	Luxembourg N=2 q/Q (%) 95% CI	Netherlands N=16 q/Q (%) 95% CI	Norway N=1 q/Q (%) 95% CI	Poland N=12 q/Q (%) 95% CI	Slovenia N=9 q/Q (%) 95% CI	Spain N=14 q/Q (%) 95% CI	Sweden N=6 q/Q (%) 95% CI
Primary medical specialty (Q16)											
Oncologist**											
	881/1092 (80.7) [78.2; 83.0]	49/65 (75.4) [63.1; 85.2]	105/130 (80.8) [72.9; 87.2]	115/156 (73.7) [66.1; 80.4]	24/26 (92.3) [74.9; 99.1]	140/169 (82.8) [76.3; 88.2]	9/13 (69.2) [38.6; 90.9]	122/156 (78.2) [70.9; 84.4]	108/117 (92.3) [85.9; 96.4]	151/182 (83.0) [76.7; 88.1]	58/78 (74.4) [63.2; 83.6]
Other											
	176/208 (84.6) [79.0; 89.2]	33/39 (84.6) [69.5; 94.1]	109/130 (83.8) [76.4; 89.7]	0/0	0/0	34/39 (87.2) [72.6; 95.7]	0/0	0/0	0/0	0/0	0/0
Years working with oncology patients (Q17)											
<5 years											
	17/26 (65.4) [44.3; 82.8]	0/0	0/0	0/0	0/0	8/13 (61.5) [31.6; 86.1]	0/0	0/0	0/0	9/13 (69.2) [38.6; 90.9]	0/0
5-<10 years											
	250/286 (87.4) [83.0; 91.0]	23/26 (88.5) [69.8; 97.6]	58/65 (89.2) [79.1; 95.6]	20/26 (76.9) [56.4; 91.0]	12/13 (92.3) [64.0; 99.8]	53/65 (81.5) [70.0; 90.1]	0/0	0/0	50/52 (96.2) [86.8; 99.5]	34/39 (87.2) [72.6; 95.7]	0/0
10-<15 years											
	273/338	12/13	21/26	39/52	12/13	45/52	0/0	53/65	35/39	39/52	17/26

	Overall N=100 q/Q (%) 95% CI	Austria N=8 q/Q (%) 95% CI	Croatia N=20 q/Q (%) 95% CI	Italy N=12 q/Q (%) 95% CI	Luxembourg N=2 q/Q (%) 95% CI	Netherlands N=16 q/Q (%) 95% CI	Norway N=1 q/Q (%) 95% CI	Poland N=12 q/Q (%) 95% CI	Slovenia N=9 q/Q (%) 95% CI	Spain N=14 q/Q (%) 95% CI	Sweden N=6 q/Q (%) 95% CI
≥15 years	(80.8) [76.2; 84.8]	(92.3) [64.0; 99.8]	(80.8) [60.6; 93.4]	(75.0) [61.1; 86.0]	(92.3) [64.0; 99.8]	(86.5) [74.2; 94.4]		(81.5) [70.0; 90.1]	(89.7) [75.8; 97.1]	(75.0) [61.1; 86.0]	(65.4) [44.3; 82.8]
Prefer not to answer	510/624 (81.7) [78.5; 84.7]	45/52 (86.5) [74.2; 94.4]	135/169 (79.9) [73.0; 85.6]	56/78 (71.8) [60.5; 81.4]	0/0	68/78 (87.2) [77.7; 93.7]	9/13 (69.2) [38.6; 90.9]	64/78 (82.1) [71.7; 89.8]	23/26 (88.5) [69.8; 97.6]	69/78 (88.5) [79.2; 94.6]	41/52 (78.8) [65.3; 88.9]
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	7/26 (26.9) [11.6; 47.8]	2/13 (15.4) [1.9; 45.4]	0/0	0/0	0/0	0/0	0/0	5/13 (38.5) [13.9; 68.4]	0/0	0/0	0/0
1-5	870/1066 (81.6) [79.2; 83.9]	45/52 (86.5) [74.2; 94.4]	162/195 (83.1) [77.1; 88.1]	71/104 (68.3) [58.4; 77.1]	24/26 (92.3) [74.9; 99.1]	161/195 (82.6) [76.5; 87.6]	0/0	122/156 (78.2) [70.9; 84.4]	97/104 (93.3) [86.6; 97.3]	141/169 (83.4) [77.0; 88.7]	47/65 (72.3) [59.8; 82.7]
6-10	108/143 (75.5) [67.6; 82.3]	25/39 (64.1) [47.2; 78.8]	42/52 (80.8) [67.5; 90.4]	0/0	0/0	0/0	9/13 (69.2) [38.6; 90.9]	0/0	11/13 (84.6) [54.6; 98.1]	10/13 (76.9) [46.2; 95.0]	11/13 (84.6) [54.6; 98.1]
>10	48/52	12/13	10/13	13/13	0/0	13/13	0/0	0/0	0/0	0/0	0/0

	Overall N=100 q/Q (%) 95% CI	Austria N=8 q/Q (%) 95% CI	Croatia N=20 q/Q (%) 95% CI	Italy N=12 q/Q (%) 95% CI	Luxembourg N=2 q/Q (%) 95% CI	Netherlands N=16 q/Q (%) 95% CI	Norway N=1 q/Q (%) 95% CI	Poland N=12 q/Q (%) 95% CI	Slovenia N=9 q/Q (%) 95% CI	Spain N=14 q/Q (%) 95% CI	Sweden N=6 q/Q (%) 95% CI
I don't know/am not sure	(92.3) [81.5; 97.9]	(92.3) [64.0; 99.8]	(76.9) [46.2; 95.0]	(100.0) [75.3; 100.0]		(100.0) [75.3; 100.0]					
Last time you prescribed Piqray (Q19)	31/39 (79.5) [63.5; 90.7]	0/0	0/0	31/39 (79.5) [63.5; 90.7]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
<3 months ago	607/728 (83.4) [80.5; 86.0]	57/65 (87.7) [77.2; 94.5]	130/156 (83.3) [76.5; 88.8]	30/39 (76.9) [60.7; 88.9]	24/26 (92.3) [74.9; 99.1]	132/156 (84.6) [78.0; 89.9]	9/13 (69.2) [38.6; 90.9]	63/78 (80.8) [70.3; 88.8]	47/52 (90.4) [79.0; 96.8]	68/78 (87.2) [77.7; 93.7]	47/65 (72.3) [59.8; 82.7]
3-<6 months ago	342/429 (79.7) [75.6; 83.4]	23/26 (88.5) [69.8; 97.6]	67/78 (85.9) [76.2; 92.7]	54/78 (69.2) [57.8; 79.2]	0/0	42/52 (80.8) [67.5; 90.4]	0/0	48/65 (73.8) [61.5; 84.0]	23/26 (88.5) [69.8; 97.6]	74/91 (81.3) [71.8; 88.7]	11/13 (84.6) [54.6; 98.1]
I don't know/am not sure	95/130 (73.1) [64.6; 80.5]	2/13 (15.4) [1.9; 45.4]	17/26 (65.4) [44.3; 82.8]	18/26 (69.2) [48.2; 85.7]	0/0	0/0	0/0	11/13 (84.6) [54.6; 98.1]	38/39 (97.4) [86.5; 99.9]	9/13 (69.2) [38.6; 90.9]	0/0
Missing Data	13/13 (100.0)	0/0	0/0	13/13 (100.0)	0/0	0/0	0/0	0/0	0/0	0/0	0/0

	Overall N=100 q/Q (%) 95% CI	Austria N=8 q/Q (%) 95% CI	Croatia N=20 q/Q (%) 95% CI	Italy N=12 q/Q (%) 95% CI	Luxembourg N=2 q/Q (%) 95% CI	Netherlands N=16 q/Q (%) 95% CI	Norway N=1 q/Q (%) 95% CI	Poland N=12 q/Q (%) 95% CI	Slovenia N=9 q/Q (%) 95% CI	Spain N=14 q/Q (%) 95% CI	Sweden N=6 q/Q (%) 95% CI
Past investigator for one of the Piqray clinical trials (Q20)	[75.3; 100.0]			[75.3; 100.0]							
Yes	284/351 (80.9) [76.4; 84.9]	11/13 (84.6) [54.6; 98.1]	34/39 (87.2) [72.6; 95.7]	85/117 (72.6) [63.6; 80.5]	0/0	44/52 (84.6) [71.9; 93.1]	0/0	12/13 (92.3) [64.0; 99.8]	23/26 (88.5) [69.8; 97.6]	64/78 (82.1) [71.7; 89.8]	11/13 (84.6) [54.6; 98.1]
No	745/910 (81.9) [79.2; 84.3]	69/78 (88.5) [79.2; 94.6]	180/221 (81.4) [75.7; 86.3]	17/26 (65.4) [44.3; 82.8]	24/26 (92.3) [74.9; 99.1]	117/143 (81.8) [74.5; 87.8]	9/13 (69.2) [38.6; 90.9]	110/143 (76.9) [69.1; 83.6]	85/91 (93.4) [86.2; 97.5]	87/104 (83.7) [75.1; 90.2]	47/65 (72.3) [59.8; 82.7]
I don't know/am not sure	15/26 (57.7) [36.9; 76.6]	2/13 (15.4) [1.9; 45.4]	0/0	0/0	0/0	13/13 (100.0) [75.3; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data	13/13 (100.0) [75.3; 100.0]	0/0	0/0	13/13 (100.0) [75.3; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Received the Guide for HCPs (Q1)											
Yes	909/1105	82/104	168/195	107/143	24/26	165/195	0/0	102/130	83/91	120/143	58/78

	Overall N=100 q/Q (%) 95% CI	Austria N=8 q/Q (%) 95% CI	Croatia N=20 q/Q (%) 95% CI	Italy N=12 q/Q (%) 95% CI	Luxembourg N=2 q/Q (%) 95% CI	Netherlands N=16 q/Q (%) 95% CI	Norway N=1 q/Q (%) 95% CI	Poland N=12 q/Q (%) 95% CI	Slovenia N=9 q/Q (%) 95% CI	Spain N=14 q/Q (%) 95% CI	Sweden N=6 q/Q (%) 95% CI
No	(82.3) [79.9; 84.5]	(78.8) [69.7; 86.2]	(86.2) [80.5; 90.7]	(74.8) [66.9; 81.7]	(92.3) [74.9; 99.1]	(84.6) [78.8; 89.4]		(78.5) [70.4; 85.2]	(91.2) [83.4; 96.1]	(83.9) [76.9; 89.5]	(74.4) [63.2; 83.6]
I don't know/am not sure	68/91 (74.7) [64.5; 83.3]	0/0	7/13 (53.8) [25.1; 80.8]	8/13 (61.5) [31.6; 86.1]	0/0	0/0	9/13 (69.2) [38.6; 90.9]	9/13 (69.2) [38.6; 90.9]	13/13 (100.0) [75.3; 100.0]	22/26 (84.6) [65.1; 95.6]	0/0
Read the Guide for HCPs (Q2) Yes***	80/104 (76.9) [67.6; 84.6]	0/0	39/52 (75.0) [61.1; 86.0]	0/0	0/0	9/13 (69.2) [38.6; 90.9]	0/0	11/13 (84.6) [54.6; 98.1]	12/13 (92.3) [64.0; 99.8]	9/13 (69.2) [38.6; 90.9]	0/0
Yes, all of it	890/1079 (82.5) [80.1; 84.7]	82/104 (78.8) [69.7; 86.2]	168/195 (86.2) [80.5; 90.7]	107/143 (74.8) [66.9; 81.7]	24/26 (92.3) [74.9; 99.1]	157/182 (86.3) [80.4; 90.9]	0/0	102/130 (78.5) [70.4; 85.2]	72/78 (92.3) [84.0; 97.1]	120/143 (83.9) [76.9; 89.5]	58/78 (74.4) [63.2; 83.6]
Yes, some of it	541/650 (83.2) [80.1; 86.0]	60/78 (76.9) [66.0; 85.7]	134/156 (85.9) [79.4; 90.9]	70/91 (76.9) [66.9; 85.1]	24/26 (92.3) [74.9; 99.1]	80/91 (87.9) [79.4; 93.8]	0/0	61/78 (78.2) [67.4; 86.8]	26/26 (100.0) [86.8; 100.0]	46/52 (88.5) [76.6; 95.6]	40/52 (76.9) [63.2; 87.5]
	349/429 (81.4)	22/26 (84.6)	34/39 (87.2)	37/52 (71.2)	0/0	77/91 (84.6)	0/0	41/52 (78.8)	46/52 (88.5)	74/91 (81.3)	18/26 (69.2)

	Overall N=100 q/Q (%) 95% CI	Austria N=8 q/Q (%) 95% CI	Croatia N=20 q/Q (%) 95% CI	Italy N=12 q/Q (%) 95% CI	Luxembourg N=2 q/Q (%) 95% CI	Netherlands N=16 q/Q (%) 95% CI	Norway N=1 q/Q (%) 95% CI	Poland N=12 q/Q (%) 95% CI	Slovenia N=9 q/Q (%) 95% CI	Spain N=14 q/Q (%) 95% CI	Sweden N=6 q/Q (%) 95% CI
No	[77.3; 84.9]	[65.1; 95.6]	[72.6; 95.7]	[56.9; 82.9]		[75.5; 91.3]		[65.3; 88.9]	[76.6; 95.6]	[71.8; 88.7]	[48.2; 85.7]
	8/13 (61.5) [31.6; 86.1]	0/0	0/0	0/0	0/0	8/13 (61.5) [31.6; 86.1]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	11/13 (84.6) [54.6; 98.1]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	11/13 (84.6) [54.6; 98.1]	0/0	0/0
Missing Data											
	148/195 (75.9) [69.3; 81.7]	0/0	46/65 (70.8) [58.2; 81.4]	8/13 (61.5) [31.6; 86.1]	0/0	9/13 (69.2) [38.6; 90.9]	9/13 (69.2) [38.6; 90.9]	20/26 (76.9) [56.4; 91.0]	25/26 (96.2) [80.4; 99.9]	31/39 (79.5) [63.5; 90.7]	0/0

N=Number of eligible healthcare professionals with an individual composite primary endpoint score; CI=Confidence Interval.

*Weighted composite knowledge score (i.e., primary endpoint) is an aggregate of the following survey questions: 4A, 5A-C, 6, 8A-C, 10, and 12-15. It is calculated as q, the number of all correctly answered questions divided by Q, the number of all answered questions (i.e., questions that were answered either correct or not correct – unanswered questions are excluded). Success criteria on the primary endpoint is defined as the observed estimate of the weighted composite knowledge level of at least 70% across these key questions.

**Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

***Yes= "Yes, some of it" + "Yes, all of it".

Table 15-6 Primary endpoint – knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia (Q5c) – correct responders – overall, by country and by healthcare professional characteristics

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Primary medical specialty (Q16)											
Oncologist*	64/84 (76.2) [65.7; 84.8]	2/5 (40.0) [5.3; 85.3]	10/10 (100.0) [69.2; 100.0]	6/12 (50.0) [21.1; 78.9]	2/2 (100.0) [15.8; 100.0]	8/13 (61.5) [31.6; 86.1]	1/1 (100.0) [2.5; 100.0]	10/12 (83.3) [51.6; 97.9]	9/9 (100.0) [66.4; 100.0]	11/14 (78.6) [49.2; 95.3]	5/6 (83.3) [35.9; 99.6]
Other	14/16 (87.5) [61.7; 98.4]	2/3 (66.7) [9.4; 99.2]	9/10 (90.0) [55.5; 99.7]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	3/3 (100.0) [29.2; 100.0]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]
Missing Data	0/2 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	0/1 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]
Years working with oncology patients (Q17)											
<5 years	2/2 (100.0) [15.8; 100.0]	0/0 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [0.0; 84.2]
5-<10 years	16/22 (72.7) [48.8; 91.2]	1/2 (50.0) [1.1; 98.9]	5/5 (100.0) [69.2; 100.0]	1/2 (50.0) [21.1; 78.9]	1/1 (100.0) [15.8; 100.0]	2/5 (40.0) [1.1; 98.9]	0/0 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 84.2]	4/4 (100.0) [69.2; 100.0]	2/3 (66.7) [9.4; 99.2]	0/0 (0.0) [0.0; 84.2]

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
10-<15 years	(72.7) [49.8; 89.3]	(50.0) [1.3; 98.7]	(100.0) [47.8; 100.0]	(50.0) [1.3; 98.7]	(100.0) [2.5; 100.0]	(40.0) [5.3; 85.3]			(100.0) [39.8; 100.0]	(66.7) [9.4; 99.2]	
≥15 years	21/26 (80.8) [60.6; 93.4]	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	2/4 (50.0) [6.8; 93.2]	1/1 (100.0) [2.5; 100.0]	4/4 (100.0) [39.8; 100.0]	0/0	4/5 (80.0) [28.4; 99.5]	3/3 (100.0) [29.2; 100.0]	2/4 (50.0) [6.8; 93.2]	2/2 (100.0) [15.8; 100.0]
Prefer not to answer	38/48 (79.2) [65.0; 89.5]	2/4 (50.0) [6.8; 93.2]	12/13 (92.3) [64.0; 99.8]	3/6 (50.0) [11.8; 88.2]	0/0	4/6 (66.7) [22.3; 95.7]	1/1 (100.0) [2.5; 100.0]	5/6 (83.3) [35.9; 99.6]	2/2 (100.0) [15.8; 100.0]	6/6 (100.0) [54.1; 100.0]	3/4 (75.0) [19.4; 99.4]
Missing Data	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	0/2 (0.0) [0.0; 84.2]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0
1-5	65/82	2/4	15/15	3/8	2/2	10/15	0/0	10/12	8/8	11/13	4/5

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
6-10	(79.3) [68.9; 87.4]	(50.0) [6.8; 93.2]	(100.0) [78.2; 100.0]	(37.5) [8.5; 75.5]	(100.0) [15.8; 100.0]	(66.7) [38.4; 88.2]		(83.3) [51.6; 97.9]	(100.0) [63.1; 100.0]	(84.6) [54.6; 98.1]	(80.0) [28.4; 99.5]
>10	7/11 (63.6) [30.8; 89.1]	1/3 (33.3) [0.8; 90.6]	3/4 (75.0) [19.4; 99.4]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	4/4 (100.0) [39.8; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data	2/3 (66.7) [9.4; 99.2]	0/0	0/0	2/3 (66.7) [9.4; 99.2]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Last time you prescribed Piqray (Q19)	0/2 (0.0) [0.0; 84.2]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0
<3 months ago	44/56 (78.6)	3/5 (60.0)	11/12 (91.7)	1/3 (33.3)	2/2 (100.0)	8/12 (66.7)	1/1 (100.0)	5/6 (83.3)	4/4 (100.0)	5/6 (83.3)	4/5 (80.0)

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
3-<6 months ago	[65.6; 88.4]	[14.7; 94.7]	[61.5; 99.8]	[0.8; 90.6]	[15.8; 100.0]	[34.9; 90.1]	[2.5; 100.0]	[35.9; 99.6]	[39.8; 100.0]	[35.9; 99.6]	[28.4; 99.5]
	26/33 (78.8)	1/2 (50.0)	6/6 (100.0)	3/6 (50.0)	0/0	3/4 (75.0)	0/0	4/5 (80.0)	2/2 (100.0)	6/7 (85.7)	1/1 (100.0)
	[61.1; 91.0]	[1.3; 98.7]	[54.1; 100.0]	[11.8; 88.2]		[19.4; 99.4]		[28.4; 99.5]	[15.8; 100.0]	[42.1; 99.6]	[2.5; 100.0]
I don't know/am not sure											
	7/10 (70.0)	0/1 (0.0)	2/2 (100.0)	1/2 (50.0)	0/0	0/0	0/0	1/1 (100.0)	3/3 (100.0)	0/1 (0.0)	0/0
	[34.8; 93.3]	[0.0; 97.5]	[15.8; 100.0]	[1.3; 98.7]				[2.5; 100.0]	[29.2; 100.0]	[0.0; 97.5]	
Missing Data											
	1/3 (33.3)	0/0	0/0	1/2 (50.0)	0/0	0/1 (0.0)	0/0	0/0	0/0	0/0	0/0
	[0.8; 90.6]			[1.3; 98.7]		[0.0; 97.5]					
Past investigator for one of the Piqray clinical trials (Q20)											
Yes											
	16/27 (59.3)	0/1 (0.0)	3/3 (100.0)	3/9 (33.3)	0/0	2/4 (50.0)	0/0	1/1 (100.0)	2/2 (100.0)	4/6 (66.7)	1/1 (100.0)
	[38.8; 77.6]	[0.0; 97.5]	[29.2; 100.0]	[7.5; 70.1]		[6.8; 93.2]		[2.5; 100.0]	[15.8; 100.0]	[22.3; 95.7]	[2.5; 100.0]
No											
	60/70 (85.7)	4/6 (66.7)	16/17 (94.1)	2/2 (100.0)	2/2 (100.0)	8/11 (72.7)	1/1 (100.0)	9/11 (81.8)	7/7 (100.0)	7/8 (87.5)	4/5 (80.0)

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
I don't know/am not sure	[75.3; 92.9]	[22.3; 95.7]	[71.3; 99.9]	[15.8; 100.0]	[15.8; 100.0]	[39.0; 94.0]	[2.5; 100.0]	[48.2; 97.7]	[59.0; 100.0]	[47.3; 99.7]	[28.4; 99.5]
	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data											
	1/3 (33.3) [0.8; 90.6]	0/0	0/0	1/2 (50.0) [1.3; 98.7]	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0
Received the Guide for HCPs (Q1)											
Yes	66/87 (75.9) [65.5; 84.4]	4/8 (50.0) [15.7; 84.3]	15/15 (100.0) [78.2; 100.0]	5/12 (41.7) [15.2; 72.3]	2/2 (100.0) [15.8; 100.0]	11/16 (68.8) [41.3; 89.0]	0/0	8/10 (80.0) [44.4; 97.5]	7/7 (100.0) [59.0; 100.0]	9/11 (81.8) [48.2; 97.7]	5/6 (83.3) [35.9; 99.6]
No											
	7/7 (100.0) [59.0; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	0/0
I don't know/am not sure											
	5/8 (62.5) [24.5; 91.5]	0/0	3/4 (75.0) [19.4; 99.4]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	0/0

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Read the Guide for HCPs (Q2)											
Yes**											
	64/85 (75.3) [64.7; 84.0]	4/8 (50.0) [15.7; 84.3]	15/15 (100.0) [78.2; 100.0]	5/12 (41.7) [15.2; 72.3]	2/2 (100.0) [15.8; 100.0]	10/15 (66.7) [38.4; 88.2]	0/0	8/10 (80.0) [44.4; 97.5]	6/6 (100.0) [54.1; 100.0]	9/11 (81.8) [48.2; 97.7]	5/6 (83.3) [35.9; 99.6]
Yes, all of it											
	38/51 (74.5) [60.4; 85.7]	3/6 (50.0) [11.8; 88.2]	12/12 (100.0) [73.5; 100.0]	4/8 (50.0) [15.7; 84.3]	2/2 (100.0) [15.8; 100.0]	4/7 (57.1) [18.4; 90.1]	0/0	5/6 (83.3) [35.9; 99.6]	2/2 (100.0) [15.8; 100.0]	3/4 (75.0) [19.4; 99.4]	3/4 (75.0) [19.4; 99.4]
Yes, some of it											
	26/34 (76.5) [58.8; 89.3]	1/2 (50.0) [1.3; 98.7]	3/3 (100.0) [29.2; 100.0]	1/4 (25.0) [0.6; 80.6]	0/0	6/8 (75.0) [34.9; 96.8]	0/0	3/4 (75.0) [19.4; 99.4]	4/4 (100.0) [39.8; 100.0]	6/7 (85.7) [42.1; 99.6]	2/2 (100.0) [15.8; 100.0]
No											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

[illegible]

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
10-<15 years	20/22 (90.9) [70.8; 98.9]	2/2 (100.0) [15.8; 100.0]	5/5 (100.0) [47.8; 100.0]	2/2 (100.0) [15.8; 100.0]	1/1 (100.0) [2.5; 100.0]	4/5 (80.0) [28.4; 99.5]	0/0	0/0	4/4 (100.0) [39.8; 100.0]	2/3 (66.7) [9.4; 99.2]	0/0
≥15 years	18/26 (69.2) [48.2; 85.7]	1/1 (100.0) [2.5; 100.0]	1/2 (50.0) [1.3; 98.7]	2/4 (50.0) [6.8; 93.2]	1/1 (100.0) [2.5; 100.0]	4/4 (100.0) [39.8; 100.0]	0/0	3/5 (60.0) [14.7; 94.7]	2/3 (66.7) [9.4; 99.2]	3/4 (75.0) [19.4; 99.4]	1/2 (50.0) [1.3; 98.7]
Prefer not to answer	38/48 (79.2) [65.0; 89.5]	3/4 (75.0) [19.4; 99.4]	11/13 (84.6) [54.6; 98.1]	4/6 (66.7) [22.3; 95.7]	0/0	5/6 (83.3) [35.9; 99.6]	0/1 (0.0) [0.0; 97.5]	4/6 (66.7) [22.3; 95.7]	2/2 (100.0) [15.8; 100.0]	6/6 (100.0) [54.1; 100.0]	3/4 (75.0) [19.4; 99.4]
Missing Data	0/2 (0.0) [0.0; 84.2]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	2/2 (100.0) [15.8; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
6-10	63/82 (76.8) [66.2; 85.4]	3/4 (75.0) [19.4; 99.4]	12/15 (80.0) [51.9; 95.7]	5/8 (62.5) [24.5; 91.5]	2/2 (100.0) [15.8; 100.0]	12/15 (80.0) [51.9; 95.7]	0/0	7/12 (58.3) [27.7; 84.8]	7/8 (87.5) [47.3; 99.7]	12/13 (92.3) [64.0; 99.8]	3/5 (60.0) [14.7; 94.7]
>10	8/11 (72.7) [39.0; 94.0]	2/3 (66.7) [9.4; 99.2]	4/4 (100.0) [39.8; 100.0]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	0/0	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	4/4 (100.0) [39.8; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data	2/3 (66.7) [9.4; 99.2]	0/0	0/0	2/3 (66.7) [9.4; 99.2]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Last time you prescribed Piqray (Q19)	2/2 (100.0) [15.8; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
<3 months ago	44/56	4/5	10/12	2/3	2/2	10/12	0/1	4/6	3/4	6/6	3/5

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
3-<6 months ago	(78.6) [65.6; 88.4]	(80.0) [28.4; 99.5]	(83.3) [51.6; 97.9]	(66.7) [9.4; 99.2]	(100.0) [15.8; 100.0]	(83.3) [51.6; 97.9]	(0.0) [0.0; 97.5]	(66.7) [22.3; 95.7]	(75.0) [19.4; 99.4]	(100.0) [54.1; 100.0]	(60.0) [14.7; 94.7]
I don't know/am not sure	25/33 (75.8) [57.7; 88.9]	2/2 (100.0) [15.8; 100.0]	6/6 (100.0) [54.1; 100.0]	4/6 (66.7) [22.3; 95.7]	0/0	3/4 (75.0) [19.4; 99.4]	0/0	2/5 (40.0) [5.3; 85.3]	2/2 (100.0) [15.8; 100.0]	5/7 (71.4) [29.0; 96.3]	1/1 (100.0) [2.5; 100.0]
Missing Data	7/10 (70.0) [34.8; 93.3]	0/1 (0.0) [0.0; 97.5]	1/2 (50.0) [1.3; 98.7]	1/2 (50.0) [1.3; 98.7]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	3/3 (100.0) [29.2; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0
Past investigator for one of the Piqray clinical trials (Q20)	3/3 (100.0) [29.2; 100.0]	0/0	0/0	2/2 (100.0) [15.8; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Yes	22/27 (81.5) [61.9; 93.7]	1/1 (100.0) [2.5; 100.0]	3/3 (100.0) [29.2; 100.0]	6/9 (66.7) [29.9; 92.5]	0/0	4/4 (100.0) [39.8; 100.0]	0/0	0/1 (0.0) [0.0; 97.5]	2/2 (100.0) [15.8; 100.0]	5/6 (83.3) [35.9; 99.6]	1/1 (100.0) [2.5; 100.0]
No	53/70	5/6	14/17	1/2	2/2	8/11	0/1	7/11	6/7	7/8	3/5

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
I don't know/am not sure	(75.7) [64.0; 85.2]	(83.3) [35.9; 99.6]	(82.4) [56.6; 96.2]	(50.0) [1.3; 98.7]	(100.0) [15.8; 100.0]	(72.7) [39.0; 94.0]	(0.0) [0.0; 97.5]	(63.6) [30.8; 89.1]	(85.7) [42.1; 99.6]	(87.5) [47.3; 99.7]	(60.0) [14.7; 94.7]
Missing Data	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Received the Guide for HCPs (Q1)	3/3 (100.0) [29.2; 100.0]	0/0	0/0	2/2 (100.0) [15.8; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Yes	68/87 (78.2) [68.0; 86.3]	6/8 (75.0) [34.9; 96.8]	13/15 (86.7) [59.5; 98.3]	9/12 (75.0) [42.8; 94.5]	2/2 (100.0) [15.8; 100.0]	13/16 (81.3) [54.4; 96.0]	0/0	6/10 (60.0) [26.2; 87.8]	6/7 (85.7) [42.1; 99.6]	9/11 (81.8) [48.2; 97.7]	4/6 (66.7) [22.3; 95.7]
No	4/7 (57.1) [18.4; 90.1]	0/0	0/1 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	0/0
I don't know/am not sure	7/8 (87.5)	0/0	4/4 (100.0)	0/0	0/0	1/1 (100.0)	0/0	0/1 (0.0)	1/1 (100.0)	1/1 (100.0)	0/0

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Read the Guide for HCPs (Q2)	[47.3; 99.7]		[39.8; 100.0]			[2.5; 100.0]		[0.0; 97.5]	[2.5; 100.0]	[2.5; 100.0]	
Yes**											
	68/85 (80.0) [69.9; 87.9]	6/8 (75.0) [34.9; 96.8]	13/15 (86.7) [59.5; 98.3]	9/12 (75.0) [42.8; 94.5]	2/2 (100.0) [15.8; 100.0]	13/15 (86.7) [59.5; 98.3]	0/0	6/10 (60.0) [26.2; 87.8]	6/6 (100.0) [54.1; 100.0]	9/11 (81.8) [48.2; 97.7]	4/6 (66.7) [22.3; 95.7]
Yes, all of it											
	42/51 (82.4) [69.1; 91.6]	4/6 (66.7) [22.3; 95.7]	11/12 (91.7) [61.5; 99.8]	6/8 (75.0) [34.9; 96.8]	2/2 (100.0) [15.8; 100.0]	5/7 (71.4) [29.0; 96.3]	0/0	5/6 (83.3) [35.9; 99.6]	2/2 (100.0) [15.8; 100.0]	4/4 (100.0) [39.8; 100.0]	3/4 (75.0) [19.4; 99.4]
Yes, some of it											
	26/34 (76.5) [58.8; 89.3]	2/2 (100.0) [15.8; 100.0]	2/3 (66.7) [9.4; 99.2]	3/4 (75.0) [19.4; 99.4]	0/0	8/8 (100.0) [63.1; 100.0]	0/0	1/4 (25.0) [0.6; 80.6]	4/4 (100.0) [39.8; 100.0]	5/7 (71.4) [29.0; 96.3]	1/2 (50.0) [1.3; 98.7]
No											
	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Table 15-8 Primary endpoint – knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray (Q8b) – correct responders – overall, by country and by healthcare professional characteristics

[illegible]

[illegible]

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
6-10	56/82 (68.3) [57.1; 78.1]	3/4 (75.0) [19.4; 99.4]	13/15 (86.7) [59.5; 98.3]	2/8 (25.0) [3.2; 65.1]	2/2 (100.0) [15.8; 100.0]	10/15 (66.7) [38.4; 88.2]	0/0	7/12 (58.3) [27.7; 84.8]	8/8 (100.0) [63.1; 100.0]	9/13 (69.2) [38.6; 90.9]	2/5 (40.0) [5.3; 85.3]
>10	9/11 (81.8) [48.2; 97.7]	2/3 (66.7) [9.4; 99.2]	4/4 (100.0) [39.8; 100.0]	0/0 (0.0) [0.0; 97.5]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [0.0; 97.5]	0/1 (0.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	4/4 (100.0) [39.8; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]
Missing Data	3/3 (100.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	3/3 (100.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]	0/0 (0.0) [29.2; 100.0]
Last time you prescribed Piqray (Q19)	2/2 (100.0) [15.8; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]	0/0 (0.0) [2.5; 100.0]
<3 months ago	38/56	5/5	10/12	1/3	2/2	7/12	1/1	4/6	3/4	3/6	2/5

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
3-<6 months ago	(67.9) [54.0; 79.7]	(100.0) [47.8; 100.0]	(83.3) [51.6; 97.9]	(33.3) [0.8; 90.6]	(100.0) [15.8; 100.0]	(58.3) [27.7; 84.8]	(100.0) [2.5; 100.0]	(66.7) [22.3; 95.7]	(75.0) [19.4; 99.4]	(50.0) [11.8; 88.2]	(40.0) [5.3; 85.3]
I don't know/am not sure	24/33 (72.7) [54.5; 86.7]	1/2 (50.0) [1.3; 98.7]	6/6 (100.0) [54.1; 100.0]	2/6 (33.3) [4.3; 77.7]	0/0	4/4 (100.0) [39.8; 100.0]	0/0	2/5 (40.0) [5.3; 85.3]	2/2 (100.0) [15.8; 100.0]	6/7 (85.7) [42.1; 99.6]	1/1 (100.0) [2.5; 100.0]
Missing Data	9/10 (90.0) [55.5; 99.7]	0/1 (0.0) [0.0; 97.5]	2/2 (100.0) [15.8; 100.0]	2/2 (100.0) [15.8; 100.0]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	3/3 (100.0) [29.2; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0
Past investigator for one of the Piqray clinical trials (Q20)	3/3 (100.0) [29.2; 100.0]	0/0	0/0	2/2 (100.0) [15.8; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Yes	17/27 (63.0) [42.4; 80.6]	1/1 (100.0) [2.5; 100.0]	3/3 (100.0) [29.2; 100.0]	4/9 (44.4) [13.7; 78.8]	0/0	3/4 (75.0) [19.4; 99.4]	0/0	1/1 (100.0) [2.5; 100.0]	1/2 (50.0) [1.3; 98.7]	3/6 (50.0) [11.8; 88.2]	1/1 (100.0) [2.5; 100.0]
No	53/70	5/6	15/17	1/2	2/2	7/11	1/1	6/11	7/7	7/8	2/5

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
I don't know/am not sure	(75.7) [64.0; 85.2]	(83.3) [35.9; 99.6]	(88.2) [63.6; 98.5]	(50.0) [1.3; 98.7]	(100.0) [15.8; 100.0]	(63.6) [30.8; 89.1]	(100.0) [2.5; 100.0]	(54.5) [23.4; 83.3]	(100.0) [59.0; 100.0]	(87.5) [47.3; 99.7]	(40.0) [5.3; 85.3]
Missing Data	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Received the Guide for HCPs (Q1)	3/3 (100.0) [29.2; 100.0]	0/0	0/0	2/2 (100.0) [15.8; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Yes	61/87 (70.1) [59.4; 79.5]	6/8 (75.0) [34.9; 96.8]	14/15 (93.3) [68.1; 99.8]	6/12 (50.0) [21.1; 78.9]	2/2 (100.0) [15.8; 100.0]	11/16 (68.8) [41.3; 89.0]	0/0	6/10 (60.0) [26.2; 87.8]	6/7 (85.7) [42.1; 99.6]	7/11 (63.6) [30.8; 89.1]	3/6 (50.0) [11.8; 88.2]
No	6/7 (85.7) [42.1; 99.6]	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	0/0
I don't know/am not sure	7/8 (87.5)	0/0	3/4 (75.0)	0/0	0/0	1/1 (100.0)	0/0	1/1 (100.0)	1/1 (100.0)	1/1 (100.0)	0/0

	Overall N=102 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Read the Guide for HCPs (Q2)	[47.3; 99.7]		[19.4; 99.4]			[2.5; 100.0]		[2.5; 100.0]	[2.5; 100.0]	[2.5; 100.0]	
Yes**											
	59/85 (69.4) [58.5; 79.0]	6/8 (75.0) [34.9; 96.8]	14/15 (93.3) [68.1; 99.8]	6/12 (50.0) [21.1; 78.9]	2/2 (100.0) [15.8; 100.0]	10/15 (66.7) [38.4; 88.2]	0/0	6/10 (60.0) [26.2; 87.8]	5/6 (83.3) [35.9; 99.6]	7/11 (63.6) [30.8; 89.1]	3/6 (50.0) [11.8; 88.2]
Yes, all of it											
	40/51 (78.4) [64.7; 88.7]	5/6 (83.3) [35.9; 99.6]	11/12 (91.7) [61.5; 99.8]	4/8 (50.0) [15.7; 84.3]	2/2 (100.0) [15.8; 100.0]	6/7 (85.7) [42.1; 99.6]	0/0	4/6 (66.7) [22.3; 95.7]	2/2 (100.0) [15.8; 100.0]	3/4 (75.0) [19.4; 99.4]	3/4 (75.0) [19.4; 99.4]
Yes, some of it											
	19/34 (55.9) [37.9; 72.8]	1/2 (50.0) [1.3; 98.7]	3/3 (100.0) [29.2; 100.0]	2/4 (50.0) [6.8; 93.2]	0/0	4/8 (50.0) [15.7; 84.3]	0/0	2/4 (50.0) [6.8; 93.2]	3/4 (75.0) [19.4; 99.4]	4/7 (57.1) [18.4; 90.1]	0/2 (0.0) [0.0; 84.2]
No											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Table 15-9 Primary endpoint – knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10) – Correct responders – overall, by country and by healthcare professional characteristics

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Primary medical specialty (Q16)											
Oncologist*	64/84 (76.2) [65.7; 84.8]	4/5 (80.0) [28.4; 99.5]	8/10 (80.0) [44.4; 97.5]	9/12 (75.0) [42.8; 94.5]	2/2 (100.0) [15.8; 100.0]	10/13 (76.9) [46.2; 95.0]	1/1 (100.0) [2.5; 100.0]	8/12 (66.7) [34.9; 90.1]	7/9 (77.8) [40.0; 97.2]	10/14 (71.4) [41.9; 91.6]	5/6 (83.3) [35.9; 99.6]
Other	11/16 (68.8) [41.3; 89.0]	3/3 (100.0) [29.2; 100.0]	6/10 (60.0) [26.2; 87.8]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	2/3 (66.7) [9.4; 99.2]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]
Missing Data	2/3 (66.7) [9.4; 99.2]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [0.0; 0.0]	1/2 (50.0) [1.3; 98.7]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]
Years working with oncology patients (Q17)											
<5 years	1/2 (50.0) [1.3; 98.7]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/1 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	1/1 (100.0) [2.5; 100.0]	0/0 (0.0) [0.0; 0.0]
5-<10 years	20/22 (90.9) [78.4; 98.4]	2/2 (100.0) [100.0; 100.0]	5/5 (100.0) [100.0; 100.0]	2/2 (100.0) [100.0; 100.0]	1/1 (50.0) [1.3; 98.7]	5/5 (100.0) [100.0; 100.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	3/4 (75.0) [37.5; 93.8]	2/3 (66.7) [22.2; 93.3]	0/0 (0.0) [0.0; 0.0]

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
10-<15 years	(90.9) [70.8; 98.9]	(100.0) [15.8; 100.0]	(100.0) [47.8; 100.0]	(100.0) [15.8; 100.0]	(100.0) [2.5; 100.0]	(100.0) [47.8; 100.0]			(75.0) [19.4; 99.4]	(66.7) [9.4; 99.2]	
≥15 years	20/26 (76.9) [56.4; 91.0]	1/1 (100.0) [2.5; 100.0]	1/2 (50.0) [1.3; 98.7]	3/4 (75.0) [19.4; 99.4]	1/1 (100.0) [2.5; 100.0]	3/4 (75.0) [19.4; 99.4]	0/0	4/5 (80.0) [28.4; 99.5]	3/3 (100.0) [29.2; 100.0]	2/4 (50.0) [6.8; 93.2]	2/2 (100.0) [15.8; 100.0]
Prefer not to answer	34/48 (70.8) [55.9; 83.0]	4/4 (100.0) [39.8; 100.0]	8/13 (61.5) [31.6; 86.1]	4/6 (66.7) [22.3; 95.7]	0/0	4/6 (66.7) [22.3; 95.7]	1/1 (100.0) [2.5; 100.0]	4/6 (66.7) [22.3; 95.7]	1/2 (50.0) [1.3; 98.7]	5/6 (83.3) [35.9; 99.6]	3/4 (75.0) [19.4; 99.4]
Missing Data	0/2 (0.0) [0.0; 84.2]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	2/3 (66.7) [9.4; 99.2]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	1/2 (50.0) [1.3; 98.7]	0/0	0/0	0/0	0/0	0/0
1-5	63/82	4/4	11/15	6/8	2/2	11/15	0/0	8/12	7/8	9/13	5/5

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
6-10	(76.8) [66.2; 85.4]	(100.0) [39.8; 100.0]	(73.3) [44.9; 92.2]	(75.0) [34.9; 96.8]	(100.0) [15.8; 100.0]	(73.3) [44.9; 92.2]		(66.7) [34.9; 90.1]	(87.5) [47.3; 99.7]	(69.2) [38.6; 90.9]	(100.0) [47.8; 100.0]
>10	7/11 (63.6) [30.8; 89.1]	2/3 (66.7) [9.4; 99.2]	3/4 (75.0) [19.4; 99.4]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]
I don't know/am not sure	3/4 (75.0) [19.4; 99.4]	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data	2/3 (66.7) [9.4; 99.2]	0/0	0/0	2/3 (66.7) [9.4; 99.2]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Last time you prescribed Piqray (Q19)	2/3 (66.7) [9.4; 99.2]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	1/2 (50.0) [1.3; 98.7]	0/0	0/0	0/0	0/0	0/0
<3 months ago	44/56 (78.6)	5/5 (100.0)	9/12 (75.0)	2/3 (66.7)	2/2 (100.0)	9/12 (75.0)	1/1 (100.0)	4/6 (66.7)	3/4 (75.0)	5/6 (83.3)	4/5 (80.0)

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
3-<6 months ago	[65.6; 88.4]	[47.8; 100.0]	[42.8; 94.5]	[9.4; 99.2]	[15.8; 100.0]	[42.8; 94.5]	[2.5; 100.0]	[22.3; 95.7]	[19.4; 99.4]	[35.9; 99.6]	[28.4; 99.5]
	26/33 (78.8)	2/2 (100.0)	5/6 (83.3)	5/6 (83.3)	0/0	3/4 (75.0)	0/0	4/5 (80.0)	1/2 (50.0)	5/7 (71.4)	1/1 (100.0)
	[61.1; 91.0]	[15.8; 100.0]	[35.9; 99.6]	[35.9; 99.6]		[19.4; 99.4]		[28.4; 99.5]	[1.3; 98.7]	[29.0; 96.3]	[2.5; 100.0]
I don't know/am not sure											
	4/10 (40.0)	0/1 (0.0)	0/2 (0.0)	1/2 (50.0)	0/0	0/0	0/0	0/1 (0.0)	3/3 (100.0)	0/1 (0.0)	0/0
	[12.2; 73.8]	[0.0; 97.5]	[0.0; 84.2]	[1.3; 98.7]				[0.0; 97.5]	[29.2; 100.0]	[0.0; 97.5]	
Missing Data											
	3/4 (75.0)	0/0	0/0	2/2 (100.0)	0/0	1/2 (50.0)	0/0	0/0	0/0	0/0	0/0
	[19.4; 99.4]			[15.8; 100.0]		[1.3; 98.7]					
Past investigator for one of the Piqray clinical trials (Q20)											
Yes											
	22/27 (81.5)	1/1 (100.0)	2/3 (66.7)	7/9 (77.8)	0/0	3/4 (75.0)	0/0	1/1 (100.0)	1/2 (50.0)	6/6 (100.0)	1/1 (100.0)
	[61.9; 93.7]	[2.5; 100.0]	[9.4; 99.2]	[40.0; 97.2]		[19.4; 99.4]		[2.5; 100.0]	[1.3; 98.7]	[54.1; 100.0]	[2.5; 100.0]
No											
	51/70 (72.9)	6/6 (100.0)	12/17 (70.6)	1/2 (50.0)	2/2 (100.0)	8/11 (72.7)	1/1 (100.0)	7/11 (63.6)	6/7 (85.7)	4/8 (50.0)	4/5 (80.0)

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
I don't know/am not sure	[60.9; 82.8]	[54.1; 100.0]	[44.0; 89.7]	[1.3; 98.7]	[15.8; 100.0]	[39.0; 94.0]	[2.5; 100.0]	[30.8; 89.1]	[42.1; 99.6]	[15.7; 84.3]	[28.4; 99.5]
	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data											
	3/4 (75.0) [19.4; 99.4]	0/0	0/0	2/2 (100.0) [15.8; 100.0]	0/0	1/2 (50.0) [1.3; 98.7]	0/0	0/0	0/0	0/0	0/0
Received the Guide for HCPs (Q1)											
Yes	69/88 (78.4) [68.4; 86.5]	7/8 (87.5) [47.3; 99.7]	13/15 (86.7) [59.5; 98.3]	10/12 (83.3) [51.6; 97.9]	2/2 (100.0) [15.8; 100.0]	12/17 (70.6) [44.0; 89.7]	0/0	7/10 (70.0) [34.8; 93.3]	5/7 (71.4) [29.0; 96.3]	8/11 (72.7) [39.0; 94.0]	5/6 (83.3) [35.9; 99.6]
No											
	4/7 (57.1) [18.4; 90.1]	0/0	0/1 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	0/0
I don't know/am not sure											
	4/8 (50.0) [15.7; 84.3]	0/0	1/4 (25.0) [0.6; 80.6]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	0/0

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Read the Guide for HCPs (Q2)											
Yes**											
	68/86 (79.1) [69.0; 87.1]	7/8 (87.5) [47.3; 99.7]	13/15 (86.7) [59.5; 98.3]	10/12 (83.3) [51.6; 97.9]	2/2 (100.0) [15.8; 100.0]	12/16 (75.0) [47.6; 92.7]	0/0	7/10 (70.0) [34.8; 93.3]	4/6 (66.7) [22.3; 95.7]	8/11 (72.7) [39.0; 94.0]	5/6 (83.3) [35.9; 99.6]
Yes, all of it											
	41/52 (78.8) [65.3; 88.9]	5/6 (83.3) [35.9; 99.6]	11/12 (91.7) [61.5; 99.8]	7/8 (87.5) [47.3; 99.7]	2/2 (100.0) [15.8; 100.0]	6/8 (75.0) [34.9; 96.8]	0/0	3/6 (50.0) [11.8; 88.2]	2/2 (100.0) [15.8; 100.0]	2/4 (50.0) [6.8; 93.2]	3/4 (75.0) [19.4; 99.4]
Yes, some of it											
	27/34 (79.4) [62.1; 91.3]	2/2 (100.0) [15.8; 100.0]	2/3 (66.7) [9.4; 99.2]	3/4 (75.0) [19.4; 99.4]	0/0	6/8 (75.0) [34.9; 96.8]	0/0	4/4 (100.0) [39.8; 100.0]	2/4 (50.0) [6.8; 93.2]	6/7 (85.7) [42.1; 99.6]	2/2 (100.0) [15.8; 100.0]
No											
	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

[illegible]

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
10-<15 years	20/22 (90.9) [70.8; 98.9]	2/2 (100.0) [15.8; 100.0]	5/5 (100.0) [47.8; 100.0]	1/2 (50.0) [1.3; 98.7]	1/1 (100.0) [2.5; 100.0]	4/5 (80.0) [28.4; 99.5]	0/0	0/0	4/4 (100.0) [39.8; 100.0]	3/3 (100.0) [29.2; 100.0]	0/0
≥15 years	23/26 (88.5) [69.8; 97.6]	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	3/4 (75.0) [19.4; 99.4]	1/1 (100.0) [2.5; 100.0]	4/4 (100.0) [39.8; 100.0]	0/0	5/5 (100.0) [47.8; 100.0]	2/3 (66.7) [9.4; 99.2]	4/4 (100.0) [39.8; 100.0]	1/2 (50.0) [1.3; 98.7]
Prefer not to answer	42/48 (87.5) [74.8; 95.3]	4/4 (100.0) [39.8; 100.0]	12/13 (92.3) [64.0; 99.8]	4/6 (66.7) [22.3; 95.7]	0/0	5/6 (83.3) [35.9; 99.6]	1/1 (100.0) [2.5; 100.0]	6/6 (100.0) [54.1; 100.0]	2/2 (100.0) [15.8; 100.0]	4/6 (66.7) [22.3; 95.7]	4/4 (100.0) [39.8; 100.0]
Missing Data	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	3/3 (100.0) [29.2; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	2/2 (100.0) [15.8; 100.0]	0/0	0/0	0/0	0/0	0/0

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
6-10	72/82 (87.8) [78.7; 94.0]	4/4 (100.0) [39.8; 100.0]	14/15 (93.3) [68.1; 99.8]	5/8 (62.5) [24.5; 91.5]	2/2 (100.0) [15.8; 100.0]	13/15 (86.7) [59.5; 98.3]	0/0	12/12 (100.0) [73.5; 100.0]	7/8 (87.5) [47.3; 99.7]	11/13 (84.6) [54.6; 98.1]	4/5 (80.0) [28.4; 99.5]
>10	10/11 (90.9) [58.7; 99.8]	2/3 (66.7) [9.4; 99.2]	4/4 (100.0) [39.8; 100.0]	0/0 (00.0) [2.5; 100.0]	0/0 (00.0) [2.5; 100.0]	0/0 (00.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	4/4 (100.0) [39.8; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (00.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data	2/3 (66.7) [9.4; 99.2]	0/0 (00.0) [2.5; 100.0]	0/0 (00.0) [2.5; 100.0]	2/3 (66.7) [9.4; 99.2]	0/0 (00.0) [2.5; 100.0]	0/0 (00.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Last time you prescribed Piqray (Q19)	3/3 (100.0) [29.2; 100.0]	0/0 (00.0) [2.5; 100.0]	0/0 (00.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0 (00.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	0/0	0/0	0/0	0/0	0/0
<3 months ago	52/56	5/5	11/12	3/3	2/2	10/12	1/1	6/6	4/4	6/6	4/5

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
3-<6 months ago	(92.9) [82.7; 98.0]	(100.0) [47.8; 100.0]	(91.7) [61.5; 99.8]	(100.0) [29.2; 100.0]	(100.0) [15.8; 100.0]	(83.3) [51.6; 97.9]	(100.0) [2.5; 100.0]	(100.0) [54.1; 100.0]	(100.0) [39.8; 100.0]	(100.0) [54.1; 100.0]	(80.0) [28.4; 99.5]
I don't know/am not sure	28/33 (84.8) [68.1; 94.9]	2/2 (100.0) [15.8; 100.0]	6/6 (100.0) [54.1; 100.0]	3/6 (50.0) [11.8; 88.2]	0/0	4/4 (100.0) [39.8; 100.0]	0/0	5/5 (100.0) [47.8; 100.0]	2/2 (100.0) [15.8; 100.0]	5/7 (71.4) [29.0; 96.3]	1/1 (100.0) [2.5; 100.0]
Missing Data	7/10 (70.0) [34.8; 93.3]	0/1 (0.0) [0.0; 97.5]	2/2 (100.0) [15.8; 100.0]	1/2 (50.0) [1.3; 98.7]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	2/3 (66.7) [9.4; 99.2]	1/1 (100.0) [2.5; 100.0]	0/0
Past investigator for one of the Piqray clinical trials (Q20)	4/4 (100.0) [39.8; 100.0]	0/0	0/0	2/2 (100.0) [15.8; 100.0]	0/0	2/2 (100.0) [15.8; 100.0]	0/0	0/0	0/0	0/0	0/0
Yes	23/27 (85.2) [66.3; 95.8]	1/1 (100.0) [2.5; 100.0]	3/3 (100.0) [29.2; 100.0]	6/9 (66.7) [29.9; 92.5]	0/0	3/4 (75.0) [19.4; 99.4]	0/0	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	6/6 (100.0) [54.1; 100.0]	1/1 (100.0) [2.5; 100.0]
No	63/70	6/6	16/17	1/2	2/2	10/11	1/1	11/11	6/7	6/8	4/5

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
I don't know/am not sure	(90.0) [80.5; 95.9]	(100.0) [54.1; 100.0]	(94.1) [71.3; 99.9]	(50.0) [1.3; 98.7]	(100.0) [15.8; 100.0]	(90.9) [58.7; 99.8]	(100.0) [2.5; 100.0]	(100.0) [71.5; 100.0]	(85.7) [42.1; 99.6]	(75.0) [34.9; 96.8]	(80.0) [28.4; 99.5]
Missing Data	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Received the Guide for HCPs (Q1)	4/4 (100.0) [39.8; 100.0]	0/0	0/0	2/2 (100.0) [15.8; 100.0]	0/0	2/2 (100.0) [15.8; 100.0]	0/0	0/0	0/0	0/0	0/0
Yes	78/88 (88.6) [80.1; 94.4]	7/8 (87.5) [47.3; 99.7]	14/15 (93.3) [68.1; 99.8]	9/12 (75.0) [42.8; 94.5]	2/2 (100.0) [15.8; 100.0]	15/17 (88.2) [63.6; 98.5]	0/0	10/10 (100.0) [69.2; 100.0]	6/7 (85.7) [42.1; 99.6]	10/11 (90.9) [58.7; 99.8]	5/6 (83.3) [35.9; 99.6]
No	5/7 (71.4) [29.0; 96.3]	0/0	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/2 (50.0) [1.3; 98.7]	0/0
I don't know/am not sure	8/8 (100.0)	0/0	4/4 (100.0)	0/0	0/0	1/1 (100.0)	0/0	1/1 (100.0)	1/1 (100.0)	1/1 (100.0)	0/0

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Read the Guide for HCPs (Q2)	[63.1; 100.0]		[39.8; 100.0]			[2.5; 100.0]		[2.5; 100.0]	[2.5; 100.0]	[2.5; 100.0]	
Yes**											
	76/86 (88.4) [79.7; 94.3]	7/8 (87.5) [47.3; 99.7]	14/15 (93.3) [68.1; 99.8]	9/12 (75.0) [42.8; 94.5]	2/2 (100.0) [15.8; 100.0]	14/16 (87.5) [61.7; 98.4]	0/0	10/10 (100.0) [69.2; 100.0]	5/6 (83.3) [35.9; 99.6]	10/11 (90.9) [58.7; 99.8]	5/6 (83.3) [35.9; 99.6]
Yes, all of it											
	48/52 (92.3) [81.5; 97.9]	5/6 (83.3) [35.9; 99.6]	11/12 (91.7) [61.5; 99.8]	6/8 (75.0) [34.9; 96.8]	2/2 (100.0) [15.8; 100.0]	8/8 (100.0) [63.1; 100.0]	0/0	6/6 (100.0) [54.1; 100.0]	2/2 (100.0) [15.8; 100.0]	4/4 (100.0) [39.8; 100.0]	4/4 (100.0) [39.8; 100.0]
Yes, some of it											
	28/34 (82.4) [65.5; 93.2]	2/2 (100.0) [15.8; 100.0]	3/3 (100.0) [29.2; 100.0]	3/4 (75.0) [19.4; 99.4]	0/0	6/8 (75.0) [34.9; 96.8]	0/0	4/4 (100.0) [39.8; 100.0]	3/4 (75.0) [19.4; 99.4]	6/7 (85.7) [42.1; 99.6]	1/2 (50.0) [1.3; 98.7]
No											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Table 15-11 Primary endpoint – knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13) – correct responders – overall, by country and by healthcare professional characteristics

	Overall N=101 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Primary medical specialty (Q16)											
Oncologist*	71/84 (84.5) [75.0; 91.5]	4/5 (80.0) [28.4; 99.5]	5/10 (50.0) [18.7; 81.3]	11/12 (91.7) [61.5; 99.8]	2/2 (100.0) [15.8; 100.0]	12/13 (92.3) [64.0; 99.8]	0/1 (0.0) [0.0; 97.5]	11/12 (91.7) [61.5; 99.8]	9/9 (100.0) [66.4; 100.0]	14/14 (100.0) [76.8; 100.0]	3/6 (50.0) [11.8; 88.2]
Other	9/16 (56.3) [29.9; 80.2]	3/3 (100.0) [29.2; 100.0]	4/10 (40.0) [12.2; 73.8]	0/0 0/0	0/0 0/0	2/3 (66.7) [9.4; 99.2]	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
Missing Data	1/1 (100.0) [2.5; 100.0]	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	1/1 (100.0) [2.5; 100.0]	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
Years working with oncology patients (Q17)											
<5 years	2/2 (100.0) [15.8; 100.0]	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	1/1 (100.0) [2.5; 100.0]	0/0 0/0	0/0 0/0	0/0 0/0	1/1 (100.0) [2.5; 100.0]	0/0 0/0
5-<10 years	19/22	2/2	3/5	2/2	1/1	4/5	0/0	0/0	4/4	3/3	0/0

	Overall N=101 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
10-<15 years	(86.4) [65.1; 97.1]	(100.0) [15.8; 100.0]	(60.0) [14.7; 94.7]	(100.0) [15.8; 100.0]	(100.0) [2.5; 100.0]	(80.0) [28.4; 99.5]			(100.0) [39.8; 100.0]	(100.0) [29.2; 100.0]	
≥15 years	21/26 (80.8) [60.6; 93.4]	1/1 (100.0) [2.5; 100.0]	1/2 (50.0) [1.3; 98.7]	3/4 (75.0) [19.4; 99.4]	1/1 (100.0) [2.5; 100.0]	3/4 (75.0) [19.4; 99.4]	0/0	5/5 (100.0) [47.8; 100.0]	3/3 (100.0) [29.2; 100.0]	4/4 (100.0) [39.8; 100.0]	0/2 (0.0) [0.0; 84.2]
Prefer not to answer	37/48 (77.1) [62.7; 88.0]	4/4 (100.0) [39.8; 100.0]	5/13 (38.5) [13.9; 68.4]	6/6 (100.0) [54.1; 100.0]	0/0	6/6 (100.0) [54.1; 100.0]	0/1 (0.0) [0.0; 97.5]	5/6 (83.3) [35.9; 99.6]	2/2 (100.0) [15.8; 100.0]	6/6 (100.0) [54.1; 100.0]	3/4 (75.0) [19.4; 99.4]
Missing Data	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0
Within the past 12 months, how many patients have you prescribed Piqray (Q18)	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
1-5	69/82	4/4	8/15	8/8	2/2	13/15	0/0	11/12	8/8	13/13	2/5

	Overall N=101 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
6-10	(84.1) [74.4; 91.3]	(100.0) [39.8; 100.0]	(53.3) [26.6; 78.7]	(100.0) [63.1; 100.0]	(100.0) [15.8; 100.0]	(86.7) [59.5; 98.3]		(91.7) [61.5; 99.8]	(100.0) [63.1; 100.0]	(100.0) [75.3; 100.0]	(40.0) [5.3; 85.3]
>10	6/11 (54.5) [23.4; 83.3]	2/3 (66.7) [9.4; 99.2]	1/4 (25.0) [0.6; 80.6]	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]
I don't know/am not sure	3/4 (75.0) [19.4; 99.4]	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data	2/3 (66.7) [9.4; 99.2]	0/0	0/0	2/3 (66.7) [9.4; 99.2]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Last time you prescribed Piqray (Q19)	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
<3 months ago	44/56 (78.6)	5/5 (100.0)	5/12 (41.7)	3/3 (100.0)	2/2 (100.0)	11/12 (91.7)	0/1 (0.0)	5/6 (83.3)	4/4 (100.0)	6/6 (100.0)	3/5 (60.0)

	Overall N=101 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
3-<6 months ago	[65.6; 88.4]	[47.8; 100.0]	[15.2; 72.3]	[29.2; 100.0]	[15.8; 100.0]	[61.5; 99.8]	[0.0; 97.5]	[35.9; 99.6]	[39.8; 100.0]	[54.1; 100.0]	[14.7; 94.7]
	29/33 (87.9)	2/2 (100.0)	4/6 (66.7)	6/6 (100.0)	0/0	3/4 (75.0)	0/0	5/5 (100.0)	2/2 (100.0)	7/7 (100.0)	0/1 (0.0)
	[71.8; 96.6]	[15.8; 100.0]	[22.3; 95.7]	[54.1; 100.0]		[19.4; 99.4]		[47.8; 100.0]	[15.8; 100.0]	[59.0; 100.0]	[0.0; 97.5]
I don't know/am not sure											
	6/10 (60.0)	0/1 (0.0)	0/2 (0.0)	1/2 (50.0)	0/0	0/0	0/0	1/1 (100.0)	3/3 (100.0)	1/1 (100.0)	0/0
	[26.2; 87.8]	[0.0; 97.5]	[0.0; 84.2]	[1.3; 98.7]				[2.5; 100.0]	[29.2; 100.0]	[2.5; 100.0]	
Missing Data											
	2/2 (100.0)	0/0	0/0	1/1 (100.0)	0/0	1/1 (100.0)	0/0	0/0	0/0	0/0	0/0
	[15.8; 100.0]			[2.5; 100.0]		[2.5; 100.0]					
Past investigator for one of the Piqray clinical trials (Q20)											
Yes											
	23/27 (85.2)	1/1 (100.0)	0/3 (0.0)	9/9 (100.0)	0/0	4/4 (100.0)	0/0	1/1 (100.0)	2/2 (100.0)	6/6 (100.0)	0/1 (0.0)
	[66.3; 95.8]	[2.5; 100.0]	[0.0; 70.8]	[66.4; 100.0]		[39.8; 100.0]		[2.5; 100.0]	[15.8; 100.0]	[54.1; 100.0]	[0.0; 97.5]
No											
	55/70 (78.6)	6/6 (100.0)	9/17 (52.9)	1/2 (50.0)	2/2 (100.0)	9/11 (81.8)	0/1 (0.0)	10/11 (90.9)	7/7 (100.0)	8/8 (100.0)	3/5 (60.0)

	Overall N=101 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
I don't know/am not sure	[67.1; 87.5]	[54.1; 100.0]	[27.8; 77.0]	[1.3; 98.7]	[15.8; 100.0]	[48.2; 97.7]	[0.0; 97.5]	[58.7; 99.8]	[59.0; 100.0]	[63.1; 100.0]	[14.7; 94.7]
	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data											
	2/2 (100.0) [15.8; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Received the Guide for HCPs (Q1)											
Yes	73/86 (84.9) [75.5; 91.7]	7/8 (87.5) [47.3; 99.7]	8/15 (53.3) [26.6; 78.7]	11/11 (100.0) [71.5; 100.0]	2/2 (100.0) [15.8; 100.0]	15/16 (93.8) [69.8; 99.8]	0/0	9/10 (90.0) [55.5; 99.7]	7/7 (100.0) [59.0; 100.0]	11/11 (100.0) [71.5; 100.0]	3/6 (50.0) [11.8; 88.2]
No	4/7 (57.1) [18.4; 90.1]	0/0	0/1 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	0/0
I don't know/am not sure	4/8 (50.0) [15.7; 84.3]	0/0	1/4 (25.0) [0.6; 80.6]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	1/1 (100.0) [2.5; 100.0]	0/0

	Overall N=101 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=17 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Read the Guide for HCPs (Q2)											
Yes**											
	71/84 (84.5) [75.0; 91.5]	7/8 (87.5) [47.3; 99.7]	8/15 (53.3) [26.6; 78.7]	11/11 (100.0) [71.5; 100.0]	2/2 (100.0) [15.8; 100.0]	14/15 (93.3) [68.1; 99.8]	0/0	9/10 (90.0) [55.5; 99.7]	6/6 (100.0) [54.1; 100.0]	11/11 (100.0) [71.5; 100.0]	3/6 (50.0) [11.8; 88.2]
Yes, all of it											
	41/50 (82.0) [68.6; 91.4]	5/6 (83.3) [35.9; 99.6]	7/12 (58.3) [27.7; 84.8]	7/7 (100.0) [59.0; 100.0]	2/2 (100.0) [15.8; 100.0]	6/7 (85.7) [42.1; 99.6]	0/0	6/6 (100.0) [54.1; 100.0]	2/2 (100.0) [15.8; 100.0]	4/4 (100.0) [39.8; 100.0]	2/4 (50.0) [6.8; 93.2]
Yes, some of it											
	30/34 (88.2) [72.5; 96.7]	2/2 (100.0) [15.8; 100.0]	1/3 (33.3) [0.8; 90.6]	4/4 (100.0) [39.8; 100.0]	0/0	8/8 (100.0) [63.1; 100.0]	0/0	3/4 (75.0) [19.4; 99.4]	4/4 (100.0) [39.8; 100.0]	7/7 (100.0) [59.0; 100.0]	1/2 (50.0) [1.3; 98.7]
No											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Table 15-12 Primary endpoint – knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14) – correct responders – overall, by country and by healthcare professional characteristics

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Primary medical specialty (Q16)											
Oncologist*	52/84 (61.9) [50.7; 72.3]	2/5 (40.0) [5.3; 85.3]	6/10 (60.0) [26.2; 87.8]	6/12 (50.0) [21.1; 78.9]	2/2 (100.0) [15.8; 100.0]	10/13 (76.9) [46.2; 95.0]	0/1 (0.0) [0.0; 97.5]	8/12 (66.7) [34.9; 90.1]	9/9 (100.0) [66.4; 100.0]	6/14 (42.9) [17.7; 71.1]	3/6 (50.0) [11.8; 88.2]
Other	11/16 (68.8) [41.3; 89.0]	3/3 (100.0) [29.2; 100.0]	5/10 (50.0) [18.7; 81.3]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	3/3 (100.0) [29.2; 100.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]
Years working with oncology patients (Q17)											
<5 years	0/2 (0.0) [0.0; 84.2]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/1 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	0/1 (0.0) [0.0; 97.5]	0/0 (0.0) [0.0; 0.0]
5-<10 years	19/22 (86.4) [65.1; 97.1]	2/2 (100.0) [15.8; 100.0]	4/5 (80.0) [28.4; 99.5]	2/2 (100.0) [15.8; 100.0]	1/1 (100.0) [2.5; 100.0]	4/5 (80.0) [28.4; 99.5]	0/0 (0.0) [0.0; 0.0]	0/0 (0.0) [0.0; 0.0]	4/4 (100.0) [39.8; 100.0]	2/3 (66.7) [9.4; 99.2]	0/0 (0.0) [0.0; 0.0]

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
10-<15 years	17/26 (65.4) [44.3; 82.8]	1/1 (100.0) [2.5; 100.0]	0/2 (0.0) [0.0; 84.2]	2/4 (50.0) [6.8; 93.2]	1/1 (100.0) [2.5; 100.0]	4/4 (100.0) [39.8; 100.0]	0/0	4/5 (80.0) [28.4; 99.5]	3/3 (100.0) [29.2; 100.0]	1/4 (25.0) [0.6; 80.6]	1/2 (50.0) [1.3; 98.7]
≥15 years	27/48 (56.3) [41.2; 70.5]	2/4 (50.0) [6.8; 93.2]	7/13 (53.8) [25.1; 80.8]	2/6 (33.3) [4.3; 77.7]	0/0	5/6 (83.3) [35.9; 99.6]	0/1 (0.0) [0.0; 97.5]	4/6 (66.7) [22.3; 95.7]	2/2 (100.0) [15.8; 100.0]	3/6 (50.0) [11.8; 88.2]	2/4 (50.0) [6.8; 93.2]
Prefer not to answer	0/2 (0.0) [0.0; 84.2]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0
Within the past 12 months, how many patients have you prescribed Piqray (Q18)											
1-5	54/82 (65.9) [54.6; 76.0]	3/4 (75.0) [19.4; 99.4]	9/15 (60.0) [32.3; 83.7]	3/8 (37.5) [8.5; 75.5]	2/2 (100.0) [15.8; 100.0]	12/15 (80.0) [51.9; 95.7]	0/0	8/12 (66.7) [34.9; 90.1]	8/8 (100.0) [63.1; 100.0]	6/13 (46.2) [19.2; 74.9]	3/5 (60.0) [14.7; 94.7]
6-10	3/11 (27.3) [6.0; 61.0]	1/3 (33.3) [0.8; 90.6]	1/4 (25.0) [0.6; 80.6]	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]

[illegible]

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Past investigator for one of the Piqray clinical trials (Q20)	1/1 (100.0) [2.5; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	Yes										
	15/27 (55.6) [35.3; 74.5]	0/1 (0.0) [0.0; 97.5]	3/3 (100.0) [29.2; 100.0]	4/9 (44.4) [13.7; 78.8]	0/0	3/4 (75.0) [19.4; 99.4]	0/0	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	1/6 (16.7) [0.4; 64.1]	1/1 (100.0) [2.5; 100.0]
No	46/70 (65.7) [53.4; 76.7]	5/6 (83.3) [35.9; 99.6]	8/17 (47.1) [23.0; 72.2]	1/2 (50.0) [1.3; 98.7]	2/2 (100.0) [15.8; 100.0]	9/11 (81.8) [48.2; 97.7]	0/1 (0.0) [0.0; 97.5]	7/11 (63.6) [30.8; 89.1]	7/7 (100.0) [59.0; 100.0]	5/8 (62.5) [24.5; 91.5]	2/5 (40.0) [5.3; 85.3]
	I don't know/am not sure										
	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
Missing Data											
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	Received the Guide for HCPs (Q1)										

[illegible]

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
No	19/33 (57.6) [39.2; 74.5]	1/2 (50.0) [1.3; 98.7]	2/3 (66.7) [9.4; 99.2]	0/4 (0.0) [0.0; 60.2]	0/0	6/7 (85.7) [42.1; 99.6]	0/0	2/4 (50.0) [6.8; 93.2]	4/4 (100.0) [39.8; 100.0]	3/7 (42.9) [9.9; 81.6]	1/2 (50.0) [1.3; 98.7]
I don't know/am not sure	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0
	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

[illegible]

[illegible]

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
	2/4 (50.0) [6.8; 93.2]	0/1 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
I don't know/am not sure											
	1/3 (33.3) [0.8; 90.6]	0/0	0/0	1/3 (33.3) [0.8; 90.6]	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Last time you prescribed Piqray (Q19)											
<3 months ago											
	32/56 (57.1) [43.2; 70.3]	2/5 (40.0) [5.3; 85.3]	7/12 (58.3) [27.7; 84.8]	3/3 (100.0) [29.2; 100.0]	0/2 (0.0) [0.0; 84.2]	8/12 (66.7) [34.9; 90.1]	0/1 (0.0) [0.0; 97.5]	2/6 (33.3) [4.3; 77.7]	3/4 (75.0) [19.4; 99.4]	4/6 (66.7) [22.3; 95.7]	3/5 (60.0) [14.7; 94.7]
3-<6 months ago											
	14/33 (42.4) [25.5; 60.8]	2/2 (100.0) [15.8; 100.0]	2/6 (33.3) [4.3; 77.7]	0/6 (0.0) [0.0; 45.9]	0/0	2/4 (50.0) [6.8; 93.2]	0/0	3/5 (60.0) [14.7; 94.7]	1/2 (50.0) [1.3; 98.7]	4/7 (57.1) [18.4; 90.1]	0/1 (0.0) [0.0; 97.5]
I don't know/am not sure											
	3/10 (30.0) [6.7; 65.2]	0/1 (0.0) [0.0; 97.5]	0/2 (0.0) [0.0; 84.2]	0/2 (0.0) [0.0; 84.2]	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	3/3 (100.0) [29.2; 100.0]	0/1 (0.0) [0.0; 97.5]	0/0
Missing Data											
	1/1	0/0	0/0	1/1	0/0	0/0	0/0	0/0	0/0	0/0	0/0

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Past investigator for one of the Piqray clinical trials (Q20)	(100.0)			(100.0)							
	[2.5; 100.0]			[2.5; 100.0]							
	Yes										
	16/27 (59.3) [38.8; 77.6]	1/1 (100.0) [2.5; 100.0]	2/3 (66.7) [9.4; 99.2]	3/9 (33.3) [7.5; 70.1]	0/0	3/4 (75.0) [19.4; 99.4]	0/0	1/1 (100.0) [2.5; 100.0]	2/2 (100.0) [15.8; 100.0]	4/6 (66.7) [22.3; 95.7]	0/1 (0.0) [0.0; 97.5]
	No										
I don't know/am not sure	32/70 (45.7) [33.7; 58.1]	3/6 (50.0) [11.8; 88.2]	7/17 (41.2) [18.4; 67.1]	0/2 (0.0) [0.0; 84.2]	0/2 (0.0) [0.0; 84.2]	6/11 (54.5) [23.4; 83.3]	0/1 (0.0) [0.0; 97.5]	4/11 (36.4) [10.9; 69.2]	5/7 (71.4) [29.0; 96.3]	4/8 (50.0) [15.7; 84.3]	3/5 (60.0) [14.7; 94.7]
	Missing Data										
	1/2 (50.0) [1.3; 98.7]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	1/1 (100.0) [2.5; 100.0]	0/0	0/0	0/0	0/0	0/0
	Received the Guide for HCPs (Q1)										
	Yes										

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
No	46/85 (54.1) [43.0; 65.0]	4/8 (50.0) [15.7; 84.3]	8/15 (53.3) [26.6; 78.7]	4/11 (36.4) [10.9; 69.2]	0/2 (0.0) [0.0; 84.2]	10/15 (66.7) [38.4; 88.2]	0/0	5/10 (50.0) [18.7; 81.3]	5/7 (71.4) [29.0; 96.3]	7/11 (63.6) [30.8; 89.1]	3/6 (50.0) [11.8; 88.2]
I don't know/am not sure	2/7 (28.6) [3.7; 71.0]	0/0	0/1 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	1/2 (50.0) [1.3; 98.7]	0/0
Read the Guide for HCPs (Q2)	2/8 (25.0) [3.2; 65.1]	0/0	1/4 (25.0) [0.6; 80.6]	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/1 (0.0) [0.0; 97.5]	1/1 (100.0) [2.5; 100.0]	0/1 (0.0) [0.0; 97.5]	0/0
Yes**	46/83 (55.4) [44.1; 66.3]	4/8 (50.0) [15.7; 84.3]	8/15 (53.3) [26.6; 78.7]	4/11 (36.4) [10.9; 69.2]	0/2 (0.0) [0.0; 84.2]	10/14 (71.4) [41.9; 91.6]	0/0	5/10 (50.0) [18.7; 81.3]	5/6 (83.3) [35.9; 99.6]	7/11 (63.6) [30.8; 89.1]	3/6 (50.0) [11.8; 88.2]
Yes, all of it	24/50 (48.0) [33.7; 62.6]	2/6 (33.3) [4.3; 77.7]	5/12 (41.7) [15.2; 72.3]	3/7 (42.9) [9.9; 81.6]	0/2 (0.0) [0.0; 84.2]	5/7 (71.4) [29.0; 96.3]	0/0	2/6 (33.3) [4.3; 77.7]	2/2 (100.0) [15.8; 100.0]	3/4 (75.0) [19.4; 99.4]	2/4 (50.0) [6.8; 93.2]
Yes, some of it	22/33	2/2	3/3	1/4	0/0	5/7	0/0	3/4	3/4	4/7	1/2

	Overall N=100 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=12 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=16 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
No	(66.7) [48.2; 82.0]	(100.0) [15.8; 100.0]	(100.0) [29.2; 100.0]	(25.0) [0.6; 80.6]		(71.4) [29.0; 96.3]		(75.0) [19.4; 99.4]	(75.0) [19.4; 99.4]	(57.1) [18.4; 90.1]	(50.0) [1.3; 98.7]
I don't know/am not sure	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0
	0/1 (0.0) [0.0; 97.5]	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/1 (0.0) [0.0; 97.5]	0/0	0/0

N=Number of eligible healthcare professionals who answered the corresponding question; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals in each category who answered the question; CI=Confidence Interval.

*Oncologist= "Radiologist/Radiation Oncologist" + "Medical Oncologist".

**Yes= "Yes, some of it" + "Yes, all of it".

Table 15-14 Other endpoints – knowledge levels: overall and by country

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Knowledge that hyperglycemia is a risk associated with treatment with Piqray (Q4a)											
	100/102 (98.0) [93.1; 99.8]	8/8 (100.0) [63.1; 100.0]	20/20 (100.0) [83.2; 100.0]	13/13 (100.0) [75.3; 100.0]	2/2 (100.0) [15.8; 100.0]	16/17 (94.1) [71.3; 99.9]	1/1 (100.0) [2.5; 100.0]	12/12 (100.0) [73.5; 100.0]	9/9 (100.0) [66.4; 100.0]	13/14 (92.9) [66.1; 99.8]	6/6 (100.0) [54.1; 100.0]
Knowledge that pneumonitis is a risk associated with treatment with Piqray (Q4b)											
	41/102 (40.2) [30.6; 50.4]	2/8 (25.0) [3.2; 65.1]	10/20 (50.0) [27.2; 72.8]	6/13 (46.2) [19.2; 74.9]	2/2 (100.0) [15.8; 100.0]	8/17 (47.1) [23.0; 72.2]	1/1 (100.0) [2.5; 100.0]	3/12 (25.0) [5.5; 57.2]	4/9 (44.4) [13.7; 78.8]	2/14 (14.3) [1.8; 42.8]	3/6 (50.0) [11.8; 88.2]
Knowledge that severe cutaneous reactions are a risk associated with treatment with Piqray (Q4c)											
	81/102 (79.4) [70.3; 86.8]	6/8 (75.0) [34.9; 96.8]	18/20 (90.0) [68.3; 98.8]	10/13 (76.9) [46.2; 95.0]	2/2 (100.0) [15.8; 100.0]	16/17 (94.1) [71.3; 99.9]	1/1 (100.0) [2.5; 100.0]	6/12 (50.0) [21.1; 78.9]	7/9 (77.8) [40.0; 97.2]	11/14 (78.6) [49.2; 95.3]	4/6 (66.7) [22.3; 95.7]
Knowledge that suicidal ideation is not a risk associated with treatment with Piqray (Q4d)											
	100/102	8/8	20/20	13/13	2/2	17/17	1/1	12/12	9/9	12/14	6/6

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Knowledge that onychomycosis is not a risk associated with treatment with Piqray (Q4e)	(98.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(85.7)	(100.0)
	[93.1; 99.8]	[63.1; 100.0]	[83.2; 100.0]	[75.3; 100.0]	[15.8; 100.0]	[80.5; 100.0]	[2.5; 100.0]	[73.5; 100.0]	[66.4; 100.0]	[57.2; 98.2]	[54.1; 100.0]
	98/102	8/8	20/20	12/13	1/2	16/17	1/1	12/12	9/9	13/14	6/6
	(96.1) [90.3; 98.9]	(100.0) [63.1; 100.0]	(100.0) [83.2; 100.0]	(92.3) [64.0; 99.8]	(50.0) [1.3; 98.7]	(94.1) [71.3; 99.9]	(100.0) [2.5; 100.0]	(100.0) [73.5; 100.0]	(100.0) [66.4; 100.0]	(92.9) [66.1; 99.8]	(100.0) [54.1; 100.0]
Knowledge that excessive thirst is a sign/symptom of hyperglycemia (Q5a)	99/102	7/8	20/20	13/13	2/2	17/17	1/1	11/12	9/9	14/14	5/6
	(97.1) [91.6; 99.4]	(87.5) [47.3; 99.7]	(100.0) [83.2; 100.0]	(100.0) [75.3; 100.0]	(100.0) [15.8; 100.0]	(100.0) [80.5; 100.0]	(100.0) [2.5; 100.0]	(91.7) [61.5; 99.8]	(100.0) [66.4; 100.0]	(100.0) [76.8; 100.0]	(83.3) [35.9; 99.6]
	98/102	7/8	20/20	13/13	2/2	17/17	1/1	10/12	8/9	14/14	6/6
	(96.1) [90.3; 98.9]	(87.5) [47.3; 99.7]	(100.0) [83.2; 100.0]	(100.0) [75.3; 100.0]	(100.0) [15.8; 100.0]	(100.0) [80.5; 100.0]	(100.0) [2.5; 100.0]	(83.3) [51.6; 97.9]	(88.9) [51.8; 99.7]	(100.0) [76.8; 100.0]	(100.0) [54.1; 100.0]
Knowledge that increased frequency or amount of urination is a sign/symptom of hyperglycemia (Q5b)											
Knowledge that increased appetite with weight loss is a sign/symptom of hyperglycemia	98/102	7/8	20/20	13/13	2/2	17/17	1/1	10/12	8/9	14/14	6/6
	(96.1) [90.3; 98.9]	(87.5) [47.3; 99.7]	(100.0) [83.2; 100.0]	(100.0) [75.3; 100.0]	(100.0) [15.8; 100.0]	(100.0) [80.5; 100.0]	(100.0) [2.5; 100.0]	(83.3) [51.6; 97.9]	(88.9) [51.8; 99.7]	(100.0) [76.8; 100.0]	(100.0) [54.1; 100.0]
	98/102	7/8	20/20	13/13	2/2	17/17	1/1	10/12	8/9	14/14	6/6
	(96.1) [90.3; 98.9]	(87.5) [47.3; 99.7]	(100.0) [83.2; 100.0]	(100.0) [75.3; 100.0]	(100.0) [15.8; 100.0]	(100.0) [80.5; 100.0]	(100.0) [2.5; 100.0]	(83.3) [51.6; 97.9]	(88.9) [51.8; 99.7]	(100.0) [76.8; 100.0]	(100.0) [54.1; 100.0]

[illegible]

[illegible]

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
	82/102 (80.4) [71.4; 87.6]	4/8 (50.0) [15.7; 84.3]	16/20 (80.0) [56.3; 94.3]	12/13 (92.3) [64.0; 99.8]	2/2 (100.0) [15.8; 100.0]	13/17 (76.5) [50.1; 93.2]	1/1 (100.0) [2.5; 100.0]	11/12 (91.7) [61.5; 99.8]	8/9 (88.9) [51.8; 99.7]	11/14 (78.6) [49.2; 95.3]	4/6 (66.7) [22.3; 95.7]
Knowledge that a fasting glucose and HbA1c should be obtained before a patient starts treatment with Piqray (Q8a)											
	95/102 (93.1) [86.4; 97.2]	7/8 (87.5) [47.3; 99.7]	19/20 (95.0) [75.1; 99.9]	12/13 (92.3) [64.0; 99.8]	2/2 (100.0) [15.8; 100.0]	16/17 (94.1) [71.3; 99.9]	1/1 (100.0) [2.5; 100.0]	12/12 (100.0) [73.5; 100.0]	8/9 (88.9) [51.8; 99.7]	13/14 (92.9) [66.1; 99.8]	5/6 (83.3) [35.9; 99.6]
Knowledge that the patient's level of blood glucose should be optimized, as applicable, before a patient starts treatment with Piqray? (Q8b)											
	74/102 (72.5) [62.8; 80.9]	6/8 (75.0) [34.9; 96.8]	18/20 (90.0) [68.3; 98.8]	7/13 (53.8) [25.1; 80.8]	2/2 (100.0) [15.8; 100.0]	12/17 (70.6) [44.0; 89.7]	1/1 (100.0) [2.5; 100.0]	7/12 (58.3) [27.7; 84.8]	8/9 (88.9) [51.8; 99.7]	10/14 (71.4) [41.9; 91.6]	3/6 (50.0) [11.8; 88.2]
Knowledge that the patient should be counselled about the risk of hyperglycemia before a patient starts treatment with Piqray (Q8c)											
	92/102 (90.2)	7/8 (87.5)	19/20 (95.0)	11/13 (84.6)	2/2 (100.0)	15/17 (88.2)	1/1 (100.0)	9/12 (75.0)	9/9 (100.0)	14/14 (100.0)	5/6 (83.3)

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Knowledge that the dose of their current antihyperglycemia medication, if applicable, does not need to be increased before a patient starts treatment with Piqray (Q8d)	[82.7; 95.2] 74/102 (72.5) [62.8; 80.9]	[47.3; 99.7] 5/8 (62.5) [24.5; 91.5]	[75.1; 99.9] 16/20 (80.0) [56.3; 94.3]	[54.6; 98.1] 13/13 (100.0) [75.3; 100.0]	[15.8; 100.0] 0/2 (0.0) [0.0; 84.2]	[63.6; 98.5] 12/17 (70.6) [44.0; 89.7]	[2.5; 100.0] 1/1 (100.0) [2.5; 100.0]	[42.8; 94.5] 11/12 (91.7) [61.5; 99.8]	[66.4; 100.0] 5/9 (55.6) [21.2; 86.3]	[76.8; 100.0] 6/14 (42.9) [17.7; 71.1]	[35.9; 99.6] 5/6 (83.3) [35.9; 99.6]
Knowledge that the Piqray Prescriber's/HCP Guide for Hyperglycemia and SmPC does not require a diabetologist to be consulted for patients who are not diabetic before a patient starts treatment with Piqray (Q8e)	89/102 (87.3) [79.2; 93.0]	6/8 (75.0) [34.9; 96.8]	14/20 (70.0) [45.7; 88.1]	12/13 (92.3) [64.0; 99.8]	1/2 (50.0) [1.3; 98.7]	16/17 (94.1) [71.3; 99.9]	1/1 (100.0) [2.5; 100.0]	12/12 (100.0) [73.5; 100.0]	8/9 (88.9) [51.8; 99.7]	13/14 (92.9) [66.1; 99.8]	6/6 (100.0) [54.1; 100.0]
Knowledge that "the monitoring schedule of fasting glucose levels for patients receiving Piqray is the same for all patients with, and without, risk factors for hyperglycemia" is not correct (Q9)	55/103	3/8	9/20	7/13	0/2	13/18	0/1	5/12	7/9	8/14	3/6

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
	(53.4) [43.3; 63.3]	(37.5) [8.5; 75.5]	(45.0) [23.1; 68.5]	(53.8) [25.1; 80.8]	(0.0) [0.0; 84.2]	(72.2) [46.5; 90.3]	(0.0) [0.0; 97.5]	(41.7) [15.2; 72.3]	(77.8) [40.0; 97.2]	(57.1) [28.9; 82.3]	(50.0) [11.8; 88.2]
Knowledge of when a FPG test should be performed after starting treatment with Piqray (Q10)											
	77/103 (74.8) [65.2; 82.8]	7/8 (87.5) [47.3; 99.7]	14/20 (70.0) [45.7; 88.1]	10/13 (76.9) [46.2; 95.0]	2/2 (100.0) [15.8; 100.0]	13/18 (72.2) [46.5; 90.3]	1/1 (100.0) [2.5; 100.0]	8/12 (66.7) [34.9; 90.1]	7/9 (77.8) [40.0; 97.2]	10/14 (71.4) [41.9; 91.6]	5/6 (83.3) [35.9; 99.6]
Knowledge of the frequency for HbA1c testing to be performed for all patients treated with Piqray (Q11)											
	75/102 (73.5) [63.9; 81.8]	6/8 (75.0) [34.9; 96.8]	13/20 (65.0) [40.8; 84.6]	9/13 (69.2) [38.6; 90.9]	2/2 (100.0) [15.8; 100.0]	13/17 (76.5) [50.1; 93.2]	1/1 (100.0) [2.5; 100.0]	7/12 (58.3) [27.7; 84.8]	9/9 (100.0) [66.4; 100.0]	11/14 (78.6) [49.2; 95.3]	4/6 (66.7) [22.3; 95.7]
Knowledge that for fasting glucose values that are ≤ 250 mg/dL (≤ 13.9 mmol/L), no Piqray dose adjustment is required, and it is recommended to manage by initiating or intensifying oral antihyperglycemic treatment (Q12)											
	91/103 (88.3) [80.5; 93.8]	7/8 (87.5) [47.3; 99.7]	19/20 (95.0) [75.1; 99.9]	9/13 (69.2) [38.6; 90.9]	2/2 (100.0) [15.8; 100.0]	16/18 (88.9) [65.3; 98.6]	1/1 (100.0) [2.5; 100.0]	12/12 (100.0) [73.5; 100.0]	8/9 (88.9) [51.8; 99.7]	12/14 (85.7) [57.2; 98.2]	5/6 (83.3) [35.9; 99.6]

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Knowledge of which fasting glucose values require Piqray dosing to be interrupted (Q13)											
	81/101 (80.2) [71.1; 87.5]	7/8 (87.5) [47.3; 99.7]	9/20 (45.0) [23.1; 68.5]	11/12 (91.7) [61.5; 99.8]	2/2 (100.0) [15.8; 100.0]	15/17 (88.2) [63.6; 98.5]	0/1 (0.0) [0.0; 97.5]	11/12 (91.7) [61.5; 99.8]	9/9 (100.0) [66.4; 100.0]	14/14 (100.0) [76.8; 100.0]	3/6 (50.0) [11.8; 88.2]
Knowledge that “if Piqray dosing is interrupted due to elevations in fasting glucose >250 mg/dL (>13.9 mmol/L), and fasting glucose decreases to ≤160 mg/dL (≤8.9 mmol/L) within 3-5 days under appropriate antihyperglycemia treatment, Piqray can be resumed at the starting dose level of 300 mg/day” is not accurate (Q14)											
	63/100 (63.0) [52.8; 72.4]	5/8 (62.5) [24.5; 91.5]	11/20 (55.0) [31.5; 76.9]	6/12 (50.0) [21.1; 78.9]	2/2 (100.0) [15.8; 100.0]	13/16 (81.3) [54.4; 96.0]	0/1 (0.0) [0.0; 97.5]	8/12 (66.7) [34.9; 90.1]	9/9 (100.0) [66.4; 100.0]	6/14 (42.9) [17.7; 71.1]	3/6 (50.0) [11.8; 88.2]
Knowledge of what frequency should fasting glucose be monitored when hyperglycemia occurs and patients are treated with antihyperglycemic medications (Q15)											
	50/100 (50.0)	4/8 (50.0)	9/20 (45.0)	4/12 (33.3)	0/2 (0.0)	10/16 (62.5)	0/1 (0.0)	5/12 (41.7)	7/9 (77.8)	8/14 (57.1)	3/6 (50.0)

	Overall	Austria	Croatia	Italy	Luxembourg	Netherlands	Norway	Poland	Slovenia	Spain	Sweden
	N=103	N=8	N=20	N=13	N=2	N=18	N=1	N=12	N=9	N=14	N=6
	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI
	[39.8; 60.2]	[15.7; 84.3]	[23.1; 68.5]	[9.9; 65.1]	[0.0; 84.2]	[35.4; 84.8]	[0.0; 97.5]	[15.2; 72.3]	[40.0; 97.2]	[28.9; 82.3]	[11.8; 88.2]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=non-missing;
CI=Confidence Interval.

Table 15-15 Other endpoints – knowledge levels: receipt and reading of the Piqray Prescriber's/HCP Guide for Hyperglycemia, overall and by country

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Received the Guide for HCPs (Q1)											
Yes											
	88/103 (85.4) [77.1; 91.6]	8/8 (100.0) [63.1; 100.0]	15/20 (75.0) [50.9; 91.3]	12/13 (92.3) [64.0; 99.8]	2/2 (100.0) [15.8; 100.0]	17/18 (94.4) [72.7; 99.9]	0/1 (0.0) [0.0; 97.5]	10/12 (83.3) [51.6; 97.9]	7/9 (77.8) [40.0; 97.2]	11/14 (78.6) [49.2; 95.3]	6/6 (100.0) [54.1; 100.0]
No											
	7/103 (6.8) [2.8; 13.5]	0/8 (0.0) [0.0; 36.9]	1/20 (5.0) [0.1; 24.9]	1/13 (7.7) [0.2; 36.0]	0/2 (0.0) [0.0; 84.2]	0/18 (0.0) [0.0; 18.5]	1/1 (100.0) [2.5; 100.0]	1/12 (8.3) [0.2; 38.5]	1/9 (11.1) [0.3; 48.2]	2/14 (14.3) [1.8; 42.8]	0/6 (0.0) [0.0; 45.9]
I don't know/am not sure											
	8/103 (7.8) [3.4; 14.7]	0/8 (0.0) [0.0; 36.9]	4/20 (20.0) [5.7; 43.7]	0/13 (0.0) [0.0; 24.7]	0/2 (0.0) [0.0; 84.2]	1/18 (5.6) [0.1; 27.3]	0/1 (0.0) [0.0; 97.5]	1/12 (8.3) [0.2; 38.5]	1/9 (11.1) [0.3; 48.2]	1/14 (7.1) [0.2; 33.9]	0/6 (0.0) [0.0; 45.9]
Read the Guide for HCPs (Q2)											
Yes*											
	86/88 (97.7) [92.0; 99.7]	8/8 (100.0) [63.1; 100.0]	15/15 (100.0) [78.2; 100.0]	12/12 (100.0) [73.5; 100.0]	2/2 (100.0) [15.8; 100.0]	16/17 (94.1) [71.3; 99.9]	0/0	10/10 (100.0) [69.2; 100.0]	6/7 (85.7) [42.1; 99.6]	11/11 (100.0) [71.5; 100.0]	6/6 (100.0) [54.1; 100.0]
Yes, all of it											
	52/88	6/8	12/15	8/12	2/2	8/17	0/0	6/10	2/7	4/11	4/6

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
Yes, some of it	(59.1) [48.1; 69.5]	(75.0) [34.9; 96.8]	(80.0) [51.9; 95.7]	(66.7) [34.9; 90.1]	(100.0) [15.8; 100.0]	(47.1) [23.0; 72.2]		(60.0) [26.2; 87.8]	(28.6) [3.7; 71.0]	(36.4) [10.9; 69.2]	(66.7) [22.3; 95.7]
	34/88 (38.6) [28.4; 49.6]	2/8 (25.0) [3.2; 65.1]	3/15 (20.0) [4.3; 48.1]	4/12 (33.3) [9.9; 65.1]	0/2 (0.0) [0.0; 84.2]	8/17 (47.1) [23.0; 72.2]	0/0	4/10 (40.0) [12.2; 73.8]	4/7 (57.1) [18.4; 90.1]	7/11 (63.6) [30.8; 89.1]	2/6 (33.3) [4.3; 77.7]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=Number of healthcare professionals who answered the question; CI=Confidence Interval.

*Yes= "Yes, some of it" + "Yes, all of it".

[illegible]

	Overall N=103 n/M (%) 95% CI	Austria N=8 n/M (%) 95% CI	Croatia N=20 n/M (%) 95% CI	Italy N=13 n/M (%) 95% CI	Luxembourg N=2 n/M (%) 95% CI	Netherlands N=18 n/M (%) 95% CI	Norway N=1 n/M (%) 95% CI	Poland N=12 n/M (%) 95% CI	Slovenia N=9 n/M (%) 95% CI	Spain N=14 n/M (%) 95% CI	Sweden N=6 n/M (%) 95% CI
	4/103 (3.9) [1.1; 9.6]	0/8 (0.0) [0.0; 36.9]	1/20 (5.0) [0.1; 24.9]	0/13 (0.0) [0.0; 24.7]	0/2 (0.0) [0.0; 84.2]	0/18 (0.0) [0.0; 18.5]	0/1 (0.0) [0.0; 97.5]	1/12 (8.3) [0.2; 38.5]	0/9 (0.0) [0.0; 33.6]	2/14 (14.3) [1.8; 42.8]	0/6 (0.0) [0.0; 45.9]
The European Medicines Agency website											
	5/103 (4.9) [1.6; 11.0]	1/8 (12.5) [0.3; 52.7]	0/20 (0.0) [0.0; 16.8]	2/13 (15.4) [1.9; 45.4]	1/2 (50.0) [1.3; 98.7]	0/18 (0.0) [0.0; 18.5]	0/1 (0.0) [0.0; 97.5]	0/12 (0.0) [0.0; 26.5]	0/9 (0.0) [0.0; 33.6]	1/14 (7.1) [0.2; 33.9]	0/6 (0.0) [0.0; 45.9]
Clinical practice guidelines											
	9/103 (8.7) [4.1; 15.9]	0/8 (0.0) [0.0; 36.9]	0/20 (0.0) [0.0; 16.8]	1/13 (7.7) [0.2; 36.0]	0/2 (0.0) [0.0; 84.2]	1/18 (5.6) [0.1; 27.3]	0/1 (0.0) [0.0; 97.5]	2/12 (16.7) [2.1; 48.4]	2/9 (22.2) [2.8; 60.0]	1/14 (7.1) [0.2; 33.9]	2/6 (33.3) [4.3; 77.7]
A representative from Novartis											
	4/103 (3.9) [1.1; 9.6]	1/8 (12.5) [0.3; 52.7]	1/20 (5.0) [0.1; 24.9]	0/13 (0.0) [0.0; 24.7]	0/2 (0.0) [0.0; 84.2]	0/18 (0.0) [0.0; 18.5]	1/1 (100.0) [2.5; 100.0]	0/12 (0.0) [0.0; 26.5]	0/9 (0.0) [0.0; 33.6]	1/14 (7.1) [0.2; 33.9]	0/6 (0.0) [0.0; 45.9]
Other											
	6/103 (5.8) [2.2; 12.2]	0/8 (0.0) [0.0; 36.9]	0/20 (0.0) [0.0; 16.8]	0/13 (0.0) [0.0; 24.7]	0/2 (0.0) [0.0; 84.2]	2/18 (11.1) [1.4; 34.7]	0/1 (0.0) [0.0; 97.5]	0/12 (0.0) [0.0; 26.5]	0/9 (0.0) [0.0; 33.6]	2/14 (14.3) [1.8; 42.8]	2/6 (33.3) [4.3; 77.7]
I don't know/am not sure											
	0/103 (0.0)	0/8 (0.0)	0/20 (0.0)	0/13 (0.0)	0/2 (0.0)	0/18 (0.0)	0/1 (0.0)	0/12 (0.0)	0/9 (0.0)	0/14 (0.0)	0/6 (0.0)

	Overall	Austria	Croatia	Italy	Luxembourg	Netherlands	Norway	Poland	Slovenia	Spain	Sweden
	N=103	N=8	N=20	N=13	N=2	N=18	N=1	N=12	N=9	N=14	N=6
	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M	n/M
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI	95% CI
	[0.0; 3.5]	[0.0; 36.9]	[0.0; 16.8]	[0.0; 24.7]	[0.0; 84.2]	[0.0; 18.5]	[0.0; 97.5]	[0.0; 26.5]	[0.0; 33.6]	[0.0; 23.2]	[0.0; 45.9]

N=Number of eligible healthcare professionals; n=Number of healthcare professionals who answered the question correctly; M=non-missing;
CI=Confidence Interval.

15.3 Appendix 3 – Survey Administration and Analysis Sets, and Survey eligibility

422 HCPs were invited to complete the survey with 125 HCPs (29.6%) completing the eligibility questions. Of HCPs who completed the eligibility questions, 103 HCPs (82.4%) were eligible for the survey with 100 HCPs (23.7%) completing all primary endpoint and secondary endpoint questions ([Table 15-1](#)).

15.3.1 Austria

In Austria, 71 invitations were issued to prescribers. There were 8 prescribers who started the survey, and 0 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 8 eligible HCPs completed the survey, 11.3% of the issued invitation letters ([Table 15-1](#)).

15.3.2 Croatia

In Croatia, 50 invitations were issued to prescribers. There were 21 prescribers who started the survey, and 1 respondent was found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 20 eligible HCPs completed the survey, 40.0% of the issued invitation letters ([Table 15-1](#)).

15.3.3 Italy

In Italy, 87 invitations were issued to prescribers. There were 29 prescribers who started the survey, and 16 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 13 eligible HCPs completed the survey, 14.9% of the issued invitation letters ([Table 15-1](#)).

15.3.4 Luxembourg

In Luxembourg, 12 invitations were issued to prescribers. There were 2 prescribers who started the survey, and 0 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 2 eligible HCPs completed the survey, 16.7% of the issued invitation letters ([Table 15-1](#)).

15.3.5 Netherlands

In the Netherlands, 63 invitations were issued to prescribers. There were 20 prescribers who started the survey, and 2 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 18 eligible HCPs completed the survey, 28.6% of the issued invitation letters ([Table 15-1](#)).

15.3.6 Norway

In Norway, 2 invitations were issued to prescribers. There was 1 prescriber who started the survey, and 0 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 1 eligible respondent completed the survey, 50.0% of the issued invitation letters ([Table 15-1](#)).

15.3.7 Poland

In Poland, 40 invitations were issued to prescribers. There were 15 prescribers who started the survey, and 3 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 12 eligible HCPs completed the survey, 30.0% of the issued invitation letters ([Table 15-1](#)).

15.3.8 Slovenia

In Slovenia, 20 invitations were issued to prescribers. There were 9 prescribers who started the survey, and 0 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 9 eligible HCPs completed the survey, 45.0 % of the issued invitation letters ([Table 15-1](#)).

15.3.9 Spain

In Spain, 63 invitations were issued to prescribers. There were 14 prescribers who started the survey, and 0 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 14 eligible HCPs completed the survey, 22.2 % of the issued invitation letters ([Table 15-1](#)).

15.3.10 Sweden

In Sweden, 11 invitations were issued to prescribers. There were 6 prescribers who started the survey, and 0 HCPs were found ineligible through the screening questions and 0 HCPs did not complete the survey. A total of 6 eligible HCPs completed the survey, 54.5% of the issued invitation letters ([Table 15-1](#)).